leflunomide has been researched along with Rheumatoid Arthritis in 607 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare efficacy and safety of two different combination csDMARD therapy in Methotrexate-failed Rheumatoid arthritis patients." | 9.51 | Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. ( Belani, PJ; Kavadichanda, CG; Negi, VS, 2022) |
| "The present work is aimed at exploring the clinical efficacy and safety of methotrexate (MTX) and leflunomide (LEF) combination therapy for rheumatoid arthritis." | 9.51 | Combination of Methotrexate and Leflunomide Is Efficient and Safe for 60 Patients with Rheumatoid Arthritis. ( Chen, F; Du, H; He, S; Wang, L; Wang, Y, 2022) |
| "Leflunomide (LEF) is a conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of rheumatoid arthritis." | 9.34 | Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study. ( Deng, D; Li, M; Li, S; Tian, L; Wang, T; Wu, J; Yang, J; Zeng, F; Zhou, J; Zou, J, 2020) |
| "To investigate the efficacy and safety of tacrolimus (TAC) versus leflunomide (LEF) when combined with methotrexate (MTX) in rheumatoid arthritis (RA) patients." | 9.30 | Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. ( Baek, HJ; Cha, HS; Choi, IA; Jun, JB; Kang, SW; Kang, YM; Lee, YJ; Park, SH; Shin, K; Song, YW, 2019) |
| "The objective of this study is to investigate whether the addition of double-filtration plasmapheresis (DFPP) to leflunomide and methotrexate repairs MRI bone erosion in patients with long-standing rheumatoid arthritis (RA)." | 9.27 | MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. ( Lan, G; Lu, W; Sun, F; Wang, L; Xu, P; Yu, X; Zhang, L, 2018) |
| "The aim of this study was to determine the efficacy and safety of a weekly dose of leflunomide (50 mg/week) in early rheumatoid arthritis patients with mild or moderate disease activity." | 9.22 | Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. ( Bi, LQ; Chen, LN; Fang, YF; Gu, F; Guo, JL; Hao, YJ; Li, R; Li, XF; Li, ZG; Liu, HX; Liu, XY; Luo, Y; Mei, YF; Ren, LM; Su, Y; Sun, LY; Zhang, ZL; Zhang, ZY; Zhao, JX; Zhu, P, 2016) |
| " High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7." | 9.20 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. ( Corluy, L; De Brabanter, G; De Cock, D; Durnez, A; Geens, E; Geusens, P; Joly, J; Joos, R; Langenaken, C; Lenaerts, J; Meyfroidt, S; Raeman, F; Ravelingien, I; Remans, J; Sileghem, A; Taelman, V; Van der Elst, K; Van Essche, E; Vander Cruyssen, B; Vandevyvere, K; Vanhoof, J; Verschueren, P; Westhovens, R, 2015) |
| " Methotrexate (MTX) and Leflunomide (LEF) combination has a better efficacy in the treatment of active rheumatoid arthritis (RA), but hepatotoxicity was observed." | 9.20 | Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. ( Chen, Z; Li, XM; Li, XP; Li, ZG; Su, Y; Xiang, N; Yang, M; Zhang, MJ; Zhao, DB; Zhu, P; Zuo, XX, 2015) |
| "To evaluate the clinical efficacy and safety of Huayu Tongbi Recipe (HTR) combined methotrexate (MTX) in treating refractory rheumatoid arthritis (RRA)." | 9.20 | [Treatment of Refractory Rheumatoid Arthritis by Huayu Tongbi Recipe Combined Methotrexate]. ( Chen, XM; Chu, YL; Huang, QC; Huang, RY; Liu, ZH; Yan, JY, 2015) |
| "Combination use of methotrexate (MTX) and leflunomide (LEF) has been proved effective in the treatment of active rheumatoid arthritis (RA)." | 9.17 | Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. ( Chen, Z; Li, XM; Li, XP; Li, ZJ; Xu, L, 2013) |
| "To study whether the effects of Leflunomide were different in treating patients with rheumatoid arthritis (RA) of different Chinese medical syndrome patterns." | 9.17 | [Effects of leflunomide in treating patients with rheumatoid arthritis of different Chinese medical syndrome patterns]. ( Li, WQ; Wang, ZM; Wu, Y, 2013) |
| "Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones." | 9.16 | Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide. ( Chlubek, D; Dziedziejko, V; Kurzawski, M; Ossowski, A; Parafiniuk, M; Pawlik, A; Piatek, J; Safranow, K, 2012) |
| "To evaluate the effects of double filtration plasmapheresis (DFPP) in combination with leflunomide and methotrexate (MTX) on magnetic resonance imaging (MRI)-detected inflammatory changes (synovitis and bone edema) in patients with early rheumatoid arthritis (RA) with high disease activity." | 9.16 | Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. ( Lan, G; Liu, J; Lu, W; Ping, L; Tian, J; Wang, L; Wang, X; Xu, P; Yu, X, 2012) |
| "In order to compare the efficacy and toxicity of methotrexate and leflunomide for the treatment of rheumatoid arthritis, a double-blind randomized clinical trial was carried out at the Department of Medicine, Jinnah Medical College Hospital, Korangi, Karachi." | 9.15 | Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. ( Hameed, K; Ishaq, M; Mirza, AI; Muhammad, JS, 2011) |
| "Leflunomide is a disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis (RA)." | 9.15 | Leflunomide in Pakistani patients with rheumatoid arthritis: prospective study in daily rheumatology practice. ( Ahmad, NM; Farman, S; Ghafoor, E; Hameed, R; Saeed, MA; Umair, M, 2011) |
| "We undertook this study to evaluate the effects of leflunomide, an oral pyrimidine synthesis inhibitor, on the serum chemokine levels in patients with active rheumatoid arthritis (RA) who were refractory to treatment with methotrexate (MTX) or did not tolerated MTX treatment." | 9.14 | The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. ( Chwiecko, J; Kita, J; Klimiuk, PA; Sierakowski, S, 2009) |
| "To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha combination therapy in a group of patients with active rheumatoid arthritis (RA)." | 9.14 | Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. ( Baldi, C; De Stefano, R; Frati, E; Galeazzi, M; Hammoud, M; Menza, L; Nargi, F, 2010) |
| "Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce." | 9.14 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. ( Bornholdt, K; Hein, G; Kellner, H, 2010) |
| "To analyse the effects of leflunomide and methotrexate treatment on matrix metalloproteinase (MMP) activity levels in alpha2 macroglobulin/MMP (alpha2M/MMP) complexes in the systemic circulation of rheumatoid arthritis (RA) patients." | 9.13 | Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients. ( DeGroot, J; Hanemaaijer, R; Huizinga, TW; Kraan, MC; Tchetverikov, I; van El, B, 2008) |
| "The objective of this study was to assess the efficacy and tolerability of a combination of leflunomide (LEF) and chloroquin (ChL) in patients with rheumatoid arthritis (RA)." | 9.12 | Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study. ( Andel, I; Leeb, BF; Rintelen, B; Sautner, J, 2006) |
| "This study assessed the efficacy and safety of combination (COMB) of cyclosporine (CSA) and leflunomide (LEF) versus each drug alone, in the treatment of severe rheumatoid arthritis (RA)." | 9.12 | Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. ( Andrianakos, A; Antoniades, C; Charalambopoulos, D; Karanikolas, G; Katsilambros, N, 2006) |
| "Rheumatoid arthritis patients who develop refractoriness are left with no alternatives other than leflunomide and costly biological response modifiers." | 9.12 | Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. ( Antony, T; Jose, VM; Paul, BJ; Thomas, T, 2006) |
| "To study effects of leflunomide on inflammatory and destructive processes in patients with early rheumatoid arthritis (RA)." | 9.12 | [An antidestructive effect of leflunomide in early rheumatoid arthritis]. ( Aleksandrova, EN; Balabanova, RM; Kashevarov, RIu; Oliunin, IuA; Smirnov, AV, 2006) |
| "The objective of this study was to determine the neurophysiological effects of leflunomide on peripheral nerves in rheumatoid arthritis." | 9.12 | Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. ( Bleasel, JF; McGill, N; Richards, BL; Richards, GW; Spies, J; Vaile, J; Youssef, PP, 2007) |
| "Methotrexate (MTX) is a first-line disease-modifying antirheumatic drugs (DMARD) in rheumatoid arthritis (RA)." | 9.12 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. ( Jakubicz, D; Wisłowska, M, 2007) |
| "To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years." | 9.12 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. ( Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D, 2007) |
| "Evaluation of effectiveness and safety of leflunomide treatment in patients with active rheumatoid arthritis in whom methotrexate was ineffective or contraindicated." | 9.12 | [Leflunomide as a second choice treatment in patients with rheumatoid arthritis]. ( Bachta, A; Dudek, A; Raczkiewicz-Papierska, A; Sułek, M; Tłustochowicz, M; Zawadyl, B, 2007) |
| "To assess the safety and effectiveness of leflunomide (LNF) using 100 mg/week in patients with rheumatoid arthritis (RA)." | 9.11 | Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. ( Arroyo-Borrego, S; Dávalos-Zugasti, ME; Jaimes-Hernández, J; Robles-San Román, M; Suárez-Otero, R, 2004) |
| "To compare the efficacy and safety profile of two daily maintenance doses of leflunomide, 10 mg and 20 mg, for the treatment of active rheumatoid arthritis (RA)." | 9.11 | Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. ( Poór, G; Strand, V, 2004) |
| "To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label extension study in patients with rheumatoid arthritis (RA)." | 9.11 | Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. ( Bathon, J; Caldwell, J; Cannon, GW; Coleman, P; Crawford, B; Curtis, D; Cush, J; Fernando, I; Furst, DE; Genovese, M; Kantor, S; Kavanaugh, A; Keystone, E; Kopp, E; Kremer, J; Lindsley, HB; Luggen, M; Markenson, J; Ruderman, E; Simpson, K; Strand, V; Waltuck, J; Weisman, M, 2004) |
| "Leflunomide is an immunomodulatory agent that was recently approved for the treatment of rheumatoid arthritis (RA)." | 9.11 | Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. ( Bambery, P; Govindrajan, S; Khullar, M; Reddy, SV; Wanchu, A, 2005) |
| "To study therapeutic potential of a novel basic drug leflunomide in suppression of activity and progression of rheumatoid arthritis (RA)." | 9.11 | [Experience in long-term therapy of active rheumatoid arthritis with leflunomide]. ( Brodetskaia, KA; Chichasova, NV; Igolkina, EV; Imametdinova, GR, 2005) |
| "To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis." | 9.10 | Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. ( Bathon, JM; Bensen, WM; Caldwell, JR; Cannon, GW; Coleman, P; Crawford, B; Curtis, DL; Cush, JJ; Fernando, I; Furst, DE; Genovese, MC; Kaine, JL; Kantor, SM; Keystone, E; Kopp, EJ; Kremer, JM; Lindsley, HB; Luggen, ME; Markenson, JA; Ruderman, EM; Simpson, K; Strand, V; Waltuck, J; Weisman, MH, 2002) |
| "Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day thereafter) in the 2 phase III studies and who completed 2 years of treatment were offered inclusion in the open-label extension phase and were maintained on the same dosage of leflunomide." | 9.10 | The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. ( Breedveld, F; Deighton, C; Emery, P; Kalden, JR; Rozman, B; Schattenkirchner, M; Sörensen, H, 2003) |
| "To evaluate the efficacy and safety of leflunomide in comparison with methotrexate (MTX) on patients with rheumatoid arthritis (RA) in China." | 9.10 | Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. ( Bao, C; Chen, S; Ding, C; Gu, Y; He, P; Lao, Z; Li, X; Liu, J; Ma, J; Ni, L; Sun, L; Xu, J; Xu, S; Yu, Q, 2003) |
| "Leflunomide (LFL) is a modern immunomodulating medication belonging to the group of drugs that favourably affect the course of rheumatoid arthritis (RA)." | 9.10 | Leflunomide in the treatment of refractory rheumatoid arthritis. ( Andreev, SA; Batalov, AZ; Kuzmanova, SI; Russafov, PB; Solakov, PT; Staikova, ND, 2003) |
| "To compare disease-related medical care and productivity costs, and utilities, in 482 patients with rheumatoid arthritis randomised to receive leflunomide, methotrexate or placebo during a 12-month period." | 9.10 | Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. ( Bombardier, C; Maetzel, A; Strand, V; Tugwell, P; Wells, G, 2002) |
| "To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA)." | 9.10 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. ( Johnson, DM; Kiely, PD, 2002) |
| "To assess the therapeutic effect of leflunomide in weekly dose of 100 mg in patients with refractory rheumatoid arthritis." | 9.10 | Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. ( Jakez-Ocampo, J; Llorente, L; Richaud-Patin, Y; Simón, JA, 2002) |
| "Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis." | 9.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "To examine the safety and pharmacokinetics of and clinical response to leflunomide, a de novo pyrimidine synthesis inhibitor, when administered to patients with active rheumatoid arthritis (RA) who have been receiving long-term methotrexate therapy." | 9.09 | Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. ( Byrne, VM; Coblyn, JS; Helfgott, SM; Kaymakcian, MV; Kremer, JM; Maier, AL; Morrell, M; Strand, V; Weinblatt, ME, 1999) |
| "To assess the efficacy of leflunomide or methotrexate compared with placebo in improving function and health-related quality of life in patients with active rheumatoid arthritis (RA), and to examine correlations between response status (as defined by the American College of Rheumatology [ACR] response criteria) and improvement in these measures." | 9.09 | Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. ( Bombardier, C; Crawford, B; Dorrier, C; Maetzel, A; Strand, V; Thompson, A; Tugwell, P; Wells, G, 1999) |
| "Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA)." | 9.09 | Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. ( Caldwell, J; Cannon, G; Cohen, S; Fleischmann, R; Fox, R; Furst, D; Hurley, F; Kaine, J; Loew-Friedrich, I; Moreland, L; Olsen, N; Schiff, M; Sharp, J; Strand, V; Weaver, A, 1999) |
| "To compare the clinical efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis (RA)." | 9.09 | A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. ( Bjorneboe, O; Breedveld, FC; Dahl, R; Dawes, PT; Emery, P; Gömör, B; Horslev-Petersen, K; Kaltwasser, JP; Lemmel, EM; Loew-Friedrich, I; Molloy, M; Nordström, D; Oed, C; Rodriguez De La Serna, A; Rosenburg, R; Tikly, M; Van Den Bosch, F, 2000) |
| "Leflunomide is a novel immunomodulating drug that has recently been approved as a disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA)." | 9.09 | Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. ( Breedveld, FC; de Koster, BM; Elferink, JG; Kraan, MC; Post, WJ; Tak, PP, 2000) |
| "Leflunomide and methotrexate have proven to be efficacious in reducing joint inflammation and slowing destruction in clinical trials of patients with rheumatoid arthritis (RA)." | 9.09 | Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine ( Barg, EC; Breedveld, FC; Emery, P; Farnell, J; Kraan, MC; Reece, RJ; Rosenburg, R; Smeets, TJ; Tak, PP; Veale, DJ, 2000) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 9.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "The efficacy and safety of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA) were evaluated and the comparison with methotrexate's (MTX's) was performed in a 12-week, single-blind, randomized, parallel trial for treating 81 patients with RA." | 9.09 | A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis. ( Hu, Y; Liu, P; Tu, S, 2001) |
| "We previously reported that the new disease modifying antirheumatic drug leflunomide resulted in significant improvement in functional ability compared with placebo and sulfasalazine in a 6 month double blind, randomized, Phase III trial in rheumatoid arthritis (RA)." | 9.09 | Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. ( Jones, P; Kalden, JR; Kvien, TK; Oed, C; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Williams, BD; Williams, RB, 2001) |
| "358 patients with rheumatoid arthritis in a double blind trial were randomly allocated to receive either leflunomide 20 mg/day, placebo, or sulfasalazine 2 g/day." | 9.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Three 6-12-month, double-blind, randomized, controlled trials have shown leflunomide (LEF; 20 mg/day, loading dose 100 mg x 3 days) to be effective and safe for the treatment of rheumatoid arthritis (RA)." | 9.09 | Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. ( Caldwell, J; Cannon, GW; Cohen, S; Fox, R; Furst, D; Kaine, J; Moreland, L; Olsen, N; Schiff, M; Sharp, J; Strand, V; Weaver, A, 2001) |
| "To assess the safety and effectiveness of leflunomide versus placebo in patients with active rheumatoid arthritis (RA) treated for 6 months." | 9.08 | Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. ( Campion, G; Dimitrijevic, M; Domljan, Z; Dordevic, J; Jajic, I; Mihajlovic, D; Mladenovic, V; Popovic, M; Rozman, B; Zivkovic, M, 1995) |
| "A novel immunomodulating drug, leflunomide has been shown recently to be effective and well tolerated in patients suffering from rheumatoid arthritis (RA)." | 9.08 | Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. ( Bartlett, RR; Dimitrijevic, M, 1996) |
| " The concomitant administration of Leflunomide (LEF) with Chinese herbal medicine (CHM) provides a potential solution to preventing the adverse drug reactions (ADRs) induced by LEF during the treatment of rheumatoid arthritis (RA)." | 9.05 | The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis. ( Liu, L; Wang, W; Zhou, H, 2020) |
| "To systematically evaluate the effects of Tripterygium Glycosides Tablets alone or in combination with methotrexate(MTX) and leflunomide(LEF) on the levels of pro-inflammatory cytokines in patients or animal models with rheumatoid arthritis(RA), and to provide reference for clinical application and related basic research, this study systematically searched databases of CNKI, VIP, WanFang, PubMed, Embase and Cochrane Library, collected relevant clinical or animal experimental studies, used risk assessment tools to evaluate the quality of research, and used Revman 5." | 9.05 | [Systematic reviews of effects of Tripterygium Glycosides Tablets on pro-inflammatory factors in rheumatoid arthritis]. ( Chen, WJ; Fan, YF; Guo, MQ; Li, HZ; Li, TX; Li, YQ; Lin, N; Lyu, C; Tian, YG; Wang, JX; Wang, XY; Wu, HY; Xue, ZP; Yang, J; Zhang, YQ; Zhu, CY, 2020) |
| "We aimed to assess the relative efficacy and tolerability of monotherapy with leflunomide or tacrolimus at recommended dosages in rheumatoid arthritis (RA) patients." | 8.98 | Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. ( Bae, SC; Lee, YH, 2018) |
| "To evaluate the relative risk (RR) of pulmonary disease among patients with rheumatoid arthritis (RA) treated with leflunomide (LEF)." | 8.93 | Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. ( Carey, JJ; Conway, R; Coughlan, RJ; Low, C; O'Donnell, MJ, 2016) |
| "Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis." | 8.87 | Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011) |
| "Leflunomide (LMF) is an immunemodulatory drug used in the therapy of Rheumatoid Arthritis (RA)." | 8.85 | Pregnancy course and neonatal outcome after exposure to leflunomide--2 cases report and review of literature. ( Banas, T; Batko, B; Górnisiewicz, T; Hajdyla-Banaś, I; Pityńska-Korab, E; Rydz-Stryszowska, I; Skura, A, 2009) |
| "The efficacy and safety of the combination of leflunomide (Arava) with biological agents in treatment of rheumatoid arthritisiare presented." | 8.84 | [The efficacy and safety of the combination of leflunomide (Arava) and biological agents in treatment of rheumatoid arthritis]. ( Novak, S, 2008) |
| "To systematically review the evidence from clinical trials on the efficacy and toxicity of leflunomide for the treatment of active rheumatoid arthritis (RA)." | 8.82 | Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. ( Osiri, M; Robinson, V; Shea, B; Strand, V; Suarez-Almazor, M; Tugwell, P; Wells, G, 2003) |
| "To determine, by consensus, the optimal use of leflunomide in rheumatoid arthritis (RA), using a multidisciplinary panel of experts and performing meta-analyses of available data." | 8.82 | Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. ( Kiely, P; Kirkham, B; Lawson, T; Maddison, P; Moots, R; Proudfoot, D; Reece, R; Scott, D; Sword, R; Taggart, A; Thwaites, C; Williams, E, 2005) |
| "To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into sequential therapy, consisting of the most frequently used disease-modifying antirheumatic drugs (DMARDs), for patients with rheumatoid arthritis in specialised, i." | 8.82 | Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency. ( Brecht, JG; Gromnica-Ihle, E; Huppertz, E; Schädlich, PK; Schneider, M; Straub, C; Zeidler, H; Zink, A, 2005) |
| "An Expert Panel Meeting was held in May 2004 to assess experience with combination therapy with leflunomide and biological agents in the treatment of rheumatoid arthritis (RA), to identify both optimal use of such combinations and precautions for use." | 8.82 | Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. ( Alvaro-Gracia, JM; Antoni, C; Combe, B; Emery, P; Kalden, JR; Kremer, JM; Smolen, JS; Strand, CV; Van Riel, P, 2005) |
| "Leflunomide (Arava(trade mark), Hoescht Marion Roussel, now Aventis Pharma) is a new, oral disease modifying antirheumatic drug (DMARD) for the treatment of active rheumatoid arthritis (RA)." | 8.81 | Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. ( Alldred, A; Emery, P, 2001) |
| "Leflunomide is a new second-line drug for rheumatoid arthritis." | 8.81 | [Leflunomide in the treatment of rheumatoid arthritis]. ( Wendling, D, 2002) |
| "Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis." | 8.81 | Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. ( Harisdangkul, V; Sanders, S, 2002) |
| "Leflunomide, a novel drug with proven efficacy in rheumatoid arthritis, is an isoxazol derivative structurally unrelated to other immunomodulatory drugs." | 8.80 | Mechanism of action of leflunomide in rheumatoid arthritis. ( Fox, RI, 1998) |
| "Leflunomide is a novel isoxazol drug with disease modifying properties for the treatment of rheumatoid arthritis (RA)." | 8.80 | Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group. ( Rozman, B, 1998) |
| "Methotrexate is currently one of the most widely prescribed disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA)." | 8.80 | Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. ( Kremer, JM, 1999) |
| "Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA)." | 8.80 | Mechanism of action for leflunomide in rheumatoid arthritis. ( Fox, RI; Frangou, CG; Herrmann, ML; Kirschbaum, BJ; Morris, RE; Strand, V; Wahl, GM, 1999) |
| "A77 1726, the active metabolite of leflunomide, is an immunomodulator which inhibits cell proliferation in activated lymphocytes in patients with active rheumatoid arthritis." | 8.80 | Leflunomide: a review of its use in active rheumatoid arthritis. ( Jarvis, B; Prakash, A, 1999) |
| "Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA)." | 8.80 | Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. ( Herrmann, ML; Kirschbaum, BJ; Schleyerbach, R, 2000) |
| "Leflunomide, the newest disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA), acts by inhibiting dihydroorotate dehydrogenase, the rate-limiting enzyme in the pathway for pyrimidine production." | 8.80 | The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review. ( Schattenkirchner, M, 2000) |
| "To assess the effectiveness, safety and cost implications of leflunomide treatment for rheumatoid arthritis." | 8.80 | Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. ( Debroe, S; Hewitson, PJ; McBride, A; Milne, R, 2000) |
| "In 1999, leflunomide was introduced for the treatment of active rheumatoid arthritis." | 8.80 | [Leflunomide for active rheumatoid arthritis]. ( Andresen, PN; Hansen, G; Hørslev-Petersen, K, 2000) |
| "Leflunomide is a commonly used treatment for rheumatoid arthritis." | 8.31 | Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis? ( Aicha, BT; Hana, S; Ines, M; Issam, S; Kawther, BA; Leila, A; Leila, M; Lobna, BA; Mouna, BS; Olfa, S; Rawdha, T; Selma, B; Takoua, BB, 2023) |
| "Rheumatoid arthritis (RA) is a disease affecting around 1% of the population in developed countries and can be treated with leflunomide." | 8.31 | The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis. ( Machaj, F; Malinowski, D; Olędzka, G; Pawlik, A; Rosik, J; Safranow, K; Szostak, B; Wiechec, E, 2023) |
| "Although Leflunomide (LEF) is effective in treating rheumatoid arthritis (RA), there are still a considerable number of patients who respond poorly to LEF treatment." | 8.31 | The prognostic value of whole-genome DNA methylation in response to Leflunomide in patients with Rheumatoid Arthritis. ( Bai, B; Chen, M; Chen, Y; Dai, B; Fan, Z; Feng, X; Fu, L; Jin, L; Jin, X; Li, J; Liao, R; Liu, H; Wang, Q; Wei, T; Xin, F; Yao, Y; Zhang, J, 2023) |
| "To compare infectious risk between leflunomide versus TNF inhibitors (TNFi), and between tacrolimus versus TNFi among rheumatoid arthritis (RA) patients receiving methotrexate (MTX)." | 8.12 | Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study. ( Ha, YJ; Kang, EH; Lee, EB; Lee, JH; Lee, YJ; Shin, A, 2022) |
| "This systematic review will provide evidence to judge whether Janus kinase inhibitors is superior to leflunomide in patients with in rheumatoid arthritis." | 8.12 | Comparative efficacy and safety of JAK inhibitors and leflunomide in rheumatoid arthritis: A protocol for systematic review and meta-analysis. ( Feng, X; Liu, J; Liu, Y; Wang, Y; Wang, Z; Yang, L; Zhang, M; Zhang, X; Zhao, D, 2022) |
| "Methotrexate and leflunomide are classic treatments for rheumatoid arthritis (RA), however, which is the best choice for patients of RA is still an important question clinically, and this meta-analysis is used to systematically evaluate and compare their efficacy and safety." | 8.02 | Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis: A protocol for systematic review and meta-analysis. ( Cao, J; Li, X; Qi, W; Xia, Y, 2021) |
| "Leflunomide is a commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA)." | 8.02 | Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. ( Cleland, LG; Hill, C; Hopkins, AM; King, C; Lee, A; McWilliams, L; Metcalf, R; Proudman, SM; Spargo, L; Wechalekar, MD; Wiese, MD, 2021) |
| "Leflunomide is a disease-modifying antirheumatic drug used in therapy for rheumatoid arthritis (RA)." | 8.02 | Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis. ( Dziedziejko, V; Malinowski, D; Paradowska-Gorycka, A; Pawlik, A; Safranow, K; Łączna, M, 2021) |
| " Leflunomide is an anti-inflammatory drug primarily used for treating rheumatoid arthritis (RA)." | 7.96 | A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. ( Hu, J; Liu, X; Peng, D; Prinz, RA; Sun, J; Wang, C; Wang, J; Xu, X, 2020) |
| "Leflunomide is a disease-modifying anti-rheumatic drug (DMARD) used in the management of rheumatoid arthritis (RA) and psoriatic arthritis." | 7.91 | Reversible alopecia areata: a little known side effect of leflunomide. ( Cusnir, I; Hall, J; Koller, G; Ye, C, 2019) |
| "Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide." | 7.88 | Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018) |
| "Rituximab is a biologic agent approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate (MTX) or leflunomide (LEF)." | 7.85 | [SUSTAINABILITY OF RITUXIMAB IN CONCOMMITANT TREATMENT WITH METHOTREXATE OR LEFLUNOMIDE IN PATIENTS WITH RHEUMATOID ARTHRITIS]. ( Boulman, N; Kaly, L; Odeh, M; Raitter, R; Rimer, D; Rosner, I; Rozenbaum, M; Slobodin, G, 2017) |
| "Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster (HZ), and the risk appears to be increased in patients treated with tofacitinib." | 7.85 | Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. ( Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K, 2017) |
| "These results demonstrate that topically applied leflunomide can be delivered effectively and deposited as teriflunomide in an arthritic joint, possibly allowing better compliance in rheumatoid arthritis patients by avoiding leflunomide's side effects." | 7.83 | Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. ( Bae, J; Park, JW, 2016) |
| "Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity." | 7.83 | Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. ( Foster, DJ; Hopkins, AM; O'Doherty, CE; Proudman, SM; Upton, RN; Wiese, MD, 2016) |
| " This study evaluated the cost-effectiveness of a treatment strategy initiated with etanercept (ETN) compared with leflunomide (LFN) after a 30% reduction in the medication cost of ETN in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX-IR)." | 7.83 | Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. ( Jeong, JH; Lee, EK; Lee, MY; Park, JH; Park, SH; Park, SK, 2016) |
| "We retrospectively investigated the inhibitory effect on radiographic joint damage (RJD) for non-biological disease-modifying antirheumatic drug (non-bioDMARD) monotherapy or methotrexate (MTX) combination therapy for rheumatoid arthritis (RA) in the disease activity score with 28 joint counts with erythrocyte sedimentation rate (DAS28) remission." | 7.81 | Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. ( Baba, H; Fukai, R; Ito, H; Katayama, K; Okubo, T; Sato, T, 2015) |
| "The association between serum uric acid concentrations and inflammation in patients with rheumatoid arthritis (RA) has been still controversial." | 7.81 | Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. ( Choe, JY; Kim, SK, 2015) |
| "Leflunomide is an immunosuppressant drug used in rheumatoid arthritis and psoriatic arthritis." | 7.81 | [Pleuro-pericarditis developed under a leflunomide therapy]. ( Figueredo, M; Ribière, J; Tarhini, A; Vandenbos, F, 2015) |
| "Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment." | 7.81 | Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015) |
| " This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting." | 7.81 | Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Corominas, H; de la Serna, AR; Díaz-Torné, C; Hernández, MV; Llobet, JM; Magallares, B; Narváez, J; Nolla, JM; Reina, D; Sanmartí, R, 2015) |
| "The aim of this work was to clarify the effect of leflunomide (LEF) on the eye dryness in patients with secondary Sjögren's syndrome associated with rheumatoid arthritis (RA-sSS) and in patients with rheumatoid arthritis (RA)." | 7.80 | The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients. ( El-Agha, S; El-Azkalany, GS; Shahin, AA, 2014) |
| "Leflunomide (LEF) is an isoxazole derivative used as disease-modifying anti-rheumatic drug (DMARD) in the treatment of rheumatoid arthritis (RA)." | 7.80 | [Acute interstitial pneumonia in patient with rheumatoid arthritis treated with leflunomide]. ( Bartosiewicz, M; Bartoszuk, I; Jakubowska, L; Kuś, J; Siemion-Szcześniak, I; Wesołowski, S, 2014) |
| "The aims of this study were to describe the rate of leflunomide discontinuation in rheumatoid arthritis (RA) patients, in standard clinical practice, and to analyse which factors could influence this rate, paying particular attention to the concomitant treatment with other disease-modifying anti-rheumatic drugs (DMARDs)." | 7.79 | Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. ( Abásolo, L; Fernández-Gutierrez, B; Fontsere, O; Jover-Jover, JA; León, L; Peña-Blanco, RC; Rodriguez-Rodriguez, L, 2013) |
| "The study included 105 patients with rheumatoid arthritis who were treated with methotrexate, leflunomide, hydroxychloroquine and biological drugs." | 7.79 | Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. ( Nardi, AE; Ornelas, AC; Pinho de Oliveira Ribeiro, N; Pinho de Oliveira, CM; Rafael de Mello Schier, A; Silva, AC, 2013) |
| "A 78-year-old woman diagnosed with rheumatoid arthritis without a history of skin tumors or immunosuppressive medication, started treatment with leflunomide." | 7.79 | Multiple eruptive keratoacanthomas associated with leflunomide. ( Bouret, AM; Frances, L; Guijarro, J; Leiva-Salinas, Mdel C; Marin, I, 2013) |
| "To determine the risk of severe infection requiring or complicating hospitalization associated with leflunomide therapy in patients with rheumatoid arthritis (RA)." | 7.79 | Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. ( Jeon, HS; Jun, JB; Yoo, HG; Yoo, WH; Yu, HM, 2013) |
| " We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease." | 7.79 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ( Bergner, R; Löffler, C; Peters, L; Schmitt, V, 2013) |
| "To assess the safety of treating patients with rheumatoid arthritis with a combination of methotrexate (MTX) and leflunomide (LEF) in comparison to MTX monotherapy, in clinical practice." | 7.79 | The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. ( Arnold, M; Bird, P; Burnet, S; de Jager, J; Griffiths, H; Littlejohn, G; Nicholls, D; Roberts, L; Scott, J; Tymms, K; Zochling, J, 2013) |
| " A careful anamnesis revealed that the patient had been taking leflunomide for rheumatoid arthritis for the last 10 years, and this was suspected to be the cause of the cough." | 7.79 | Leflunomide-induced chronic cough in a rheumatoid arthritis patient with pulmonary tuberculosis. ( Jaiswal, AK; Mishra, AK; Verma, SK, 2013) |
| "The recommendations of the European League Against Rheumatism (EULAR) for the management of rheumatoid arthritis (RA) suggest a different therapeutic approach to methotrexate (MTX) resistance according to the presence or absence of poor prognostic factors." | 7.78 | Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. ( Berberidis, C; Kapetanos, GA; Sakellariou, GT; Sayegh, FE, 2012) |
| "Leflunomide, a disease-modifying antirheumatic drug, has been shown to be effective in the management of rheumatoid arthritis (RA)." | 7.78 | Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. ( Alvarez, PA; Blanco, MV; Flagel, S; Mazzocchi, O; Saad, AK, 2012) |
| "Leflunomide is a disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis." | 7.78 | Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. ( Cleland, LG; James, M; O'Doherty, C; Proudman, SM; Schnabl, M; Spargo, L; Wiese, MD, 2012) |
| " Herein, we present a case of a 47-year-old female patient who developed Tjalma syndrome after administration of leflunomide for rheumatoid arthritis." | 7.77 | Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy. ( Bes, C; Soy, M, 2011) |
| "Leflunomide is the drug used in the therapy for rheumatoid arthritis (RA)." | 7.77 | The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. ( Chlubek, D; Dziedziejko, V; Kurzawski, M; Pawlik, A; Safranow, K, 2011) |
| "To compare the effectiveness and safety of a combination of rituximab (RTX) with either methotrexate (MTX) or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and inadequate response to anti-tumor necrosis factor agents or traditional disease-modifying antirheumatic drugs (DMARD) in a real-world setting." | 7.77 | Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Díaz-López, C; Díaz-Torné, C; Hernández, MV; Narváez, J; Nolla, JM; Rodriguez de la Serna, A; Ros, S; Ruiz, JM; Sanmartí, R; Torrente-Segarra, V, 2011) |
| " In patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), the incidence of elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST) enzymes associated with methotrexate (MTX), leflunomide (LEF) and MTX+LEF versus other DMARDs was examined." | 7.76 | Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. ( Beukelman, T; Cassell, S; Curtis, JR; Greenberg, JD; Kavanaugh, A; Kremer, JM; Onofrei, A; Reed, G; Strand, V, 2010) |
| "Sixty-four pregnant women with rheumatoid arthritis (RA) who were treated with leflunomide during pregnancy (95." | 7.76 | Birth outcomes in women who have taken leflunomide during pregnancy. ( Braddock, SR; Chambers, CD; Jin, S; Johnson, DL; Jones, KL; Lopez-Jimenez, J; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2010) |
| "The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA)." | 7.76 | Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. ( Bonassi, S; Cutolo, M; Gallo, F; Montagna, P; Moretti, S; Paolino, S; Pizzorni, C; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B, 2010) |
| "The aim of the present study was to evaluate the effect of long-term leflunomide and methotrexate (MTX) therapy during the course of rheumatoid arthritis (RA) estimated by digital X-ray radiogrammetry (DXR) and computer-aided joint space analysis (CAJSA) as diagnostic tools for the quantification of disease-related periarticular osteoporosis and joint space narrowing." | 7.75 | Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. ( Böttcher, J; Eidner, T; Hansch, A; Hein, G; Kaiser, WA; Lehmann, G; Lippold, J; Oelzner, P; Pfeil, A; Renz, DM; Wolf, G, 2009) |
| "This preliminary study focuses on early peripheral cellular immune changes after 1 month therapy with leflunomide, in 18 patients with severe rheumatoid arthritis, previously treated with methotrexate." | 7.75 | Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one month therapy with leflunomide. ( Codreanu, C; Constantin, C; Manda, G; Neagoe, I; Neagu, M, 2009) |
| "To determine whether multidrug-resistance efflux transporters are expressed on immune effector cells in synovial tissue from patients with rheumatoid arthritis (RA) and compromise the efficacy of methotrexate (MTX) and leflunomide (LEF)." | 7.75 | Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. ( Assaraf, YG; Dijkmans, BA; Jansen, G; Kraan, MC; Lems, WF; Oerlemans, R; Scheffer, GL; Scheper, RJ; Tak, PP; van der Heijden, JW; van der Laken, CJ, 2009) |
| " We treated a patient who developed polymyositis (PM) following the treatment of RA with leflunomide." | 7.75 | Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. ( Nagashima, M; Ochi, S; Taniguchi, K, 2009) |
| "Leflunomide is a disease-modifying antirheumatic drug used for the treatment of rheumatoid arthritis (RA)." | 7.75 | Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. ( Bohanec Grabar, P; Dolzan, V; Grabnar, I; Logar, D; Mrhar, A; Peterlin Masic, L; Rozman, B; Suput, D; Tomsic, M; Trdan, T, 2009) |
| "We retrospectively compared treatment impact with leflunomide (LEF) or methotrexate (MTX) on retarding joint damage and clinical symptom including a 28-joint-count Disease Activity Score/erythrocyte sedimentation rate (DAS28-ESR) between two similar groups in patients with rheumatoid arthritis (RA) over an approximately 3-year treatment." | 7.75 | Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. ( Katayama, K; Matsuno, T, 2009) |
| "Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA)." | 7.75 | The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. ( Dehler, S; Finckh, A; Gabay, C, 2009) |
| " She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | 7.74 | [Persistent diarrhea and loss of weight during therapy with leflunomide]. ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "Leflunomide is an immunomodulating agent with proven efficacy in rheumatoid arthritis." | 7.74 | Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. ( Baaj, M; El Haouri, M; Hadri, L; Hassikou, H; Safi, S; Tabache, F, 2008) |
| "to assess the security of the combined treatment with Methotrexate (MTX) and Leflunomide (LF) in patients with Rheumatoid Arthritis (RA) and to evaluate whether the dose and route of MTX administration influence on the toxicity." | 7.74 | [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis]. ( Alba, P; Albiero, E; Babini, A; Exeni, I; Gobbi, C; Nesa, L, 2007) |
| "A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX)." | 7.74 | Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. ( Blanco, LP; Castro, JS; Chirinos, E; Esteva, MH; González, M; Granados, Y; Macgregor, EG; Marín, F; Mundaraín, L; Rodríguez, MA; Rosas, A; Sánchez, G; Sanoja, G; Snih, SA; Tristano, A; Zambrano-Marín, G, 2007) |
| "A female rheumatoid arthritis patient was admitted for productive cough and general fatigue that had gradually developed after leflunomide therapy." | 7.74 | Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. ( Kingetsu, I; Kurosaka, D; Toyokawa, Y; Yamada, A; Yasuda, C; Yasuda, J; Yoshida, K, 2007) |
| "To determine the prevalence of severe infections in patients with rheumatoid arthritis (RA) prescribed leflunomide in North Canterbury, New Zealand." | 7.74 | Leflunomide-associated infections in rheumatoid arthritis. ( Chapman, PT; Jenks, KA; O'Donnell, JL; Savage, RL; Stamp, LK, 2007) |
| "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide." | 7.74 | Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis. ( Carloni, A; Giannakakis, K; Nori, G; Piciucchi, S; Poletti, V; Zobel, BB, 2008) |
| "Leflunomide is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA)." | 7.74 | Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. ( Bohanec Grabar, P; Dolzan, V; Logar, D; Rozman, B; Suput, D; Tomsic, M, 2008) |
| "Outpatients with rheumatoid arthritis on a stable leflunomide dose for >4 months were included." | 7.73 | Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. ( Brouwers, JR; Houtman, PM; Jansen, TL; Janssen, M; Keuper, R; van de Laar, MA; van Roon, EN; Yska, JP, 2005) |
| "Diarrhoea and weight loss are frequently reported adverse events in rheumatoid arthritis (RA) patients receiving the disease-modifying antirheumatic drug (DMARD) leflunomide." | 7.73 | Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. ( Vandooren, AK; Verschueren, P; Westhovens, R, 2005) |
| "To investigate the influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in rheumatoid arthritis (RA) and to compare it to infliximab in combination with other disease-modifying anti-rheumatic drugs." | 7.73 | The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. ( Creemers, MC; Flendrie, M; van Riel, PL; Welsing, PM, 2005) |
| "We report the case of a leg ulcer in a rheumatoid arthritis (RA) patient under treatment with leflunomide, discuss the influence of the drug on the aetiopathogenesis of the ulcer and describe its successful treatment." | 7.73 | Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. ( Dissemond, J; Goos, M; Knab, J, 2005) |
| "To determine whether improvements in physical function and health related quality of life (HRQOL) are sustained over 2 years of blinded treatment with leflunomide (LEF), methotrexate (MTX), or sulfasalazine (SSZ) in patients with active rheumatoid arthritis (RA)." | 7.73 | Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. ( Cannon, GW; Crawford, B; Emery, P; Kalden, JR; Scott, DL; Smolen, JS; Strand, V; Tugwell, P, 2005) |
| "To investigate the concentration-effect relationship and pharmacokinetics of leflunomide in patients with rheumatoid arthritis (RA)." | 7.73 | Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. ( Chan, V; Charles, BG; Tett, SE, 2005) |
| "To determine factors predictive for leflunomide drug survival in an outpatient population with rheumatoid arthritis in a setting of care-as-usual." | 7.73 | Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. ( Bernelot Moens, HJ; Brouwers, JR; Hoekstra, M; Jansen, TL; Tobi, H; van de Laar, MA; van Roon, EN, 2005) |
| "To investigate the anti-inflammatory effects of the active leflunomide metabolite A771726 (Lef-M) in combination with methotrexate (MTX) on synovial macrophages (SM) from rheumatoid arthritis (RA) patients co-cultured with an activated T cell line (Jurkat cell line)." | 7.73 | Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. ( Capellino, S; Cutolo, M; Montagna, P; Seriolo, B; Sulli, A; Villaggio, B, 2006) |
| "After adjustment for covariates, prednisone use increased the risk of pneumonia hospitalization (hazard ratio [HR] 1." | 7.73 | Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. ( Caplan, L; Michaud, K; Wolfe, F, 2006) |
| "Leflunomide is a disease-modifying antirheumatic drug for the treatment of active rheumatoid arthritis and psoriatic arthritis." | 7.73 | [Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis]. ( Jakob, A; Porstmann, R; Rompel, R, 2006) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | 7.73 | Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "To study the immunosuppressive and anti-inflammatory effects of combined leflunomide and methotrexate (MTX) therapy on chemokine expression in patients with rheumatoid arthritis (RA), nine patients were enrolled for the combination therapy for 24 weeks." | 7.72 | Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. ( Ho, CY; Lam, CW; Li, EK; Tam, LS; Wong, CK, 2003) |
| "Since November 1999, leflunomide (LEF), an innovative disease-modifying antirheumatic drug (DMARD), is available in Germany for treatment of rheumatoid arthritis (RA)." | 7.72 | [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]. ( Brecht, JG; Gromnica-Ihle, E; Huppertz, E; Schädlich, PK; Schneider, M; Straub, C; Zeidler, H; Zink, A, 2004) |
| "This is the first description of the development of rheumatoid nodules in 3 rheumatoid arthritis patients following leflunomide therapy." | 7.72 | [Development and/or increase of rheumatoid nodules in RA patients following leflunomide therapy]. ( Becker-Capeller, D; Braun, MG; Van Rhee, R, 2004) |
| "To report the safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) for the treatment of rheumatoid arthritis." | 7.72 | The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. ( Cohen, S; Cooley, DA; Cush, J; Genovese, M; Hansen, KE; Patel, SR; Schiff, M; Singhal, A; Sundaramurthy, S, 2004) |
| "We prospectively studied the efficacy, incidence of adverse drug reactions and withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting of care-as-usual." | 7.72 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. ( Brouwers, JR; Bruyn, GA; Griep, EN; Houtman, PM; Jansen, TL; Mourad, L; Tobi, H; Van Roon, EN; Wilffert, B, 2004) |
| " We report the first known case of leflunomide-induced aseptic meningitis, in a patient with rheumatoid arthritis." | 7.72 | Leflunomide-induced aseptic meningitis. ( Cohen, JD; Jorgensen, C; Sany, J, 2004) |
| "To assess leflunomide efficacy and tolerance in patients with rheumatoid arthritis (RA) during the first four months of the treatment." | 7.72 | [Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide]. ( Balabanova, RM; Chichasova, NV; Goriachev, DV; Loginova, TK; Makolkin, VI; Men'shikova, IV; Oliunin, IuA; Petukhova, NV; Riabkova, AA; Shostak, NA, 2004) |
| "We prospectively studied the efficacy, incidence of adverse drug reactions and withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting of care-as-usual." | 7.72 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. ( Brouwers, JR; Bruyn, GA; Griep, EN; Houtman, PM; Jansen, TL; Mourad, L; Tobi, H; Van Roon, EN; Wilffert, B, 2004) |
| "Vasculitis as a complication of leflunomide therapy in the treatment of rheumatoid arthritis has been reported." | 7.72 | Vasculitis associated with the use of leflunomide. ( Gan, BS; Harth, M; Lazarescu, A; Macdonald, J; Zhong, T, 2004) |
| "A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide." | 7.72 | Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004) |
| "To explore the feasibility of prospectively monitoring treatment efficacy and tolerability of infliximab, etanercept, and leflunomide over a two year period in patients with established rheumatoid arthritis (RA) in clinical practice using a structured protocol." | 7.71 | Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. ( Crnkic, M; Geborek, P; Petersson, IF; Saxne, T, 2002) |
| "To estimate, from a public payer's perspective, the 5-year cost effectiveness of adding leflunomide (LEF) to a sequence of disease-modifying antirheumatic drugs (DMARDs) representative of a typical rheumatoid arthritis (RA) management approach adopted by Canadian rheumatologists." | 7.71 | Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. ( Bombardier, C; Maetzel, A; Strand, V; Tugwell, P; Wells, G, 2002) |
| "To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center." | 7.71 | Leflunomide-associated weight loss in rheumatoid arthritis. ( Coblyn, JS; Helfgott, S; Shadick, N, 2001) |
| "To identify differences in rheumatoid arthritis (RA) care costs and utilization among patients receiving therapy with leflunomide (LEF) or etanercept (ETA)." | 7.71 | Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. ( Cummins, G; Doyle, J; McLaughlin, T; Yazdani, C, 2001) |
| "To compare the impact of leflunomide on resource utilization and costs relative to that of etanercept and infliximab among patients with rheumatoid arthritis (RA) in a managed care setting." | 7.71 | Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. ( Doyle, J; Huse, DM; Ollendorf, DA; Peterson, AN, 2002) |
| "To report a case of skin ulceration as a result of treatment with leflunomide for rheumatoid arthritis." | 7.71 | Leflunomide-associated skin ulceration. ( McCoy, CM, 2002) |
| "New treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis (RA) have become available." | 7.71 | A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2002) |
| "Leflunomide is a novel drug recently introduced for treatment of rheumatoid arthritis as a DMARD (disease-modifying antirheumatic drug)." | 7.70 | Severe pancytopenia after leflunomide in rheumatoid arthritis. ( Allinger, S; Auer, J; Hinterreiter, M; Kirchgatterer, A; Knoflach, P, 2000) |
| "Leflunomide, the newest disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis (RA), inhibits de novo pyrimidine biosynthesis." | 7.70 | Efficacy and safety of leflunomide in active rheumatoid arthritis. ( Emery, P; Smolen, JS, 2000) |
| " Serious adverse events were similar." | 6.84 | Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. ( de Silva, R; Fernandopulle, R; Galappatthy, P; Hart, M; Kelleher, P; Saravanamuttu, U; Senerath, U; Seneviratne, SL; Udagama, P; Weerasekera, LP; Wijayaratne, LS; Wijesinghe, H, 2017) |
| " Adverse events occurred in 53." | 6.78 | Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. ( Bolosiu, H; Cutolo, M; Perdriset, G, 2013) |
| "Leflunomide was clinically efficacious in this group of long standing resistant RA in an open study "real life" design." | 6.72 | The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. ( Caspi, D; Elkayam, O; Kaufman, I; Levartovsky, D; Litinsky, I; Paran, D; Wigler, I; Yaron, I; Yaron, M, 2006) |
| " All adverse events were documented." | 6.71 | Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. ( Brin, S; de la Serna, R; Dougados, M; Emery, P; Lemmel, EM; van Riel, P; Zerbini, CA, 2003) |
| "Leflunomide was administered at a dos of 20mg/day following a loading dose of 100mg/day for three days." | 6.71 | [Leflunomide in the treatment of rheumatoid arthritis]. ( Ben Amor, G; Ben Miled, M; Ben Rhouma, S; Boussema, F; Chérif, O; Daoud, L; Kochbati, S; Ktari, S; Rokbani, L, 2005) |
| "Leflunomide treatment was associated with a significantly greater improvement in IRE compared with methotrexate treatment (P < 0." | 6.70 | Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. ( Breedveld, FC; Emery, P; Gibbon, WW; Kraan, MC; O'Connor, PJ; Radjenovic, A; Reece, RJ; Ridgway, JP; Tak, PP; Veale, DJ, 2002) |
| "Leflunomide was well tolerated." | 6.69 | Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. ( Smolen, JS, 1999) |
| "Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA." | 6.53 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016) |
| "Rheumatoid arthritis is a chronic, highly disabling autoimmune disease that requires aggressive pharmacological treatment using immunomodulatory drugs grouped under the name of Disease-Modifying Anti-rheumatic Drugs (DMARDs)." | 6.52 | [Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review]. ( Molina Molina, MI; Pinochet Paiva, CM; Quezada Morales, JI, 2015) |
| "Leflunomide is a prodrug which is rapidly converted following oral administration and absorption to an active metabolite with anti-proliferative effects (A77 1726/teriflunomide)." | 6.49 | Safety evaluation of leflunomide in rheumatoid arthritis. ( Conaghan, PG; Keen, HI; Tett, SE, 2013) |
| "Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate." | 6.45 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "Leflunomide is an agent that affects the inflammatory process, particularly in RA." | 6.42 | Leflunomide in the treatment of rheumatoid arthritis. ( Li, EK; Tam, LS; Tomlinson, B, 2004) |
| "Leflunomide has been shown to be equal to or less efficacious than methotrexate, and may be beneficial as a second-line disease-modifying antirheumatic drug (DMARD)." | 6.41 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. ( Chong, BS; Lowder, DM; Luong, BT, 2000) |
| "Leflunomide is a selective inhibitor of de novo pyrimidine synthesis." | 6.41 | Leflunomide: mode of action in the treatment of rheumatoid arthritis. ( Breedveld, FC; Dayer, JM, 2000) |
| "Leflunomide has exerted inhibitory activity in animal models of RA." | 6.40 | Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. ( Goldenberg, MM, 1999) |
| "Leflunomide is a commonly used disease modifying antirheumatic agent." | 5.91 | Leflunomide exposure through second trimester of pregnancy: A case report. ( Alothman, R; Amiri, N; Lepik, C; Waterman, E; Yeung, J, 2023) |
| "To compare efficacy and safety of two different combination csDMARD therapy in Methotrexate-failed Rheumatoid arthritis patients." | 5.51 | Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. ( Belani, PJ; Kavadichanda, CG; Negi, VS, 2022) |
| "The present work is aimed at exploring the clinical efficacy and safety of methotrexate (MTX) and leflunomide (LEF) combination therapy for rheumatoid arthritis." | 5.51 | Combination of Methotrexate and Leflunomide Is Efficient and Safe for 60 Patients with Rheumatoid Arthritis. ( Chen, F; Du, H; He, S; Wang, L; Wang, Y, 2022) |
| "Leflunomide was stopped and restarted 5 months after the initial diagnosis at the same dosage, with a close clinical and laboratory follow-up." | 5.51 | Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. ( Carubbi, F; Cipriani, P; Di Bartolomeo, S; Giacomelli, R; Grimaldi, A; Marola, L; Picchi, G; Ricciardi, A, 2019) |
| "Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased." | 5.48 | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. ( Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC, 2018) |
| "Rheumatoid arthritis is a chronic disease of the joints, which causes joint pain and disability." | 5.48 | Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis. ( Colares, VLP; Fernandes, AMR; Fernandes, ES; Martins, MMRS; Mendes, SJF; Monteiro, CRAV; Muniz, TF; Pereira, DMS; Pereira, ICP; Silva, BLR; Sousa, NCF, 2018) |
| " Of the responders, 12% had used doses above 20 mg daily and 70% had used alternate daily dosing with leflunomide." | 5.46 | Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. ( Hopkins, AM; O'Doherty, CE; Proudman, SM; Wiese, MD, 2017) |
| "The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach." | 5.42 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. ( Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015) |
| "Leflunomide (LFN) is a disease modifying anti-rheumatic drugs (DMARDs) which acts by inhibiting the synthesis of pyrimidines." | 5.39 | Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. ( Murdaca, G; Puppo, F; Spanò, F, 2013) |
| "Leflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab." | 5.38 | Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. ( Chatzidionysiou, K; Gabay, C; Gomez-Reino, J; Hetland, ML; Kvien, TK; Lie, E; Lukina, G; Nasonov, E; Nordström, DC; Pavelka, K; Tarp, U; Tomsic, M; van Riel, PL; van Vollenhoven, RF, 2012) |
| "We identified silent liver fibrosis in patients with rheumatoid arthritis (RA) using transient elastography, and investigated medication that correlated with abnormal liver stiffness measurement (LSM) values." | 5.38 | Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. ( Han, KH; Kim, BK; Kim, SU; Lee, SK; Lee, SW; Park, HJ; Park, YB, 2012) |
| " The most significant adverse event was elevation of transaminases in eight patients (26%)." | 5.38 | Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. ( Cubidez, MF; Guzman, C; Londono, J; Santos, AM; Santos, PI; Valle-Oñate, R, 2012) |
| "In 12 patients, lung injury developed even 2 months after leflunomide withdrawal." | 5.35 | Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Ohtsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2008) |
| "Leflunomide is an isoxazole derivative structurally and functionally unrelated to other known immunomodulatory drugs." | 5.35 | The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. ( Drozdzik, M; Dziedziejko, V; Herczynska, M; Kurzawski, M; Pawlik, A; Safranow, K, 2009) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 5.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| "Rheumatoid nodules are well established manifestations of rheumatoid arthritis but in the lungs they are very rare according to the literature." | 5.35 | Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. ( Csiki, Z; Horvath, IF; Szanto, A; Szodoray, P; Zeher, M, 2008) |
| "To evaluate the cost-effectiveness of treat-to-target strategies among recently diagnosed patients with rheumatoid arthritis (RA) using methotrexate (MTX) and a step-down glucocorticoid (GC) scheme (COBRA Slim) compared with (1) this combination with either sulphasalazine (COBRA Classic) or leflunomide (COBRA Avant-Garde) in high-risk patients and (2) MTX without GCs (Tight-Step-Up, TSU) in low-risk patients." | 5.34 | Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. ( Boonen, A; De Cock, D; Joly, J; Pazmino, S; Stouten, V; Van der Elst, K; Verschueren, P; Westhovens, R, 2020) |
| "Leflunomide (LEF) is a conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of rheumatoid arthritis." | 5.34 | Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study. ( Deng, D; Li, M; Li, S; Tian, L; Wang, T; Wu, J; Yang, J; Zeng, F; Zhou, J; Zou, J, 2020) |
| "The leflunomide was stopped, and sultamicillin (IV 4x2 g/day) was started for a further 6 weeks." | 5.33 | Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report. ( Bilgici, A; Celenk, C; Kuru, O; Ulusoy, H, 2005) |
| "Leflunomide is an effective disease modifying antirheumatic drug (DMARD) in RA." | 5.33 | Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. ( Beneytout, JL; Bertin, P; Léger, DY; Liagre, B; Trèves, R; Vergne-Salle, P, 2005) |
| "Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been available in Japan since August 2003." | 5.33 | Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. ( Hirabayashi, Y; Kobayashi, N; Kudo, K; Shimizu, H, 2006) |
| "Current dosing strategies should be re-evaluated, and coping strategies for common AEs should be investigated." | 5.32 | Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. ( Aletaha, D; Eberl, G; Grisar, J; Kapral, T; Machold, KP; Smolen, JS; Stamm, T, 2003) |
| "Leflunomide is an antirheumatic agent of the type of a 'disease-modifying antirheumatic drug'." | 5.32 | Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. ( Barta, U; Bauer, HI; Elsner, P; Fischer, TW; Graefe, T, 2003) |
| "Leflunomide is a new and effective disease-modifying antirheumatic drug." | 5.31 | Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. ( Koren, G; Kozer, E; Moretti, ME, 2001) |
| "To determine the frequency of new-onset hypertension in patients with Rheumatoid arthritis taking leflunomide, in comparison with methotrexate in Asian setting." | 5.30 | Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg. ( Ishaq, M; Kumar, A; Muhammad, JS; Razzaque, S; Shohail, F, 2019) |
| "To investigate the efficacy and safety of tacrolimus (TAC) versus leflunomide (LEF) when combined with methotrexate (MTX) in rheumatoid arthritis (RA) patients." | 5.30 | Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. ( Baek, HJ; Cha, HS; Choi, IA; Jun, JB; Kang, SW; Kang, YM; Lee, YJ; Park, SH; Shin, K; Song, YW, 2019) |
| "Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA." | 5.30 | Leflunomide for the treatment of rheumatoid arthritis. ( Kremer, JM; Olsen, NJ; Strand, V, 1999) |
| "The objective of this study is to investigate whether the addition of double-filtration plasmapheresis (DFPP) to leflunomide and methotrexate repairs MRI bone erosion in patients with long-standing rheumatoid arthritis (RA)." | 5.27 | MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. ( Lan, G; Lu, W; Sun, F; Wang, L; Xu, P; Yu, X; Zhang, L, 2018) |
| "The aim of this study was to determine the efficacy and safety of a weekly dose of leflunomide (50 mg/week) in early rheumatoid arthritis patients with mild or moderate disease activity." | 5.22 | Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. ( Bi, LQ; Chen, LN; Fang, YF; Gu, F; Guo, JL; Hao, YJ; Li, R; Li, XF; Li, ZG; Liu, HX; Liu, XY; Luo, Y; Mei, YF; Ren, LM; Su, Y; Sun, LY; Zhang, ZL; Zhang, ZY; Zhao, JX; Zhu, P, 2016) |
| " High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7." | 5.20 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. ( Corluy, L; De Brabanter, G; De Cock, D; Durnez, A; Geens, E; Geusens, P; Joly, J; Joos, R; Langenaken, C; Lenaerts, J; Meyfroidt, S; Raeman, F; Ravelingien, I; Remans, J; Sileghem, A; Taelman, V; Van der Elst, K; Van Essche, E; Vander Cruyssen, B; Vandevyvere, K; Vanhoof, J; Verschueren, P; Westhovens, R, 2015) |
| " Methotrexate (MTX) and Leflunomide (LEF) combination has a better efficacy in the treatment of active rheumatoid arthritis (RA), but hepatotoxicity was observed." | 5.20 | Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. ( Chen, Z; Li, XM; Li, XP; Li, ZG; Su, Y; Xiang, N; Yang, M; Zhang, MJ; Zhao, DB; Zhu, P; Zuo, XX, 2015) |
| "To evaluate the clinical efficacy and safety of Huayu Tongbi Recipe (HTR) combined methotrexate (MTX) in treating refractory rheumatoid arthritis (RRA)." | 5.20 | [Treatment of Refractory Rheumatoid Arthritis by Huayu Tongbi Recipe Combined Methotrexate]. ( Chen, XM; Chu, YL; Huang, QC; Huang, RY; Liu, ZH; Yan, JY, 2015) |
| "Combination use of methotrexate (MTX) and leflunomide (LEF) has been proved effective in the treatment of active rheumatoid arthritis (RA)." | 5.17 | Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. ( Chen, Z; Li, XM; Li, XP; Li, ZJ; Xu, L, 2013) |
| "To study whether the effects of Leflunomide were different in treating patients with rheumatoid arthritis (RA) of different Chinese medical syndrome patterns." | 5.17 | [Effects of leflunomide in treating patients with rheumatoid arthritis of different Chinese medical syndrome patterns]. ( Li, WQ; Wang, ZM; Wu, Y, 2013) |
| "Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones." | 5.16 | Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide. ( Chlubek, D; Dziedziejko, V; Kurzawski, M; Ossowski, A; Parafiniuk, M; Pawlik, A; Piatek, J; Safranow, K, 2012) |
| "To evaluate the effects of double filtration plasmapheresis (DFPP) in combination with leflunomide and methotrexate (MTX) on magnetic resonance imaging (MRI)-detected inflammatory changes (synovitis and bone edema) in patients with early rheumatoid arthritis (RA) with high disease activity." | 5.16 | Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. ( Lan, G; Liu, J; Lu, W; Ping, L; Tian, J; Wang, L; Wang, X; Xu, P; Yu, X, 2012) |
| "In order to compare the efficacy and toxicity of methotrexate and leflunomide for the treatment of rheumatoid arthritis, a double-blind randomized clinical trial was carried out at the Department of Medicine, Jinnah Medical College Hospital, Korangi, Karachi." | 5.15 | Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. ( Hameed, K; Ishaq, M; Mirza, AI; Muhammad, JS, 2011) |
| "Leflunomide is a disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis (RA)." | 5.15 | Leflunomide in Pakistani patients with rheumatoid arthritis: prospective study in daily rheumatology practice. ( Ahmad, NM; Farman, S; Ghafoor, E; Hameed, R; Saeed, MA; Umair, M, 2011) |
| "We undertook this study to evaluate the effects of leflunomide, an oral pyrimidine synthesis inhibitor, on the serum chemokine levels in patients with active rheumatoid arthritis (RA) who were refractory to treatment with methotrexate (MTX) or did not tolerated MTX treatment." | 5.14 | The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. ( Chwiecko, J; Kita, J; Klimiuk, PA; Sierakowski, S, 2009) |
| "Adults with a clinical diagnosis of rheumatoid arthritis or psoriatic arthritis who were referred to the nursing team for counselling about starting on methotrexate, sulfasalazine or leflunomide were included." | 5.14 | Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. ( Homer, D; Jobanputra, P; Nightingale, P, 2009) |
| "To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha combination therapy in a group of patients with active rheumatoid arthritis (RA)." | 5.14 | Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. ( Baldi, C; De Stefano, R; Frati, E; Galeazzi, M; Hammoud, M; Menza, L; Nargi, F, 2010) |
| "Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce." | 5.14 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. ( Bornholdt, K; Hein, G; Kellner, H, 2010) |
| "To analyse the effects of leflunomide and methotrexate treatment on matrix metalloproteinase (MMP) activity levels in alpha2 macroglobulin/MMP (alpha2M/MMP) complexes in the systemic circulation of rheumatoid arthritis (RA) patients." | 5.13 | Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients. ( DeGroot, J; Hanemaaijer, R; Huizinga, TW; Kraan, MC; Tchetverikov, I; van El, B, 2008) |
| "Several drug trials, predominantly of Caucasian patients, have demonstrated the therapeutic role of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA)." | 5.13 | Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment. ( Chopra, A; Lagu-Joshi, V; Saluja, M; Sarmukadam, S, 2008) |
| "The objective of this study was to assess the efficacy and tolerability of a combination of leflunomide (LEF) and chloroquin (ChL) in patients with rheumatoid arthritis (RA)." | 5.12 | Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study. ( Andel, I; Leeb, BF; Rintelen, B; Sautner, J, 2006) |
| "This study assessed the efficacy and safety of combination (COMB) of cyclosporine (CSA) and leflunomide (LEF) versus each drug alone, in the treatment of severe rheumatoid arthritis (RA)." | 5.12 | Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. ( Andrianakos, A; Antoniades, C; Charalambopoulos, D; Karanikolas, G; Katsilambros, N, 2006) |
| "The observe the clinical effect of leflunomide (LEF) and total glucosides of Paeony (TGP) on rheumatoid arthritis (RA) and their influences on laboratory findings." | 5.12 | [Clinical observation on effects of leflunomid and total glucosides of paeony on rheumatoid arthritis]. ( Liu, Y; Zhao, YX, 2006) |
| "Rheumatoid arthritis patients who develop refractoriness are left with no alternatives other than leflunomide and costly biological response modifiers." | 5.12 | Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. ( Antony, T; Jose, VM; Paul, BJ; Thomas, T, 2006) |
| "To study effects of leflunomide on inflammatory and destructive processes in patients with early rheumatoid arthritis (RA)." | 5.12 | [An antidestructive effect of leflunomide in early rheumatoid arthritis]. ( Aleksandrova, EN; Balabanova, RM; Kashevarov, RIu; Oliunin, IuA; Smirnov, AV, 2006) |
| "The objective of this study was to determine the neurophysiological effects of leflunomide on peripheral nerves in rheumatoid arthritis." | 5.12 | Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. ( Bleasel, JF; McGill, N; Richards, BL; Richards, GW; Spies, J; Vaile, J; Youssef, PP, 2007) |
| "Methotrexate (MTX) is a first-line disease-modifying antirheumatic drugs (DMARD) in rheumatoid arthritis (RA)." | 5.12 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. ( Jakubicz, D; Wisłowska, M, 2007) |
| "To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years." | 5.12 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. ( Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D, 2007) |
| "Evaluation of effectiveness and safety of leflunomide treatment in patients with active rheumatoid arthritis in whom methotrexate was ineffective or contraindicated." | 5.12 | [Leflunomide as a second choice treatment in patients with rheumatoid arthritis]. ( Bachta, A; Dudek, A; Raczkiewicz-Papierska, A; Sułek, M; Tłustochowicz, M; Zawadyl, B, 2007) |
| "To assess the safety and effectiveness of leflunomide (LNF) using 100 mg/week in patients with rheumatoid arthritis (RA)." | 5.11 | Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. ( Arroyo-Borrego, S; Dávalos-Zugasti, ME; Jaimes-Hernández, J; Robles-San Román, M; Suárez-Otero, R, 2004) |
| "To compare the efficacy and safety profile of two daily maintenance doses of leflunomide, 10 mg and 20 mg, for the treatment of active rheumatoid arthritis (RA)." | 5.11 | Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. ( Poór, G; Strand, V, 2004) |
| "To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label extension study in patients with rheumatoid arthritis (RA)." | 5.11 | Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. ( Bathon, J; Caldwell, J; Cannon, GW; Coleman, P; Crawford, B; Curtis, D; Cush, J; Fernando, I; Furst, DE; Genovese, M; Kantor, S; Kavanaugh, A; Keystone, E; Kopp, E; Kremer, J; Lindsley, HB; Luggen, M; Markenson, J; Ruderman, E; Simpson, K; Strand, V; Waltuck, J; Weisman, M, 2004) |
| "Leflunomide is an immunomodulatory agent that was recently approved for the treatment of rheumatoid arthritis (RA)." | 5.11 | Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. ( Bambery, P; Govindrajan, S; Khullar, M; Reddy, SV; Wanchu, A, 2005) |
| "To study therapeutic potential of a novel basic drug leflunomide in suppression of activity and progression of rheumatoid arthritis (RA)." | 5.11 | [Experience in long-term therapy of active rheumatoid arthritis with leflunomide]. ( Brodetskaia, KA; Chichasova, NV; Igolkina, EV; Imametdinova, GR, 2005) |
| "To examine the effect of folic acid on the efficacy of methotrexate (MTX) treatment in rheumatoid arthritis (RA) at 12 months in 2 phase III randomized controlled trials (RCTs) of leflunomide in which MTX was used as a comparator." | 5.11 | Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. ( Cohen, SB; Dorrier, C; Elashoff, D; Emery, P; Furst, DE; Khanna, D; Park, GS; Paulus, HE; Simpson, KM, 2005) |
| "To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis." | 5.10 | Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. ( Bathon, JM; Bensen, WM; Caldwell, JR; Cannon, GW; Coleman, P; Crawford, B; Curtis, DL; Cush, JJ; Fernando, I; Furst, DE; Genovese, MC; Kaine, JL; Kantor, SM; Keystone, E; Kopp, EJ; Kremer, JM; Lindsley, HB; Luggen, ME; Markenson, JA; Ruderman, EM; Simpson, K; Strand, V; Waltuck, J; Weisman, MH, 2002) |
| "To evaluate the capacity of a pooled index of only the 3 patient self-report questionnaire measures among the 7 American College of Rheumatology (ACR) core data set (Core Data Set) measures to distinguish efficacy of active treatment of rheumatoid arthritis (RA) with leflunomide or methotrexate versus placebo in a randomized, controlled clinical trial, and to compare the results with those obtained using the ACR 20% response criteria (ACR20), Disease Activity Score (DAS), and other pooled indices." | 5.10 | An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in ( Amara, I; Cohen, S; Crawford, B; Felson, D; Koch, G; Pincus, T; Strand, V; Wolfe, F, 2003) |
| "Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day thereafter) in the 2 phase III studies and who completed 2 years of treatment were offered inclusion in the open-label extension phase and were maintained on the same dosage of leflunomide." | 5.10 | The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. ( Breedveld, F; Deighton, C; Emery, P; Kalden, JR; Rozman, B; Schattenkirchner, M; Sörensen, H, 2003) |
| "To evaluate the efficacy and safety of leflunomide in comparison with methotrexate (MTX) on patients with rheumatoid arthritis (RA) in China." | 5.10 | Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. ( Bao, C; Chen, S; Ding, C; Gu, Y; He, P; Lao, Z; Li, X; Liu, J; Ma, J; Ni, L; Sun, L; Xu, J; Xu, S; Yu, Q, 2003) |
| "Leflunomide (LFL) is a modern immunomodulating medication belonging to the group of drugs that favourably affect the course of rheumatoid arthritis (RA)." | 5.10 | Leflunomide in the treatment of refractory rheumatoid arthritis. ( Andreev, SA; Batalov, AZ; Kuzmanova, SI; Russafov, PB; Solakov, PT; Staikova, ND, 2003) |
| "To compare disease-related medical care and productivity costs, and utilities, in 482 patients with rheumatoid arthritis randomised to receive leflunomide, methotrexate or placebo during a 12-month period." | 5.10 | Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. ( Bombardier, C; Maetzel, A; Strand, V; Tugwell, P; Wells, G, 2002) |
| "To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA)." | 5.10 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. ( Johnson, DM; Kiely, PD, 2002) |
| "To assess the therapeutic effect of leflunomide in weekly dose of 100 mg in patients with refractory rheumatoid arthritis." | 5.10 | Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. ( Jakez-Ocampo, J; Llorente, L; Richaud-Patin, Y; Simón, JA, 2002) |
| "Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis." | 5.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "To examine the safety and pharmacokinetics of and clinical response to leflunomide, a de novo pyrimidine synthesis inhibitor, when administered to patients with active rheumatoid arthritis (RA) who have been receiving long-term methotrexate therapy." | 5.09 | Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. ( Byrne, VM; Coblyn, JS; Helfgott, SM; Kaymakcian, MV; Kremer, JM; Maier, AL; Morrell, M; Strand, V; Weinblatt, ME, 1999) |
| "To assess the efficacy of leflunomide or methotrexate compared with placebo in improving function and health-related quality of life in patients with active rheumatoid arthritis (RA), and to examine correlations between response status (as defined by the American College of Rheumatology [ACR] response criteria) and improvement in these measures." | 5.09 | Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. ( Bombardier, C; Crawford, B; Dorrier, C; Maetzel, A; Strand, V; Thompson, A; Tugwell, P; Wells, G, 1999) |
| "Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA)." | 5.09 | Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. ( Caldwell, J; Cannon, G; Cohen, S; Fleischmann, R; Fox, R; Furst, D; Hurley, F; Kaine, J; Loew-Friedrich, I; Moreland, L; Olsen, N; Schiff, M; Sharp, J; Strand, V; Weaver, A, 1999) |
| "To compare the clinical efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis (RA)." | 5.09 | A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. ( Bjorneboe, O; Breedveld, FC; Dahl, R; Dawes, PT; Emery, P; Gömör, B; Horslev-Petersen, K; Kaltwasser, JP; Lemmel, EM; Loew-Friedrich, I; Molloy, M; Nordström, D; Oed, C; Rodriguez De La Serna, A; Rosenburg, R; Tikly, M; Van Den Bosch, F, 2000) |
| "Leflunomide is a novel immunomodulating drug that has recently been approved as a disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA)." | 5.09 | Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. ( Breedveld, FC; de Koster, BM; Elferink, JG; Kraan, MC; Post, WJ; Tak, PP, 2000) |
| "Leflunomide and methotrexate have proven to be efficacious in reducing joint inflammation and slowing destruction in clinical trials of patients with rheumatoid arthritis (RA)." | 5.09 | Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine ( Barg, EC; Breedveld, FC; Emery, P; Farnell, J; Kraan, MC; Reece, RJ; Rosenburg, R; Smeets, TJ; Tak, PP; Veale, DJ, 2000) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 5.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "The efficacy and safety of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA) were evaluated and the comparison with methotrexate's (MTX's) was performed in a 12-week, single-blind, randomized, parallel trial for treating 81 patients with RA." | 5.09 | A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis. ( Hu, Y; Liu, P; Tu, S, 2001) |
| "We previously reported that the new disease modifying antirheumatic drug leflunomide resulted in significant improvement in functional ability compared with placebo and sulfasalazine in a 6 month double blind, randomized, Phase III trial in rheumatoid arthritis (RA)." | 5.09 | Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. ( Jones, P; Kalden, JR; Kvien, TK; Oed, C; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Williams, BD; Williams, RB, 2001) |
| "358 patients with rheumatoid arthritis in a double blind trial were randomly allocated to receive either leflunomide 20 mg/day, placebo, or sulfasalazine 2 g/day." | 5.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Three 6-12-month, double-blind, randomized, controlled trials have shown leflunomide (LEF; 20 mg/day, loading dose 100 mg x 3 days) to be effective and safe for the treatment of rheumatoid arthritis (RA)." | 5.09 | Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. ( Caldwell, J; Cannon, GW; Cohen, S; Fox, R; Furst, D; Kaine, J; Moreland, L; Olsen, N; Schiff, M; Sharp, J; Strand, V; Weaver, A, 2001) |
| "To assess the safety and effectiveness of leflunomide versus placebo in patients with active rheumatoid arthritis (RA) treated for 6 months." | 5.08 | Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. ( Campion, G; Dimitrijevic, M; Domljan, Z; Dordevic, J; Jajic, I; Mihajlovic, D; Mladenovic, V; Popovic, M; Rozman, B; Zivkovic, M, 1995) |
| "A novel immunomodulating drug, leflunomide has been shown recently to be effective and well tolerated in patients suffering from rheumatoid arthritis (RA)." | 5.08 | Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. ( Bartlett, RR; Dimitrijevic, M, 1996) |
| " The concomitant administration of Leflunomide (LEF) with Chinese herbal medicine (CHM) provides a potential solution to preventing the adverse drug reactions (ADRs) induced by LEF during the treatment of rheumatoid arthritis (RA)." | 5.05 | The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis. ( Liu, L; Wang, W; Zhou, H, 2020) |
| "To systematically evaluate the effects of Tripterygium Glycosides Tablets alone or in combination with methotrexate(MTX) and leflunomide(LEF) on the levels of pro-inflammatory cytokines in patients or animal models with rheumatoid arthritis(RA), and to provide reference for clinical application and related basic research, this study systematically searched databases of CNKI, VIP, WanFang, PubMed, Embase and Cochrane Library, collected relevant clinical or animal experimental studies, used risk assessment tools to evaluate the quality of research, and used Revman 5." | 5.05 | [Systematic reviews of effects of Tripterygium Glycosides Tablets on pro-inflammatory factors in rheumatoid arthritis]. ( Chen, WJ; Fan, YF; Guo, MQ; Li, HZ; Li, TX; Li, YQ; Lin, N; Lyu, C; Tian, YG; Wang, JX; Wang, XY; Wu, HY; Xue, ZP; Yang, J; Zhang, YQ; Zhu, CY, 2020) |
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "We aimed to assess the relative efficacy and tolerability of monotherapy with leflunomide or tacrolimus at recommended dosages in rheumatoid arthritis (RA) patients." | 4.98 | Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. ( Bae, SC; Lee, YH, 2018) |
| "To evaluate the relative risk (RR) of pulmonary disease among patients with rheumatoid arthritis (RA) treated with leflunomide (LEF)." | 4.93 | Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. ( Carey, JJ; Conway, R; Coughlan, RJ; Low, C; O'Donnell, MJ, 2016) |
| "A great body of evidence suggest that hydroxychloroquine, sulfasalazine, and non-fluorinated steroids can be continued throughout pregnancy, while methotrexate and leflunomide should be discontinued 3 months before pregnancy." | 4.93 | Challenges and treatment options for rheumatoid arthritis during pregnancy. ( Gerosa, M; Meroni, PL; Schioppo, T, 2016) |
| " Leflunomide (CAS 75706-12-6), a drug approved for the treatment of treat rheumatoid arthritis (RA), was identified as an inhibitor of DHODH." | 4.87 | Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases. ( Leban, J; Vitt, D, 2011) |
| "Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis." | 4.87 | Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011) |
| " The earlier use of methotrexate and the introduction of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis have changed the natural characteristics of the disease." | 4.87 | [Systemic autoimmune disorders and pregnancy]. ( Kiss, CG; Kiss, E; Poór, G, 2011) |
| "We report the case of a 60 year female patient suffering from rheumatoid arthritis for the last 25 years, under TNF-blocker and leflunomide, affected by a recurrent pneumothorax with several subpleural nodules, basal bronchiectasis and apical bullous emphysema." | 4.85 | [Referring to an unusual case: pulmonary affection and rheumatoid arthritis]. ( Borges, H; Frey, JG; Schnyder, JM; Tschopp, JM, 2009) |
| "Leflunomide (LMF) is an immunemodulatory drug used in the therapy of Rheumatoid Arthritis (RA)." | 4.85 | Pregnancy course and neonatal outcome after exposure to leflunomide--2 cases report and review of literature. ( Banas, T; Batko, B; Górnisiewicz, T; Hajdyla-Banaś, I; Pityńska-Korab, E; Rydz-Stryszowska, I; Skura, A, 2009) |
| "The efficacy and safety of the combination of leflunomide (Arava) with biological agents in treatment of rheumatoid arthritisiare presented." | 4.84 | [The efficacy and safety of the combination of leflunomide (Arava) and biological agents in treatment of rheumatoid arthritis]. ( Novak, S, 2008) |
| "Efficacy and safety of anti-tumor necrosis factor (TNF) antagonists (infliximab, etanercept, adalimumab) in combination with methotrexate for rheumatoid arthritis is well determined." | 4.84 | [Effective combination therapy of TNF antagonists with DMARDs]. ( Matsuda, T; Ohtsubo, H, 2007) |
| "A 61-year-old Caucasian woman receiving long-term anticoagulation with warfarin for recurrent thromboembolism and atrial fibrillation was found to have an elevated international normalized ratio (INR) after she started leflunomide therapy for rheumatoid arthritis." | 4.83 | Leflunomide and warfarin interaction: case report and review of the literature. ( Chonlahan, J; Halloran, MA; Hammonds, A, 2006) |
| "Leflunomide (Arava) was approved for the treatment of rheumatoid arthritis by the regulatory authorities in the US and Europe in 1998." | 4.82 | Leflunomide. ( Cohen, SB; Iqbal, I, 2003) |
| "To systematically review the evidence from clinical trials on the efficacy and toxicity of leflunomide for the treatment of active rheumatoid arthritis (RA)." | 4.82 | Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. ( Osiri, M; Robinson, V; Shea, B; Strand, V; Suarez-Almazor, M; Tugwell, P; Wells, G, 2003) |
| "The safety profile of leflunomide in the treatment of rheumatoid arthritis has been well documented in clinical trials, postmarketing surveillance, and epidemiological studies." | 4.82 | Leflunomide: a manageable safety profile. ( Breedveld, FC; Dougados, M; Emery, P; Kalden, JR; Smolen, JS; Strand, CV; van Riel, PL, 2004) |
| " This review of clinical studies shows that leflunomide is clinically efficacious and well tolerated when added to either sulfasalazine or MTX, as both an initial and ongoing treatment for rheumatoid arthritis (RA)." | 4.82 | Lefunomide in combination therapy. ( Breedveld, FC; Dougados, M; Emery, P; Kalden, JR; Smolen, JS; Strand, CV; van Riel, PL, 2004) |
| " This article reviews the place of leflunomide in clinical practice and outlines its potential applications beyond its licenced indication, rheumatoid arthritis." | 4.82 | The broadening use of leflunomide in clinical practice. ( Kiely, PD, 2004) |
| "To determine, by consensus, the optimal use of leflunomide in rheumatoid arthritis (RA), using a multidisciplinary panel of experts and performing meta-analyses of available data." | 4.82 | Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. ( Kiely, P; Kirkham, B; Lawson, T; Maddison, P; Moots, R; Proudfoot, D; Reece, R; Scott, D; Sword, R; Taggart, A; Thwaites, C; Williams, E, 2005) |
| "Treatment of rheumatoid arthritis (RA) has changed with the release of more efficient disease-modifying anti-inflammatory drugs (DMARDs) and biologicals, such as methotrexate, leflunomide and TNF blockers, respectively." | 4.82 | [Respiratory complications of new treatments for rheumatoid arthritis]. ( Lioté, H, 2004) |
| "To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into sequential therapy, consisting of the most frequently used disease-modifying antirheumatic drugs (DMARDs), for patients with rheumatoid arthritis in specialised, i." | 4.82 | Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency. ( Brecht, JG; Gromnica-Ihle, E; Huppertz, E; Schädlich, PK; Schneider, M; Straub, C; Zeidler, H; Zink, A, 2005) |
| "An Expert Panel Meeting was held in May 2004 to assess experience with combination therapy with leflunomide and biological agents in the treatment of rheumatoid arthritis (RA), to identify both optimal use of such combinations and precautions for use." | 4.82 | Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. ( Alvaro-Gracia, JM; Antoni, C; Combe, B; Emery, P; Kalden, JR; Kremer, JM; Smolen, JS; Strand, CV; Van Riel, P, 2005) |
| "Because of radiographic evidence of progressive bone loss and the inability to eliminate synovial proliferation with methotrexate, it became apparent that therapy for rheumatoid arthritis needed further advancement." | 4.81 | Rational use of new and existing disease-modifying agents in rheumatoid arthritis. ( Kremer, JM, 2001) |
| "Methotrexate and leflunomide are both effective drugs in the treatment of patients with rheumatoid arthritis." | 4.81 | Leflunomide and methotrexate. ( Laan, RF; van de Putte, LB; van Riel, PL, 2001) |
| "Leflunomide (Arava(trade mark), Hoescht Marion Roussel, now Aventis Pharma) is a new, oral disease modifying antirheumatic drug (DMARD) for the treatment of active rheumatoid arthritis (RA)." | 4.81 | Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. ( Alldred, A; Emery, P, 2001) |
| "In recent years, new disease modifying agents including leflunomide and tumour necrosis factor (TNF) antagonists have been used to treat patients with rheumatoid arthritis (RA)." | 4.81 | New disease modifying agents in adult rheumatoid arthritis. ( Koh, ET, 2001) |
| "Hoechst Marion Roussel (HMR; now Aventis Pharma) launched leflunomide (HWA-486), an immunomodulator and a disease-modifying antirheumatic drug (DMARD), for the treatment of rheumatoid arthritis (RA) in the US in late 1998 [310118]." | 4.81 | Leflunomide Aventis Pharma. ( Kaplan, MJ, 2001) |
| "Leflunomide is a novel disease-modifying antirheumatic drug (DMARD) for treatment of rheumatoid arthritis." | 4.81 | [Leflunomide--a new disease modifying anti-rheumatic agent]. ( Johnsen, V; Kvien, TK; Rødevand, E, 2001) |
| "Leflunomide is a new second-line drug for rheumatoid arthritis." | 4.81 | [Leflunomide in the treatment of rheumatoid arthritis]. ( Wendling, D, 2002) |
| "Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis." | 4.81 | Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. ( Harisdangkul, V; Sanders, S, 2002) |
| "New treatments, such as leflunomide and biologic therapy, are making an important impact on the management of rheumatoid arthritis." | 4.81 | Advances in the medical management of rheumatoid arthritis. ( Scott, DL, 2002) |
| "Leflunomide, a novel drug with proven efficacy in rheumatoid arthritis, is an isoxazol derivative structurally unrelated to other immunomodulatory drugs." | 4.80 | Mechanism of action of leflunomide in rheumatoid arthritis. ( Fox, RI, 1998) |
| "Leflunomide is a novel isoxazol drug with disease modifying properties for the treatment of rheumatoid arthritis (RA)." | 4.80 | Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group. ( Rozman, B, 1998) |
| "Methotrexate is currently one of the most widely prescribed disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA)." | 4.80 | Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. ( Kremer, JM, 1999) |
| "Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA)." | 4.80 | Mechanism of action for leflunomide in rheumatoid arthritis. ( Fox, RI; Frangou, CG; Herrmann, ML; Kirschbaum, BJ; Morris, RE; Strand, V; Wahl, GM, 1999) |
| "A77 1726, the active metabolite of leflunomide, is an immunomodulator which inhibits cell proliferation in activated lymphocytes in patients with active rheumatoid arthritis." | 4.80 | Leflunomide: a review of its use in active rheumatoid arthritis. ( Jarvis, B; Prakash, A, 1999) |
| "Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA)." | 4.80 | Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. ( Herrmann, ML; Kirschbaum, BJ; Schleyerbach, R, 2000) |
| "Leflunomide, the newest disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA), acts by inhibiting dihydroorotate dehydrogenase, the rate-limiting enzyme in the pathway for pyrimidine production." | 4.80 | The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review. ( Schattenkirchner, M, 2000) |
| "To assess the effectiveness, safety and cost implications of leflunomide treatment for rheumatoid arthritis." | 4.80 | Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. ( Debroe, S; Hewitson, PJ; McBride, A; Milne, R, 2000) |
| "In 1999, leflunomide was introduced for the treatment of active rheumatoid arthritis." | 4.80 | [Leflunomide for active rheumatoid arthritis]. ( Andresen, PN; Hansen, G; Hørslev-Petersen, K, 2000) |
| "Leflunomide is a new immunomodulatory drug that is effective in experimental models of autoimmune diseases and in allo or xenotransplantation." | 4.79 | Leflunomide and malononitrilamides. ( Morris, RE; Silva Júnior, HT, 1997) |
| "Leflunomide is a commonly used treatment for rheumatoid arthritis." | 4.31 | Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis? ( Aicha, BT; Hana, S; Ines, M; Issam, S; Kawther, BA; Leila, A; Leila, M; Lobna, BA; Mouna, BS; Olfa, S; Rawdha, T; Selma, B; Takoua, BB, 2023) |
| "Rheumatoid arthritis (RA) is a disease affecting around 1% of the population in developed countries and can be treated with leflunomide." | 4.31 | The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis. ( Machaj, F; Malinowski, D; Olędzka, G; Pawlik, A; Rosik, J; Safranow, K; Szostak, B; Wiechec, E, 2023) |
| " The present case control investigation was designed to evaluate the comparative toxicity of methotrexate and leflunomide on multiple organs in rheumatoid arthritis patients." | 4.31 | Comparative analysis of multiorgan toxicity induced by long term use of disease modifying anti-rheumatic drugs. ( Iqbal, MA; Mumtaz, T; Tahir, A; Tariq, MA, 2023) |
| "Although Leflunomide (LEF) is effective in treating rheumatoid arthritis (RA), there are still a considerable number of patients who respond poorly to LEF treatment." | 4.31 | The prognostic value of whole-genome DNA methylation in response to Leflunomide in patients with Rheumatoid Arthritis. ( Bai, B; Chen, M; Chen, Y; Dai, B; Fan, Z; Feng, X; Fu, L; Jin, L; Jin, X; Li, J; Liao, R; Liu, H; Wang, Q; Wei, T; Xin, F; Yao, Y; Zhang, J, 2023) |
| "There is a significant rate of therapeutic failure in rheumatoid arthritis (RA) patients treated with leflunomide (LEF)." | 4.12 | Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels. ( Alcaraz-Lopez, MF; Cardona-Muñoz, EG; Cerpa-Cruz, S; Corona-Sanchez, EG; Fajardo-Robledo, NS; Gamez-Nava, JI; Gonzalez-Lopez, L; Jacobo-Cuevas, H; Lopez-Roa, RI; Muñoz-Valle, JF; Perez-Guerrero, EE; Ponce-Guarneros, JM; Rodriguez-Jimenez, NA; Romero-Tejeda, EM; Saldaña-Cruz, AM; Totsuka-Sutto, SE, 2022) |
| "To compare infectious risk between leflunomide versus TNF inhibitors (TNFi), and between tacrolimus versus TNFi among rheumatoid arthritis (RA) patients receiving methotrexate (MTX)." | 4.12 | Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study. ( Ha, YJ; Kang, EH; Lee, EB; Lee, JH; Lee, YJ; Shin, A, 2022) |
| "A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7." | 4.12 | Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. ( Filippa, MG; Panopoulos, S; Sfikakis, PP; Spanos, E; Spanos, G; Tektonidou, MG; Yavropoulou, MP, 2022) |
| "This systematic review will provide evidence to judge whether Janus kinase inhibitors is superior to leflunomide in patients with in rheumatoid arthritis." | 4.12 | Comparative efficacy and safety of JAK inhibitors and leflunomide in rheumatoid arthritis: A protocol for systematic review and meta-analysis. ( Feng, X; Liu, J; Liu, Y; Wang, Y; Wang, Z; Yang, L; Zhang, M; Zhang, X; Zhao, D, 2022) |
| "Methotrexate and leflunomide are classic treatments for rheumatoid arthritis (RA), however, which is the best choice for patients of RA is still an important question clinically, and this meta-analysis is used to systematically evaluate and compare their efficacy and safety." | 4.02 | Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis: A protocol for systematic review and meta-analysis. ( Cao, J; Li, X; Qi, W; Xia, Y, 2021) |
| "Leflunomide is a commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA)." | 4.02 | Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. ( Cleland, LG; Hill, C; Hopkins, AM; King, C; Lee, A; McWilliams, L; Metcalf, R; Proudman, SM; Spargo, L; Wechalekar, MD; Wiese, MD, 2021) |
| "Leflunomide is a disease-modifying antirheumatic drug used in therapy for rheumatoid arthritis (RA)." | 4.02 | Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis. ( Dziedziejko, V; Malinowski, D; Paradowska-Gorycka, A; Pawlik, A; Safranow, K; Łączna, M, 2021) |
| "A 63-year-old Caucasian female patient with rheumatoid arthritis on methotrexate for 8 years and on leflunomide for 6 years was admitted for weakness, edema, ascites, and petechiae of the lower legs." | 3.96 | Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report. ( Girndt, M; Lübbert, C; Pliquett, RU; Schäfer, C, 2020) |
| "A case with rheumatoid arthritis and insufficient compensation under disease-modifying combined long-term therapy with methotrexate and leflunomide is reported." | 3.96 | [Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy]. ( Lange, U; Müller-Ladner, U; Steinchen, N, 2020) |
| " Leflunomide is an anti-inflammatory drug primarily used for treating rheumatoid arthritis (RA)." | 3.96 | A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. ( Hu, J; Liu, X; Peng, D; Prinz, RA; Sun, J; Wang, C; Wang, J; Xu, X, 2020) |
| " She had a history of rheumatoid arthritis and was prescribed 20 mg leflunomide and 16 mg corticosteroid daily." | 3.91 | Atypical Presentation of Choroidal Folds: Steroid-induced Central Serous Chorioretinopathy-like Maculopathy ( Afrashi, F; Çeper, SB; Değirmenci, C; Nalçacı, S, 2019) |
| " In the present study, the potential side effects of combination leflunomide and methotrexate (LEF+MTX), a conventional rheumatoid arthritis therapy used in the resolution of liver fibrosis, was investigated." | 3.91 | Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance. ( Guo, R; Ke, S; Lin, M; Su, Z; Zeng, D, 2019) |
| "Leflunomide is a disease-modifying anti-rheumatic drug (DMARD) used in the management of rheumatoid arthritis (RA) and psoriatic arthritis." | 3.91 | Reversible alopecia areata: a little known side effect of leflunomide. ( Cusnir, I; Hall, J; Koller, G; Ye, C, 2019) |
| "Oral treatment of rheumatoid arthritis (RA) with the immunomodulator, leflunomide (LEF), is associated with systemic side effects namely immunosuppression and hepatotoxicity." | 3.91 | Coated nanostructured lipid carriers targeting the joints - An effective and safe approach for the oral management of rheumatoid arthritis. ( Boraie, N; Helmy, MW; Nafee, N; Zewail, M, 2019) |
| " We report four cases of patients who developed PAH following a treatment by leflunomide for rheumatoid arthritis, psoriatic arthritis or undetermined connective tissue disease." | 3.88 | Pulmonary arterial hypertension in four patients treated by leflunomide. ( Chabanne, C; Coiffier, G; Coirier, V; Fournet, M; Jégo, P; Jouneau, S; Lescoat, A; Polard, E, 2018) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| "Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use of leflunomide." | 3.88 | Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. ( Chung, WT; Lee, SW; Lee, SY, 2018) |
| "Leflunomide is indicated for the treatment of adults with rheumatoid arthritis, yet is underutilized." | 3.85 | Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey. ( Eurich, DT; Hall, JJ; Katz, SJ; Keeling, SO; Maksymowych, WP; Schultz, M, 2017) |
| "Rituximab is a biologic agent approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate (MTX) or leflunomide (LEF)." | 3.85 | [SUSTAINABILITY OF RITUXIMAB IN CONCOMMITANT TREATMENT WITH METHOTREXATE OR LEFLUNOMIDE IN PATIENTS WITH RHEUMATOID ARTHRITIS]. ( Boulman, N; Kaly, L; Odeh, M; Raitter, R; Rimer, D; Rosner, I; Rozenbaum, M; Slobodin, G, 2017) |
| "Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster (HZ), and the risk appears to be increased in patients treated with tofacitinib." | 3.85 | Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. ( Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K, 2017) |
| "Leflunomide is a low-molecular-weight compound that is widely used in the treatment of rheumatoid arthritis." | 3.85 | The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. ( Cho, ML; Jhun, JY; Kim, EK; Lee, HJ; Lee, WS; Min, JK; Moon, SJ; Park, SH, 2017) |
| "These results demonstrate that topically applied leflunomide can be delivered effectively and deposited as teriflunomide in an arthritic joint, possibly allowing better compliance in rheumatoid arthritis patients by avoiding leflunomide's side effects." | 3.83 | Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. ( Bae, J; Park, JW, 2016) |
| "Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity." | 3.83 | Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. ( Foster, DJ; Hopkins, AM; O'Doherty, CE; Proudman, SM; Upton, RN; Wiese, MD, 2016) |
| "Leflunomide is a prodrug used primarily for treatment of rheumatoid arthritis." | 3.83 | Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS. ( Johnson-Davis, KL; Rockwood, AL; Rule, GS, 2016) |
| " This study evaluated the cost-effectiveness of a treatment strategy initiated with etanercept (ETN) compared with leflunomide (LFN) after a 30% reduction in the medication cost of ETN in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX-IR)." | 3.83 | Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. ( Jeong, JH; Lee, EK; Lee, MY; Park, JH; Park, SH; Park, SK, 2016) |
| " We report a 67-year-old woman with a 30-year history of rheumatoid arthritis, who had received treatment with leflunomide for 10 years and infliximab for 2 years." | 3.83 | Primary cardiac B cell lymphoma: Manifestation of Felty's syndrome or TNFα antagonist. ( Ameur, F; Benzerdjeb, N; Ikoli, JF; Sevestre, H, 2016) |
| "We retrospectively investigated the inhibitory effect on radiographic joint damage (RJD) for non-biological disease-modifying antirheumatic drug (non-bioDMARD) monotherapy or methotrexate (MTX) combination therapy for rheumatoid arthritis (RA) in the disease activity score with 28 joint counts with erythrocyte sedimentation rate (DAS28) remission." | 3.81 | Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. ( Baba, H; Fukai, R; Ito, H; Katayama, K; Okubo, T; Sato, T, 2015) |
| "The association between serum uric acid concentrations and inflammation in patients with rheumatoid arthritis (RA) has been still controversial." | 3.81 | Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. ( Choe, JY; Kim, SK, 2015) |
| "Leflunomide is an immunosuppressant drug used in rheumatoid arthritis and psoriatic arthritis." | 3.81 | [Pleuro-pericarditis developed under a leflunomide therapy]. ( Figueredo, M; Ribière, J; Tarhini, A; Vandenbos, F, 2015) |
| "Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment." | 3.81 | Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015) |
| " This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting." | 3.81 | Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Corominas, H; de la Serna, AR; Díaz-Torné, C; Hernández, MV; Llobet, JM; Magallares, B; Narváez, J; Nolla, JM; Reina, D; Sanmartí, R, 2015) |
| "Leflunomide is a disease-modifying antirheumatic drug with antiinflammatory and immunosuppressive activity used for the treatment of psoriatic and rheumatoid arthritis." | 3.81 | On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations. ( Bernard, MK; Czaja, K; Drabińska, B; Jodłowska, E; Kujawski, J, 2015) |
| "The aim of this work was to clarify the effect of leflunomide (LEF) on the eye dryness in patients with secondary Sjögren's syndrome associated with rheumatoid arthritis (RA-sSS) and in patients with rheumatoid arthritis (RA)." | 3.80 | The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients. ( El-Agha, S; El-Azkalany, GS; Shahin, AA, 2014) |
| "To compare the approved treatment of rheumatoid arthritis using rituximab + methotrexate (RTX + MTX) versus the off-label treatment variants of RTX in monotherapy or RTX in combination with leflunomide (RTX + LEF)." | 3.80 | Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register. ( Bussmann, A; Herzer, P; Listing, J; Richter, A; Strangfeld, A; Wilden, E; Zink, A, 2014) |
| "Leflunomide (LEF) is an isoxazole derivative used as disease-modifying anti-rheumatic drug (DMARD) in the treatment of rheumatoid arthritis (RA)." | 3.80 | [Acute interstitial pneumonia in patient with rheumatoid arthritis treated with leflunomide]. ( Bartosiewicz, M; Bartoszuk, I; Jakubowska, L; Kuś, J; Siemion-Szcześniak, I; Wesołowski, S, 2014) |
| "Nimesulide is a COX-2 inhibitor used for symptomatic relief of rheumatoid arthritis." | 3.80 | Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis. ( Abdel-Naim, AB; Al-Abbasi, FA; Al-Abd, AM; El-Eraky, WI; Khalifa, AE; Nagy, AA; Nofal, SM; Williams, RO, 2014) |
| "The aims of this study were to describe the rate of leflunomide discontinuation in rheumatoid arthritis (RA) patients, in standard clinical practice, and to analyse which factors could influence this rate, paying particular attention to the concomitant treatment with other disease-modifying anti-rheumatic drugs (DMARDs)." | 3.79 | Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. ( Abásolo, L; Fernández-Gutierrez, B; Fontsere, O; Jover-Jover, JA; León, L; Peña-Blanco, RC; Rodriguez-Rodriguez, L, 2013) |
| "The study included 105 patients with rheumatoid arthritis who were treated with methotrexate, leflunomide, hydroxychloroquine and biological drugs." | 3.79 | Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. ( Nardi, AE; Ornelas, AC; Pinho de Oliveira Ribeiro, N; Pinho de Oliveira, CM; Rafael de Mello Schier, A; Silva, AC, 2013) |
| "A 78-year-old woman diagnosed with rheumatoid arthritis without a history of skin tumors or immunosuppressive medication, started treatment with leflunomide." | 3.79 | Multiple eruptive keratoacanthomas associated with leflunomide. ( Bouret, AM; Frances, L; Guijarro, J; Leiva-Salinas, Mdel C; Marin, I, 2013) |
| "Iguratimod, a novel disease-modifying antirheumatic drug, which is now used in clinics in China and Japan, has been confirmed as a highly efficacious and safe drug for rheumatoid arthritis therapy." | 3.79 | A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. ( Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q, 2013) |
| "To determine the risk of severe infection requiring or complicating hospitalization associated with leflunomide therapy in patients with rheumatoid arthritis (RA)." | 3.79 | Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. ( Jeon, HS; Jun, JB; Yoo, HG; Yoo, WH; Yu, HM, 2013) |
| " We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease." | 3.79 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ( Bergner, R; Löffler, C; Peters, L; Schmitt, V, 2013) |
| "To assess the safety of treating patients with rheumatoid arthritis with a combination of methotrexate (MTX) and leflunomide (LEF) in comparison to MTX monotherapy, in clinical practice." | 3.79 | The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. ( Arnold, M; Bird, P; Burnet, S; de Jager, J; Griffiths, H; Littlejohn, G; Nicholls, D; Roberts, L; Scott, J; Tymms, K; Zochling, J, 2013) |
| " A careful anamnesis revealed that the patient had been taking leflunomide for rheumatoid arthritis for the last 10 years, and this was suspected to be the cause of the cough." | 3.79 | Leflunomide-induced chronic cough in a rheumatoid arthritis patient with pulmonary tuberculosis. ( Jaiswal, AK; Mishra, AK; Verma, SK, 2013) |
| "The recommendations of the European League Against Rheumatism (EULAR) for the management of rheumatoid arthritis (RA) suggest a different therapeutic approach to methotrexate (MTX) resistance according to the presence or absence of poor prognostic factors." | 3.78 | Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. ( Berberidis, C; Kapetanos, GA; Sakellariou, GT; Sayegh, FE, 2012) |
| "Leflunomide, a disease-modifying antirheumatic drug, has been shown to be effective in the management of rheumatoid arthritis (RA)." | 3.78 | Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. ( Alvarez, PA; Blanco, MV; Flagel, S; Mazzocchi, O; Saad, AK, 2012) |
| "Leflunomide is a disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis." | 3.78 | Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. ( Cleland, LG; James, M; O'Doherty, C; Proudman, SM; Schnabl, M; Spargo, L; Wiese, MD, 2012) |
| " Herein, we present a case of a 47-year-old female patient who developed Tjalma syndrome after administration of leflunomide for rheumatoid arthritis." | 3.77 | Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy. ( Bes, C; Soy, M, 2011) |
| "Leflunomide is the drug used in the therapy for rheumatoid arthritis (RA)." | 3.77 | The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. ( Chlubek, D; Dziedziejko, V; Kurzawski, M; Pawlik, A; Safranow, K, 2011) |
| "To compare the effectiveness and safety of a combination of rituximab (RTX) with either methotrexate (MTX) or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and inadequate response to anti-tumor necrosis factor agents or traditional disease-modifying antirheumatic drugs (DMARD) in a real-world setting." | 3.77 | Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Díaz-López, C; Díaz-Torné, C; Hernández, MV; Narváez, J; Nolla, JM; Rodriguez de la Serna, A; Ros, S; Ruiz, JM; Sanmartí, R; Torrente-Segarra, V, 2011) |
| " In patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), the incidence of elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST) enzymes associated with methotrexate (MTX), leflunomide (LEF) and MTX+LEF versus other DMARDs was examined." | 3.76 | Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. ( Beukelman, T; Cassell, S; Curtis, JR; Greenberg, JD; Kavanaugh, A; Kremer, JM; Onofrei, A; Reed, G; Strand, V, 2010) |
| "Sixty-four pregnant women with rheumatoid arthritis (RA) who were treated with leflunomide during pregnancy (95." | 3.76 | Birth outcomes in women who have taken leflunomide during pregnancy. ( Braddock, SR; Chambers, CD; Jin, S; Johnson, DL; Jones, KL; Lopez-Jimenez, J; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2010) |
| "The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA)." | 3.76 | Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. ( Bonassi, S; Cutolo, M; Gallo, F; Montagna, P; Moretti, S; Paolino, S; Pizzorni, C; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B, 2010) |
| "The aim of the present study was to evaluate the effect of long-term leflunomide and methotrexate (MTX) therapy during the course of rheumatoid arthritis (RA) estimated by digital X-ray radiogrammetry (DXR) and computer-aided joint space analysis (CAJSA) as diagnostic tools for the quantification of disease-related periarticular osteoporosis and joint space narrowing." | 3.75 | Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. ( Böttcher, J; Eidner, T; Hansch, A; Hein, G; Kaiser, WA; Lehmann, G; Lippold, J; Oelzner, P; Pfeil, A; Renz, DM; Wolf, G, 2009) |
| "This preliminary study focuses on early peripheral cellular immune changes after 1 month therapy with leflunomide, in 18 patients with severe rheumatoid arthritis, previously treated with methotrexate." | 3.75 | Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one month therapy with leflunomide. ( Codreanu, C; Constantin, C; Manda, G; Neagoe, I; Neagu, M, 2009) |
| "The objective of this study was to compare the effectiveness of a combination of tumour necrosis factor alpha (TNFalpha) inhibitors with either methotrexate or leflunomide in the treatment of patients with rheumatoid arthritis in a real-world setting." | 3.75 | Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. ( Dockhorn, R; Hierse, F; Kekow, J; Listing, J; Strangfeld, A; Tony, HP; von Hinueber, U; Zink, A, 2009) |
| "This post-marketing study aimed to record rates of retention, adverse effects and efficacy of leflunomide in the treatment of rheumatoid arthritis (RA)." | 3.75 | Leflunomide use in New Zealand. A national prospective post-marketing study. ( Jones, PB; Lynskey, NV; White, DH, 2009) |
| "To determine whether multidrug-resistance efflux transporters are expressed on immune effector cells in synovial tissue from patients with rheumatoid arthritis (RA) and compromise the efficacy of methotrexate (MTX) and leflunomide (LEF)." | 3.75 | Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. ( Assaraf, YG; Dijkmans, BA; Jansen, G; Kraan, MC; Lems, WF; Oerlemans, R; Scheffer, GL; Scheper, RJ; Tak, PP; van der Heijden, JW; van der Laken, CJ, 2009) |
| " We treated a patient who developed polymyositis (PM) following the treatment of RA with leflunomide." | 3.75 | Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. ( Nagashima, M; Ochi, S; Taniguchi, K, 2009) |
| "Leflunomide is a disease-modifying antirheumatic drug used for the treatment of rheumatoid arthritis (RA)." | 3.75 | Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. ( Bohanec Grabar, P; Dolzan, V; Grabnar, I; Logar, D; Mrhar, A; Peterlin Masic, L; Rozman, B; Suput, D; Tomsic, M; Trdan, T, 2009) |
| "We retrospectively compared treatment impact with leflunomide (LEF) or methotrexate (MTX) on retarding joint damage and clinical symptom including a 28-joint-count Disease Activity Score/erythrocyte sedimentation rate (DAS28-ESR) between two similar groups in patients with rheumatoid arthritis (RA) over an approximately 3-year treatment." | 3.75 | Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. ( Katayama, K; Matsuno, T, 2009) |
| "Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA)." | 3.75 | The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. ( Dehler, S; Finckh, A; Gabay, C, 2009) |
| " She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | 3.74 | [Persistent diarrhea and loss of weight during therapy with leflunomide]. ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "Leflunomide is an immunomodulating agent with proven efficacy in rheumatoid arthritis." | 3.74 | Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. ( Baaj, M; El Haouri, M; Hadri, L; Hassikou, H; Safi, S; Tabache, F, 2008) |
| "to assess the security of the combined treatment with Methotrexate (MTX) and Leflunomide (LF) in patients with Rheumatoid Arthritis (RA) and to evaluate whether the dose and route of MTX administration influence on the toxicity." | 3.74 | [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis]. ( Alba, P; Albiero, E; Babini, A; Exeni, I; Gobbi, C; Nesa, L, 2007) |
| "Cases of toxic neuropathy have been observed during treatment of rheumatoid arthritis with leflunomide." | 3.74 | Peripheral neuropathy associated with leflunomide: is there a risk patient profile? ( Bentaberry, F; Dehais, J; Dumoulin, C; Haramburu, F; Martin, K; Miremont-Salamé, G; Schaeverbeke, T, 2007) |
| "A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX)." | 3.74 | Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. ( Blanco, LP; Castro, JS; Chirinos, E; Esteva, MH; González, M; Granados, Y; Macgregor, EG; Marín, F; Mundaraín, L; Rodríguez, MA; Rosas, A; Sánchez, G; Sanoja, G; Snih, SA; Tristano, A; Zambrano-Marín, G, 2007) |
| "Two cases of leflunomide-induced peripheral neuropathy are described; in a 60-year-old woman with sero-negative polyarthralgia-myalgia syndrome and a 65-year-old man with sero-negative rheumatoid arthritis, both treated with leflunomide at 20mg/day." | 3.74 | Leflunomide-induced peripheral neuropathy. ( Kermode, AG; Kho, LK, 2007) |
| "A female rheumatoid arthritis patient was admitted for productive cough and general fatigue that had gradually developed after leflunomide therapy." | 3.74 | Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. ( Kingetsu, I; Kurosaka, D; Toyokawa, Y; Yamada, A; Yasuda, C; Yasuda, J; Yoshida, K, 2007) |
| "To determine the prevalence of severe infections in patients with rheumatoid arthritis (RA) prescribed leflunomide in North Canterbury, New Zealand." | 3.74 | Leflunomide-associated infections in rheumatoid arthritis. ( Chapman, PT; Jenks, KA; O'Donnell, JL; Savage, RL; Stamp, LK, 2007) |
| "A 60-year-old rheumatoid arthritis (RA) female with lung fibrosis was treated with leflunomide (LEF) for only 12 days, and responded well." | 3.74 | Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. ( Harada, M; Inokuma, S; Koyama, T; Niiro, H; Ohtani, R; Otsuka, T; Yoshizawa, S, 2008) |
| "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide." | 3.74 | Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis. ( Carloni, A; Giannakakis, K; Nori, G; Piciucchi, S; Poletti, V; Zobel, BB, 2008) |
| "Leflunomide is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA)." | 3.74 | Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. ( Bohanec Grabar, P; Dolzan, V; Logar, D; Rozman, B; Suput, D; Tomsic, M, 2008) |
| "Outpatients with rheumatoid arthritis on a stable leflunomide dose for >4 months were included." | 3.73 | Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. ( Brouwers, JR; Houtman, PM; Jansen, TL; Janssen, M; Keuper, R; van de Laar, MA; van Roon, EN; Yska, JP, 2005) |
| "Diarrhoea and weight loss are frequently reported adverse events in rheumatoid arthritis (RA) patients receiving the disease-modifying antirheumatic drug (DMARD) leflunomide." | 3.73 | Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. ( Vandooren, AK; Verschueren, P; Westhovens, R, 2005) |
| "To investigate the influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in rheumatoid arthritis (RA) and to compare it to infliximab in combination with other disease-modifying anti-rheumatic drugs." | 3.73 | The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. ( Creemers, MC; Flendrie, M; van Riel, PL; Welsing, PM, 2005) |
| "We report the case of a leg ulcer in a rheumatoid arthritis (RA) patient under treatment with leflunomide, discuss the influence of the drug on the aetiopathogenesis of the ulcer and describe its successful treatment." | 3.73 | Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. ( Dissemond, J; Goos, M; Knab, J, 2005) |
| "To determine whether improvements in physical function and health related quality of life (HRQOL) are sustained over 2 years of blinded treatment with leflunomide (LEF), methotrexate (MTX), or sulfasalazine (SSZ) in patients with active rheumatoid arthritis (RA)." | 3.73 | Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. ( Cannon, GW; Crawford, B; Emery, P; Kalden, JR; Scott, DL; Smolen, JS; Strand, V; Tugwell, P, 2005) |
| "We describe a 54-year-old woman with rheumatoid arthritis (RA), who developed acute respiratory failure 2 weeks after cessation of 6-week treatment with leflunomide." | 3.73 | Leflunomide induced acute interstitial pneumonia. ( Adachi, D; Akiba, H; Akiyama, Y; Hirano, M; Mimura, T; Takeishi, M, 2005) |
| "To investigate the concentration-effect relationship and pharmacokinetics of leflunomide in patients with rheumatoid arthritis (RA)." | 3.73 | Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. ( Chan, V; Charles, BG; Tett, SE, 2005) |
| "To determine factors predictive for leflunomide drug survival in an outpatient population with rheumatoid arthritis in a setting of care-as-usual." | 3.73 | Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. ( Bernelot Moens, HJ; Brouwers, JR; Hoekstra, M; Jansen, TL; Tobi, H; van de Laar, MA; van Roon, EN, 2005) |
| "Leflunomide (LEF) is indicated in adults for the treatment of active rheumatoid arthritis (RA)." | 3.73 | Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. ( Balbir-Gurman, A; Guralnik, L; Keidar, Z; Nahir, AM; Rozenbaum, M; Rozin, A; Vlodavsky, E; Yigla, M, 2006) |
| "A skin eruption consistent with subacute cutaneous lupus erythematosus (SCLE) occurred in a patient taking leflunomide for rheumatoid arthritis." | 3.73 | Subacute cutaneous lupus erythematosus associated with leflunomide. ( David-Bajar, KM; Elias, AR; Tam, CC, 2005) |
| "To investigate the anti-inflammatory effects of the active leflunomide metabolite A771726 (Lef-M) in combination with methotrexate (MTX) on synovial macrophages (SM) from rheumatoid arthritis (RA) patients co-cultured with an activated T cell line (Jurkat cell line)." | 3.73 | Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. ( Capellino, S; Cutolo, M; Montagna, P; Seriolo, B; Sulli, A; Villaggio, B, 2006) |
| "Leflunomide is a new drug for the treatment of rheumatoid arthritis." | 3.73 | [Leflunomide-related severe axonal neuropathy]. ( Antoine, JC; Camu, W; Coudeyre, E; Gabelle, A; Hillaire-Buys, D, 2005) |
| "The results and outcomes of randomized clinical trials of leflunomide and anti-TNF therapy are much better than are seen in rheumatoid arthritis patients in the community." | 3.73 | Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. ( Michaud, K; Wolfe, F, 2005) |
| "After adjustment for covariates, prednisone use increased the risk of pneumonia hospitalization (hazard ratio [HR] 1." | 3.73 | Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. ( Caplan, L; Michaud, K; Wolfe, F, 2006) |
| "Leflunomide is a disease-modifying antirheumatic drug for the treatment of active rheumatoid arthritis and psoriatic arthritis." | 3.73 | [Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis]. ( Jakob, A; Porstmann, R; Rompel, R, 2006) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | 3.73 | Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "To investigate the safety of infliximab (INF) combination therapy with leflunomide (LEF) or azathioprine (AZA) in patients with rheumatoid arthritis (RA)." | 3.73 | Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. ( Brocq, O; Cantagrel, A; Combe, B; Debiais, F; Deslandre, CJ; Kara-Terki, R; Kuntz, JL; Loet, XL; Mariette, X; Pavy, S; Perdriger, A, 2006) |
| " We present a case of biopsy-proven pulmonary alveolar proteinosis in a patient undergoing therapy with the disease-modifying antirheumatoid arthritis drug leflunomide (Arava; Aventis Pharmaceuticals, Bridgewater, NJ)." | 3.73 | Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. ( Miller, R; Wardwell, NR; Ware, LB, 2006) |
| " One such medication applied in patients with rheumatoid arthritis is leflunomide." | 3.73 | Influence of leflunomide on gastrointestinal Candida albicans infection induced in naive and arthritic newborn mice. ( Dimitrova, P; Ivanovska, N, 2006) |
| "To describe the practices of rheumatologists when prescribing the disease modifying antirheumatic drugs (DMARD) methotrexate (MTX), leflunomide (LF), etanercept (ET), and infliximab (IN) to women of childbearing age with rheumatoid arthritis (RA) and the pregnancy outcomes of patients who become pregnant while taking these medications." | 3.72 | The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. ( Bush, TM; Chakravarty, EF; Sanchez-Yamamoto, D, 2003) |
| "To study the immunosuppressive and anti-inflammatory effects of combined leflunomide and methotrexate (MTX) therapy on chemokine expression in patients with rheumatoid arthritis (RA), nine patients were enrolled for the combination therapy for 24 weeks." | 3.72 | Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. ( Ho, CY; Lam, CW; Li, EK; Tam, LS; Wong, CK, 2003) |
| "Leflunomide (Arava) is an immunomodulator, recently introduced for systemic treatment of rheumatoid arthritis." | 3.72 | [Lichenoid drug reaction to leflunomide]. ( Canonne-Courivaud, D; Carpentier, O; Dejobert, Y; Delaporte, E; Hachulla, E, 2003) |
| "Leflunomide, a new immunomodulatory agent, was prescribed to a 67-year-old female patient with rheumatoid arthritis." | 3.72 | Leflunomide-induced acute hepatitis. ( Agúndez, JA; Díaz-Rubio, M; Fernández-Gutiérrez, B; Ladero, JM; Ortega, L; Sevilla-Mantilla, C, 2004) |
| "Since November 1999, leflunomide (LEF), an innovative disease-modifying antirheumatic drug (DMARD), is available in Germany for treatment of rheumatoid arthritis (RA)." | 3.72 | [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]. ( Brecht, JG; Gromnica-Ihle, E; Huppertz, E; Schädlich, PK; Schneider, M; Straub, C; Zeidler, H; Zink, A, 2004) |
| "This is the first description of the development of rheumatoid nodules in 3 rheumatoid arthritis patients following leflunomide therapy." | 3.72 | [Development and/or increase of rheumatoid nodules in RA patients following leflunomide therapy]. ( Becker-Capeller, D; Braun, MG; Van Rhee, R, 2004) |
| "To report the safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) for the treatment of rheumatoid arthritis." | 3.72 | The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. ( Cohen, S; Cooley, DA; Cush, J; Genovese, M; Hansen, KE; Patel, SR; Schiff, M; Singhal, A; Sundaramurthy, S, 2004) |
| "We prospectively studied the efficacy, incidence of adverse drug reactions and withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting of care-as-usual." | 3.72 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. ( Brouwers, JR; Bruyn, GA; Griep, EN; Houtman, PM; Jansen, TL; Mourad, L; Tobi, H; Van Roon, EN; Wilffert, B, 2004) |
| " We report the first known case of leflunomide-induced aseptic meningitis, in a patient with rheumatoid arthritis." | 3.72 | Leflunomide-induced aseptic meningitis. ( Cohen, JD; Jorgensen, C; Sany, J, 2004) |
| "To assess leflunomide efficacy and tolerance in patients with rheumatoid arthritis (RA) during the first four months of the treatment." | 3.72 | [Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide]. ( Balabanova, RM; Chichasova, NV; Goriachev, DV; Loginova, TK; Makolkin, VI; Men'shikova, IV; Oliunin, IuA; Petukhova, NV; Riabkova, AA; Shostak, NA, 2004) |
| "Spontaneous cases of hepatic adverse events have been reported in patients with rheumatoid arthritis who were being treated with leflunomide, one of the newer disease-modifying antirheumatic drugs (DMARDs)." | 3.72 | Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. ( Bitton, A; Ernst, P; Hudson, M; Kezouh, A; Suissa, S, 2004) |
| "We prospectively studied the efficacy, incidence of adverse drug reactions and withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting of care-as-usual." | 3.72 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. ( Brouwers, JR; Bruyn, GA; Griep, EN; Houtman, PM; Jansen, TL; Mourad, L; Tobi, H; Van Roon, EN; Wilffert, B, 2004) |
| "To determine and compare the incidence of serious adverse events (AE) during treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARD), focusing on leflunomide (LEF)." | 3.72 | Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. ( Cannon, GW; Dai, W; Holden, WL; Juhaeri, J; Scarazzini, L; Stang, P, 2004) |
| "Vasculitis as a complication of leflunomide therapy in the treatment of rheumatoid arthritis has been reported." | 3.72 | Vasculitis associated with the use of leflunomide. ( Gan, BS; Harth, M; Lazarescu, A; Macdonald, J; Zhong, T, 2004) |
| "A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide." | 3.72 | Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004) |
| "To explore the feasibility of prospectively monitoring treatment efficacy and tolerability of infliximab, etanercept, and leflunomide over a two year period in patients with established rheumatoid arthritis (RA) in clinical practice using a structured protocol." | 3.71 | Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. ( Crnkic, M; Geborek, P; Petersson, IF; Saxne, T, 2002) |
| "To estimate, from a public payer's perspective, the 5-year cost effectiveness of adding leflunomide (LEF) to a sequence of disease-modifying antirheumatic drugs (DMARDs) representative of a typical rheumatoid arthritis (RA) management approach adopted by Canadian rheumatologists." | 3.71 | Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. ( Bombardier, C; Maetzel, A; Strand, V; Tugwell, P; Wells, G, 2002) |
| "To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center." | 3.71 | Leflunomide-associated weight loss in rheumatoid arthritis. ( Coblyn, JS; Helfgott, S; Shadick, N, 2001) |
| "Methotrexate (MTX) is one of the disease modifying antirheumatic drugs (DMARD) commonly used to treat rheumatoid arthritis (RA)." | 3.71 | Conventional DMARD options for patients with a suboptimal response to methotrexate. ( O'Dell, J, 2001) |
| "To identify differences in rheumatoid arthritis (RA) care costs and utilization among patients receiving therapy with leflunomide (LEF) or etanercept (ETA)." | 3.71 | Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. ( Cummins, G; Doyle, J; McLaughlin, T; Yazdani, C, 2001) |
| "Leflunomide has recently been introduced for systemic treatment of rheumatoid arthritis." | 3.71 | Vasculitis occurring during leflunomide therapy. ( Balslev, E; Holm, EA; Jemec, GB, 2001) |
| "To compare the impact of leflunomide on resource utilization and costs relative to that of etanercept and infliximab among patients with rheumatoid arthritis (RA) in a managed care setting." | 3.71 | Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. ( Doyle, J; Huse, DM; Ollendorf, DA; Peterson, AN, 2002) |
| "To report a case of skin ulceration as a result of treatment with leflunomide for rheumatoid arthritis." | 3.71 | Leflunomide-associated skin ulceration. ( McCoy, CM, 2002) |
| "New treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis (RA) have become available." | 3.71 | A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2002) |
| "Leflunomide is the first disease-modifying antirheumatic drug to be approved for rheumatoid arthritis in the past 10 years." | 3.71 | Clinical pharmacokinetics of leflunomide. ( Rozman, B, 2002) |
| "Leflunomide is a novel drug recently introduced for treatment of rheumatoid arthritis as a DMARD (disease-modifying antirheumatic drug)." | 3.70 | Severe pancytopenia after leflunomide in rheumatoid arthritis. ( Allinger, S; Auer, J; Hinterreiter, M; Kirchgatterer, A; Knoflach, P, 2000) |
| "Leflunomide, the newest disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis (RA), inhibits de novo pyrimidine biosynthesis." | 3.70 | Efficacy and safety of leflunomide in active rheumatoid arthritis. ( Emery, P; Smolen, JS, 2000) |
| " Serious adverse events were similar." | 2.84 | Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. ( de Silva, R; Fernandopulle, R; Galappatthy, P; Hart, M; Kelleher, P; Saravanamuttu, U; Senerath, U; Seneviratne, SL; Udagama, P; Weerasekera, LP; Wijayaratne, LS; Wijesinghe, H, 2017) |
| " Adverse events occurred in 53." | 2.78 | Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. ( Bolosiu, H; Cutolo, M; Perdriset, G, 2013) |
| "Leflunomide was clinically efficacious in this group of long standing resistant RA in an open study "real life" design." | 2.72 | The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. ( Caspi, D; Elkayam, O; Kaufman, I; Levartovsky, D; Litinsky, I; Paran, D; Wigler, I; Yaron, I; Yaron, M, 2006) |
| " All adverse events were documented." | 2.71 | Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. ( Brin, S; de la Serna, R; Dougados, M; Emery, P; Lemmel, EM; van Riel, P; Zerbini, CA, 2003) |
| "Leflunomide was administered at a dos of 20mg/day following a loading dose of 100mg/day for three days." | 2.71 | [Leflunomide in the treatment of rheumatoid arthritis]. ( Ben Amor, G; Ben Miled, M; Ben Rhouma, S; Boussema, F; Chérif, O; Daoud, L; Kochbati, S; Ktari, S; Rokbani, L, 2005) |
| "Leflunomide was given to 414 patients for 18." | 2.71 | [Evaluation of rheumatoid arthritis activity in clinical practice]. ( Balabanova, RM; Oliunin, IuA, 2005) |
| "Leflunomide treatment was associated with a significantly greater improvement in IRE compared with methotrexate treatment (P < 0." | 2.70 | Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. ( Breedveld, FC; Emery, P; Gibbon, WW; Kraan, MC; O'Connor, PJ; Radjenovic, A; Reece, RJ; Ridgway, JP; Tak, PP; Veale, DJ, 2002) |
| "Leflunomide was well tolerated." | 2.69 | Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. ( Smolen, JS, 1999) |
| " The highest risk of infection is associated with corticosteroids depending on the dose, so that a dosage as low as possible but stable in the perioperative period is recommended." | 2.55 | [Perioperative management of immunosuppressive treatment in patients undergoing joint surgery]. ( Krüger, K, 2017) |
| "Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA." | 2.53 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016) |
| "Rheumatoid arthritis is a chronic, highly disabling autoimmune disease that requires aggressive pharmacological treatment using immunomodulatory drugs grouped under the name of Disease-Modifying Anti-rheumatic Drugs (DMARDs)." | 2.52 | [Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review]. ( Molina Molina, MI; Pinochet Paiva, CM; Quezada Morales, JI, 2015) |
| "Leflunomide is a prodrug which is rapidly converted following oral administration and absorption to an active metabolite with anti-proliferative effects (A77 1726/teriflunomide)." | 2.49 | Safety evaluation of leflunomide in rheumatoid arthritis. ( Conaghan, PG; Keen, HI; Tett, SE, 2013) |
| "The primary goal in the treatment of rheumatoid arthritis (RA) is to maintain good quality of life by preventing joint destruction and avoiding disability." | 2.48 | [ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs]. ( Ichikawa, N; Yamanaka, H, 2012) |
| "Two patients had previous MTX-induced pneumonitis (MTX-P) prior to initiation of LEF; both died from LEIP." | 2.45 | Clinical expression of leflunomide-induced pneumonitis. ( Chikura, B; Dawson, JK; Lane, S, 2009) |
| "Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate." | 2.45 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "This paper reviews recent approaches to treatment of early rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs)." | 2.44 | Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. ( Sizova, L, 2008) |
| "The potential risk of infections related to conventional disease modifying anti-rheumatic drugs (DMARDs) is not completely clarified." | 2.44 | DMARDS and infections in rheumatoid arthritis. ( Bobbio-Pallavicini, F; Caporali, R; Caprioli, M; Montecucco, C, 2008) |
| "Rheumatoid arthritis is an autoimmune rheumatic condition of unknown origin." | 2.44 | [New ways in the management of rheumatoid arthritis in Hungary]. ( Gergely, P; Poór, G, 2007) |
| "Rheumatoid arthritis is a chronic multi-system disorder of unknown etiology with most common symptoms being persistent inflammatory synovitis, usually involving peripheral joints in a symmetrical pattern." | 2.43 | Rheumatoid arthritis: an update. ( Derk, CT, 2005) |
| " Both the efficacy and safety of leflunomide are maintained with long-term administration in patients with RA." | 2.43 | Leflunomide: long-term clinical experience and new uses. ( Behrens, F; Kaltwasser, JP, 2005) |
| "Leflunomide has a direct inhibitory effect on RANKL-mediated osteoclast differentiation by inhibiting the induction of NFATc1, the master switch regulator for osteoclast differentiation." | 2.43 | [Disease modifying antirheumatic drugs with inhibitory effect on osteoclastogenesis]. ( Urushibara, M, 2005) |
| "Rickets and osteomalacia are metabolic bone diseases due to a mineralization defect as principal pathophysiology." | 2.43 | [Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia]. ( D'Amore, M; D'Amore, S; Minenna, G, 2005) |
| "Therefore, active treatment of rheumatoid arthritis is indispensable." | 2.43 | [Rational therapeutic approach in rheumatoid arthritis]. ( Tłustochowicz, W, 2006) |
| "Older disease modifying agents for treating rheumatoid arthritis were limited by long-term toxicity." | 2.42 | Newer approaches to the treatment of rheumatoid arthritis. ( Finesilver, AG, 2003) |
| "Leflunomide is a low-molecular weight, synthetic, oral agent specifically developed for immunosuppression." | 2.42 | Leflunomide. ( Cannon, GW; Kremer, JM, 2004) |
| "Leflunomide is an agent that affects the inflammatory process, particularly in RA." | 2.42 | Leflunomide in the treatment of rheumatoid arthritis. ( Li, EK; Tam, LS; Tomlinson, B, 2004) |
| "Patients with treated hypertension should be monitored regularly when conventional NSAIDs or COX-2 inhibitors are administered." | 2.41 | Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. ( Dijkmans, BA; Nurmohamed, MT; van Halm, VP, 2002) |
| "Leflunomide(Arava) is a novel immunomodulatory drug, the primary action of which is inhibition of de-novo pyrimidine synthesis by selective inhibition of dihydro-orotate dehydrogenase." | 2.41 | [Efficacy of leflunomide]. ( Hirohata, S, 2002) |
| "Leflunomide is a newer DMARD that reduces pyrimidine synthesis, thus decreasing rheumatoid inflammation." | 2.41 | New drugs for the treatment of rheumatoid arthritis. ( Megeff, C; Schuna, AA, 2000) |
| "Leflunomide has been shown to be equal to or less efficacious than methotrexate, and may be beneficial as a second-line disease-modifying antirheumatic drug (DMARD)." | 2.41 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. ( Chong, BS; Lowder, DM; Luong, BT, 2000) |
| "Treatment with leflunomide results in significantly greater improvement of the signs and symptoms of RA than placebo for up to 2 yr and slows radiographically assessed disease progression." | 2.41 | New and future drug therapies for rheumatoid arthritis. ( Simon, LS; Yocum, D, 2000) |
| "Leflunomide is a selective inhibitor of de novo pyrimidine synthesis." | 2.41 | Leflunomide: mode of action in the treatment of rheumatoid arthritis. ( Breedveld, FC; Dayer, JM, 2000) |
| "Leflunomide's effects were consistent across three studies over two years of treatment." | 2.41 | Economic and quality-of-life impact of rheumatoid arthritis. ( Doyle, JJ, 2001) |
| "Leflunomide has exerted inhibitory activity in animal models of RA." | 2.40 | Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. ( Goldenberg, MM, 1999) |
| "Treatment with leflunomide, an inhibitor of pyrimidine synthesis, has been shown in controlled clinical trials to produce significant clinical improvement in 50% to 60% of patients with RA and delay radiologic progression of disease." | 2.40 | Therapy of rheumatoid arthritis: new developments and trends. ( , 1999) |
| "Leflunomide is a commonly used disease modifying antirheumatic agent." | 1.91 | Leflunomide exposure through second trimester of pregnancy: A case report. ( Alothman, R; Amiri, N; Lepik, C; Waterman, E; Yeung, J, 2023) |
| "Leflunomide treatment failure was defined as failure to achieve remission, the need to add other DMARDs for controlling attacks and disease progression to chronic arthritis during treatment with leflunomide." | 1.72 | Efficacy of leflunomide in the treatment of palindromic rheumatism. ( Esalatmanesh, K; Khabbazi, A; Sadri, M, 2022) |
| "Leflunomide was stopped and restarted 5 months after the initial diagnosis at the same dosage, with a close clinical and laboratory follow-up." | 1.51 | Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. ( Carubbi, F; Cipriani, P; Di Bartolomeo, S; Giacomelli, R; Grimaldi, A; Marola, L; Picchi, G; Ricciardi, A, 2019) |
| "Clinical remission is the treatment target in rheumatoid arthritis (RA)." | 1.51 | Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. ( Cai, YM; Gan, YZ; He, J; Li, J; Li, R; Li, SG; Li, ZG; Liao, H; Liu, JJ; Liu, X; Shi, LJ; Sun, XL; Xu, J; Ye, H; Zhang, RJ; Zhao, JX, 2019) |
| "Based on a pharmacokinetic (PK) study assessing the relative bioavailability of teriflunomide sodium compared to leflunomide, a population pharmacokinetic (Pop PK) analysis was firstly conducted using non-linear mixed effect model." | 1.51 | A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. ( Chen, X; Hu, P; Jiang, J; Liu, D; Wu, Y; Yao, X, 2019) |
| "Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased." | 1.48 | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. ( Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC, 2018) |
| "Rheumatoid arthritis is a chronic disease of the joints, which causes joint pain and disability." | 1.48 | Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis. ( Colares, VLP; Fernandes, AMR; Fernandes, ES; Martins, MMRS; Mendes, SJF; Monteiro, CRAV; Muniz, TF; Pereira, DMS; Pereira, ICP; Silva, BLR; Sousa, NCF, 2018) |
| " The abundance of dihydrofolate reductase (DHFR) was statistically significantly increased in RA-patient biopsies compared with controls and correlated with the administered dosage of methotrexate (MTX), the most frequently prescribed immunosuppressive drug for RA." | 1.46 | Proteome Analysis of Rheumatoid Arthritis Gut Mucosa. ( Andersen, V; Bennike, TB; Birkelund, S; Bonderup, OK; Bøgsted, M; Carlsen, TG; Christiansen, G; Ellingsen, T; Glerup, H; Meyer, MK; Stensballe, A, 2017) |
| " Of the responders, 12% had used doses above 20 mg daily and 70% had used alternate daily dosing with leflunomide." | 1.46 | Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. ( Hopkins, AM; O'Doherty, CE; Proudman, SM; Wiese, MD, 2017) |
| "Treatment with prednisone was associated with greater weight gain (β = 0." | 1.43 | Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, L; Ibrahim, S; Jorgenson, E; Michaud, K; Mikuls, TR; Sauer, BC; Teng, CC, 2016) |
| "Treatment with leflunomide (OR: 0." | 1.43 | Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia. ( Machado-Alba, JE; Machado-Duque, ME; Ruiz, AF, 2016) |
| "The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach." | 1.42 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. ( Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015) |
| "The radiological assessment of disease progression was estimated by the Sharp Score." | 1.42 | Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis? ( Böttcher, J; Hansch, A; Oelzner, P; Pfeil, A; Renz, DM; Wolf, G, 2015) |
| " Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients." | 1.42 | Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. ( Cummins, L; Duggan, E; Katikireddi, VS; Pahau, H; Shankaranarayana, S; Su, KY; Thomas, R; Videm, V, 2015) |
| "Leflunomide (LFN) is a disease modifying anti-rheumatic drugs (DMARDs) which acts by inhibiting the synthesis of pyrimidines." | 1.39 | Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. ( Murdaca, G; Puppo, F; Spanò, F, 2013) |
| "Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk." | 1.39 | Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs. ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013) |
| "Leflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab." | 1.38 | Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. ( Chatzidionysiou, K; Gabay, C; Gomez-Reino, J; Hetland, ML; Kvien, TK; Lie, E; Lukina, G; Nasonov, E; Nordström, DC; Pavelka, K; Tarp, U; Tomsic, M; van Riel, PL; van Vollenhoven, RF, 2012) |
| "We identified silent liver fibrosis in patients with rheumatoid arthritis (RA) using transient elastography, and investigated medication that correlated with abnormal liver stiffness measurement (LSM) values." | 1.38 | Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. ( Han, KH; Kim, BK; Kim, SU; Lee, SK; Lee, SW; Park, HJ; Park, YB, 2012) |
| " The most significant adverse event was elevation of transaminases in eight patients (26%)." | 1.38 | Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. ( Cubidez, MF; Guzman, C; Londono, J; Santos, AM; Santos, PI; Valle-Oñate, R, 2012) |
| "A high incidence of pancreatic cancer (PCa) in patients exposed to was observed in the German biologics register." | 1.37 | Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. ( Arkema, E; Askling, J; Davies, R; Hyrich, K; Listing, J; Neovius, M; Simard, J; Strangfeld, A; Symmons, D; Watson, K; Zink, A, 2011) |
| " In the multivariable model, the steroids dosage was a significant and independent predictor of negative ppd (p = 0." | 1.36 | Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. ( Debonis, J; Mysler, E; Schijedman, A; Tamborenea, MN; Tate, G, 2010) |
| "In 12 patients, lung injury developed even 2 months after leflunomide withdrawal." | 1.35 | Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Ohtsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2008) |
| "Leflunomide is an isoxazole derivative structurally and functionally unrelated to other known immunomodulatory drugs." | 1.35 | The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. ( Drozdzik, M; Dziedziejko, V; Herczynska, M; Kurzawski, M; Pawlik, A; Safranow, K, 2009) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 1.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| "Leflunomide is a useful and well tolerated DMARD for the treatment of RA and psoriatic arthritis in the elderly." | 1.35 | Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. ( Alivernini, S; Ferraccioli, G; Mazzotta, D; Zoli, A, 2009) |
| "Rheumatoid arthritis is one of most common chronic diseases, and represents a high cost for the health system." | 1.35 | [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia]. ( Díaz, J; González, A; Mora, C; Quintana, G, 2009) |
| "Rheumatoid nodules are well established manifestations of rheumatoid arthritis but in the lungs they are very rare according to the literature." | 1.35 | Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. ( Csiki, Z; Horvath, IF; Szanto, A; Szodoray, P; Zeher, M, 2008) |
| "Leflunomide is a drug used clinically in the treatment of rheumatoid arthritis." | 1.34 | Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. ( Nakayamada, S; Ra, C; Saito, K; Sawamukai, N; Tanaka, Y; Yamaoka, K, 2007) |
| "The leflunomide was stopped, and sultamicillin (IV 4x2 g/day) was started for a further 6 weeks." | 1.33 | Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report. ( Bilgici, A; Celenk, C; Kuru, O; Ulusoy, H, 2005) |
| "Leflunomide is an effective disease modifying antirheumatic drug (DMARD) in RA." | 1.33 | Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. ( Beneytout, JL; Bertin, P; Léger, DY; Liagre, B; Trèves, R; Vergne-Salle, P, 2005) |
| "In nine of these 12 patients pneumonitis occurred after leflunomide was added to methotrexate, usually within 12-20 weeks." | 1.33 | Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. ( Boyd, IW; Chapman, P; Highton, J; Savage, RL, 2006) |
| "Leflunomide was not able to abolish expression of metallo-proteinases in synoviocytes activated with TNF-a and IL-17." | 1.33 | The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression. ( Abruzzese, T; Aicher, WK; Alexander, D; Friedrich, B; Gondolph-Zink, B; Wülker, N, 2006) |
| " Once maximum improvement was obtained the dosage was decreased." | 1.33 | Disease modifying treatment for feline rheumatoid arthritis. ( Hanna, FY, 2005) |
| "Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been available in Japan since August 2003." | 1.33 | Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. ( Hirabayashi, Y; Kobayashi, N; Kudo, K; Shimizu, H, 2006) |
| "Current dosing strategies should be re-evaluated, and coping strategies for common AEs should be investigated." | 1.32 | Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. ( Aletaha, D; Eberl, G; Grisar, J; Kapral, T; Machold, KP; Smolen, JS; Stamm, T, 2003) |
| "Leflunomide is an antirheumatic agent of the type of a 'disease-modifying antirheumatic drug'." | 1.32 | Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. ( Barta, U; Bauer, HI; Elsner, P; Fischer, TW; Graefe, T, 2003) |
| "Leflunomide has a direct inhibitory effect on RANKL-mediated osteoclast differentiation by inhibiting the induction of NF-ATc1, the master switch regulator for osteoclast differentiation." | 1.32 | The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. ( Isobe, M; Kim, S; Kodama, T; Koga, T; Kurosawa, H; Löeffler, M; Morishita, Y; Nakagawa, T; Takayanagi, H; Taniguchi, T; Urushibara, M, 2004) |
| "Hydroxychloroquine was the most commonly cited medication for a mild disease activity/severity presentation, and methotrexate for a moderate-to-severe disease activity/severity presentation." | 1.31 | Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. ( Erkan, D; Harrison, MJ; Paget, SA; Yazici, Y, 2002) |
| "Leflunomide has recently been used effectively for the treatment of RA and may be useful for the management of patients with FS." | 1.31 | Treatment of Felty's syndrome with leflunomide. ( Khan, W; Talip, F; Walker, N; Zimmermann, B, 2001) |
| "Leflunomide is a new and effective disease-modifying antirheumatic drug." | 1.31 | Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. ( Koren, G; Kozer, E; Moretti, ME, 2001) |
| "Prior to admission, she had been treated for rheumatoid arthritis with methotrexate 7." | 1.31 | Effect of hemodialysis on leflunomide plasma concentrations. ( Beaman, JM; Hackett, LP; Illett, KF; Luxton, G, 2002) |
| "Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA." | 1.30 | Leflunomide for the treatment of rheumatoid arthritis. ( Kremer, JM; Olsen, NJ; Strand, V, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (7.08) | 18.2507 |
| 2000's | 339 (55.85) | 29.6817 |
| 2010's | 179 (29.49) | 24.3611 |
| 2020's | 46 (7.58) | 2.80 |
| Authors | Studies |
|---|---|
| Knuckley, B | 1 |
| Luo, Y | 2 |
| Thompson, PR | 1 |
| Belani, PJ | 1 |
| Kavadichanda, CG | 1 |
| Negi, VS | 1 |
| Mei, L | 1 |
| Yang, Z | 1 |
| Zhang, X | 4 |
| Liu, Z | 1 |
| Wang, M | 1 |
| Wu, X | 3 |
| Chen, X | 2 |
| Huang, Q | 1 |
| Huang, R | 1 |
| Qi, W | 1 |
| Xia, Y | 1 |
| Li, X | 2 |
| Cao, J | 1 |
| Fajardo-Robledo, NS | 1 |
| Jacobo-Cuevas, H | 1 |
| Perez-Guerrero, EE | 1 |
| Corona-Sanchez, EG | 1 |
| Saldaña-Cruz, AM | 1 |
| Romero-Tejeda, EM | 1 |
| Rodriguez-Jimenez, NA | 1 |
| Totsuka-Sutto, SE | 1 |
| Lopez-Roa, RI | 1 |
| Ponce-Guarneros, JM | 1 |
| Alcaraz-Lopez, MF | 1 |
| Cerpa-Cruz, S | 1 |
| Muñoz-Valle, JF | 1 |
| Cardona-Muñoz, EG | 1 |
| Gonzalez-Lopez, L | 1 |
| Gamez-Nava, JI | 1 |
| Kvacskay, P | 1 |
| Blank, N | 1 |
| Lorenz, HM | 2 |
| Merkt, W | 1 |
| Shin, A | 1 |
| Lee, JH | 3 |
| Ha, YJ | 4 |
| Lee, YJ | 2 |
| Lee, EB | 1 |
| Kang, EH | 4 |
| Sadri, M | 1 |
| Esalatmanesh, K | 1 |
| Khabbazi, A | 1 |
| Yavropoulou, MP | 1 |
| Filippa, MG | 1 |
| Panopoulos, S | 1 |
| Spanos, E | 1 |
| Spanos, G | 1 |
| Tektonidou, MG | 1 |
| Sfikakis, PP | 2 |
| Rawdha, T | 1 |
| Aicha, BT | 1 |
| Lobna, BA | 1 |
| Issam, S | 1 |
| Mouna, BS | 1 |
| Olfa, S | 1 |
| Selma, B | 1 |
| Takoua, BB | 1 |
| Kawther, BA | 1 |
| Leila, M | 1 |
| Hana, S | 1 |
| Ines, M | 1 |
| Leila, A | 1 |
| Barbarroja, N | 1 |
| Ruiz-Ponce, M | 1 |
| Cuesta-López, L | 1 |
| Pérez-Sánchez, C | 1 |
| López-Pedrera, C | 1 |
| Arias-de la Rosa, I | 1 |
| Collantes-Estévez, E | 1 |
| Chen, F | 1 |
| Wang, Y | 4 |
| Wang, L | 4 |
| Du, H | 1 |
| He, S | 1 |
| Kim, JW | 3 |
| Chung, SW | 3 |
| Pyo, JY | 3 |
| Chang, SH | 3 |
| Kim, MU | 3 |
| Park, CH | 3 |
| Lee, JS | 6 |
| Lee, YA | 3 |
| Park, YB | 4 |
| Lee, EY | 3 |
| Choe, JY | 5 |
| Aksoy, A | 3 |
| Kocakaya, D | 3 |
| Yalçınkaya, Y | 3 |
| Bozkurtlar, E | 3 |
| Karakurt, S | 3 |
| Eryüksel, E | 3 |
| İnanç, N | 4 |
| Zhang, M | 1 |
| Wang, Z | 1 |
| Liu, Y | 2 |
| Feng, X | 2 |
| Yang, L | 1 |
| Liu, J | 4 |
| Zhao, D | 1 |
| Yasmine, M | 1 |
| Kaouther, M | 1 |
| Dhia, K | 1 |
| Hanene, F | 1 |
| Wafa, T | 1 |
| Dorra, BN | 1 |
| Wafa, H | 1 |
| Machaj, F | 1 |
| Rosik, J | 1 |
| Szostak, B | 1 |
| Malinowski, D | 2 |
| Safranow, K | 5 |
| Olędzka, G | 1 |
| Wiechec, E | 1 |
| Pawlik, A | 5 |
| Zewail, MB | 1 |
| El-Gizawy, SA | 1 |
| Asaad, GF | 1 |
| Shabana, ME | 1 |
| El-Dakroury, WA | 1 |
| Alothman, R | 1 |
| Yeung, J | 1 |
| Waterman, E | 1 |
| Lepik, C | 1 |
| Amiri, N | 2 |
| Mumtaz, T | 1 |
| Tahir, A | 1 |
| Tariq, MA | 1 |
| Iqbal, MA | 1 |
| Nashaat, D | 1 |
| Elsabahy, M | 1 |
| Hassanein, KMA | 1 |
| El-Gindy, GA | 1 |
| Ibrahim, EH | 1 |
| Chen, Y | 1 |
| Wang, Q | 1 |
| Liu, H | 1 |
| Jin, L | 1 |
| Dai, B | 1 |
| Chen, M | 1 |
| Xin, F | 1 |
| Wei, T | 1 |
| Bai, B | 1 |
| Fan, Z | 1 |
| Li, J | 5 |
| Yao, Y | 1 |
| Liao, R | 1 |
| Zhang, J | 1 |
| Jin, X | 1 |
| Fu, L | 1 |
| Carubbi, F | 1 |
| Picchi, G | 1 |
| Di Bartolomeo, S | 1 |
| Ricciardi, A | 1 |
| Cipriani, P | 1 |
| Marola, L | 1 |
| Grimaldi, A | 1 |
| Giacomelli, R | 1 |
| Liang, C | 1 |
| Lu, C | 1 |
| Xie, D | 1 |
| Zhong, C | 1 |
| Dai, R | 1 |
| Zhang, H | 1 |
| Guan, D | 1 |
| Guo, B | 1 |
| He, B | 1 |
| Li, F | 1 |
| He, X | 1 |
| Zhang, W | 1 |
| Zhang, BT | 1 |
| Zhang, G | 1 |
| Lu, A | 1 |
| Rebić, N | 1 |
| Sayre, EC | 1 |
| Zusman, EZ | 1 |
| Baldwin, C | 1 |
| De Vera, MA | 1 |
| Pope, J | 1 |
| Rampakakis, E | 1 |
| Vaillancourt, J | 1 |
| Bessette, L | 1 |
| Lazovskis, J | 1 |
| Haraoui, B | 1 |
| Sampalis, JS | 1 |
| Onuora, S | 1 |
| Tłustochowicz, ME | 1 |
| Kisiel, B | 1 |
| Tłustochowicz, W | 2 |
| Xie, W | 1 |
| Zhang, Z | 1 |
| Lukas, C | 1 |
| Mary, J | 1 |
| Debandt, M | 1 |
| Daïen, C | 1 |
| Morel, J | 3 |
| Cantagrel, A | 3 |
| Fautrel, B | 4 |
| Combe, B | 8 |
| Değirmenci, C | 1 |
| Afrashi, F | 1 |
| Nalçacı, S | 1 |
| Çeper, SB | 1 |
| Pliquett, RU | 1 |
| Lübbert, C | 1 |
| Schäfer, C | 1 |
| Girndt, M | 1 |
| Wang, W | 1 |
| Zhou, H | 3 |
| Liu, L | 3 |
| Gomides, APM | 3 |
| de Albuquerque, CP | 3 |
| Santos, ABV | 2 |
| Bértolo, MB | 3 |
| Júnior, PL | 2 |
| Giorgi, RDN | 3 |
| Radominski, SC | 3 |
| Resende Guimarães, MFB | 1 |
| Bonfiglioli, KR | 2 |
| de Fátima Lobato da Cunha Sauma, M | 1 |
| Pereira, IA | 3 |
| Brenol, CV | 3 |
| da Mota, LMH | 2 |
| da Rocha Castelar Pinheiro, G | 1 |
| Zeng, C | 1 |
| Bai, X | 1 |
| Qin, H | 1 |
| Wang, H | 1 |
| Rong, X | 1 |
| Yan, J | 1 |
| Yang, J | 3 |
| Li, TX | 1 |
| Wang, XY | 2 |
| Xue, ZP | 1 |
| Lyu, C | 1 |
| Li, HZ | 1 |
| Fan, YF | 1 |
| Li, YQ | 1 |
| Tian, YG | 1 |
| Chen, WJ | 1 |
| Guo, MQ | 1 |
| Wang, JX | 1 |
| Wu, HY | 1 |
| Zhang, YQ | 1 |
| Zhu, CY | 1 |
| Lin, N | 1 |
| Pazmino, S | 2 |
| Boonen, A | 1 |
| Stouten, V | 2 |
| De Cock, D | 4 |
| Joly, J | 4 |
| Van der Elst, K | 4 |
| Westhovens, R | 6 |
| Verschueren, P | 5 |
| Wiese, MD | 7 |
| Hopkins, AM | 5 |
| King, C | 1 |
| Wechalekar, MD | 2 |
| Lee, A | 1 |
| Spargo, L | 2 |
| Metcalf, R | 1 |
| McWilliams, L | 1 |
| Hill, C | 1 |
| Cleland, LG | 5 |
| Proudman, SM | 8 |
| Navarro, CE | 1 |
| Enríquez-Ruano, P | 1 |
| Enríquez-Ruano, MN | 1 |
| Maljaars, J | 1 |
| Ortega-Gutierrez, S | 1 |
| Cho, T | 1 |
| Shaban, A | 1 |
| Steinchen, N | 1 |
| Müller-Ladner, U | 2 |
| Lange, U | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 2 |
| Dong, L | 1 |
| Wang, J | 1 |
| Sun, J | 1 |
| Hu, J | 1 |
| Wang, C | 1 |
| Prinz, RA | 1 |
| Peng, D | 1 |
| Liu, X | 2 |
| Xu, X | 1 |
| Deng, D | 1 |
| Zhou, J | 1 |
| Li, S | 1 |
| Tian, L | 1 |
| Zou, J | 1 |
| Wang, T | 1 |
| Wu, J | 1 |
| Zeng, F | 1 |
| Azhar, AF | 1 |
| Evanson, B | 1 |
| Parekh, PK | 1 |
| McPherson, M | 1 |
| Parperis, K | 1 |
| Faisal, M | 1 |
| Roslan, A | 1 |
| Nik Abeed, NN | 1 |
| Ban Yu-Lin, A | 1 |
| Núñez, P | 1 |
| Quera, R | 1 |
| Flores, L | 1 |
| Contreras, L | 1 |
| Cano-Jiménez, E | 1 |
| Vázquez Rodríguez, T | 1 |
| Martín-Robles, I | 1 |
| Castillo Villegas, D | 1 |
| Juan García, J | 1 |
| Bollo de Miguel, E | 1 |
| Robles-Pérez, A | 1 |
| Ferrer Galván, M | 1 |
| Mouronte Roibas, C | 1 |
| Herrera Lara, S | 1 |
| Bermudo, G | 1 |
| García Moyano, M | 1 |
| Rodríguez Portal, JA | 1 |
| Sellarés Torres, J | 1 |
| Narváez, J | 3 |
| Molina-Molina, M | 1 |
| Lillegraven, S | 1 |
| Paulshus Sundlisæter, N | 1 |
| Aga, AB | 1 |
| Sexton, J | 1 |
| Olsen, IC | 1 |
| Fremstad, H | 1 |
| Spada, C | 1 |
| Madland, TM | 1 |
| Høili, CA | 1 |
| Bakland, G | 1 |
| Lexberg, Å | 1 |
| Hansen, IJW | 1 |
| Hansen, IM | 1 |
| Haukeland, H | 1 |
| Ljoså, MA | 1 |
| Moholt, E | 1 |
| Uhlig, T | 1 |
| Solomon, DH | 2 |
| van der Heijde, D | 2 |
| Kvien, TK | 7 |
| Haavardsholm, EA | 1 |
| Zewail, M | 2 |
| Nafee, N | 2 |
| Helmy, MW | 2 |
| Boraie, N | 2 |
| Muhammad, T | 1 |
| Zafar, M | 1 |
| Quiroga, J | 1 |
| Whitehead, M | 1 |
| Łączna, M | 1 |
| Paradowska-Gorycka, A | 1 |
| Dziedziejko, V | 4 |
| Weber-Schoendorfer, C | 1 |
| Beck, E | 1 |
| Tissen-Diabaté, T | 1 |
| Schaefer, C | 1 |
| Winetsky, DE | 1 |
| Myers, J | 1 |
| Schulz, S | 1 |
| Tino, G | 1 |
| Wilck, M | 1 |
| Schultz, M | 1 |
| Keeling, SO | 1 |
| Katz, SJ | 1 |
| Maksymowych, WP | 1 |
| Eurich, DT | 1 |
| Hall, JJ | 1 |
| Wijesinghe, H | 1 |
| Galappatthy, P | 1 |
| de Silva, R | 1 |
| Seneviratne, SL | 1 |
| Saravanamuttu, U | 1 |
| Udagama, P | 1 |
| Hart, M | 1 |
| Kelleher, P | 1 |
| Senerath, U | 1 |
| Fernandopulle, R | 1 |
| Weerasekera, LP | 1 |
| Wijayaratne, LS | 1 |
| Raitter, R | 1 |
| Rimer, D | 1 |
| Boulman, N | 1 |
| Kaly, L | 1 |
| Rozenbaum, M | 2 |
| Rosner, I | 1 |
| Odeh, M | 1 |
| Slobodin, G | 1 |
| Winthrop, KL | 1 |
| Curtis, JR | 3 |
| Lindsey, S | 1 |
| Tanaka, Y | 2 |
| Yamaoka, K | 2 |
| Valdez, H | 1 |
| Hirose, T | 1 |
| Nduaka, CI | 1 |
| Mendelsohn, AM | 1 |
| Fan, H | 1 |
| Chen, C | 1 |
| Bananis, E | 1 |
| Krüger, K | 5 |
| Constantin, A | 1 |
| Baron, G | 2 |
| Dernis, E | 1 |
| Flipo, RM | 2 |
| Rist, S | 1 |
| Gottenberg, JE | 2 |
| Schaeverbeke, T | 3 |
| Soubrier, M | 1 |
| Vittecoq, O | 3 |
| Dougados, M | 7 |
| Saraux, A | 3 |
| Mariette, X | 3 |
| Ravaud, P | 2 |
| Sibilia, J | 1 |
| Bae, SC | 2 |
| Lee, YH | 2 |
| Sánchez, E | 1 |
| García de la Torre, I | 1 |
| Sacnún, M | 1 |
| Goñi, M | 1 |
| Berbotto, G | 1 |
| Paira, S | 1 |
| Musuruana, JL | 1 |
| Graf, C | 1 |
| Alvarellos, A | 1 |
| Messina, OD | 1 |
| Babini, A | 2 |
| Strusberg, I | 1 |
| Marcos, JC | 2 |
| Scherbarth, H | 1 |
| Spindler, A | 1 |
| Quinteros, A | 1 |
| Toloza, S | 1 |
| Moreno, JLC | 1 |
| Catoggio, LJ | 1 |
| Tate, G | 2 |
| Eimon, A | 1 |
| Citera, G | 1 |
| Pellet, AC | 1 |
| Nasswetter, G | 1 |
| Cardiel, MH | 2 |
| Miranda, P | 1 |
| Ballesteros, F | 2 |
| Esquivel-Valerio, JA | 2 |
| Maradiaga-Ceceña, MA | 1 |
| Acevedo-Vásquez, EM | 1 |
| García, CG | 1 |
| Tusié-Luna, T | 1 |
| Pons-Estel, BA | 2 |
| Alarcón-Riquelme, ME | 1 |
| Zhang, R | 1 |
| Hu, Y | 2 |
| Niu, H | 1 |
| Ishaq, M | 2 |
| Razzaque, S | 1 |
| Shohail, F | 1 |
| Kumar, A | 2 |
| Muhammad, JS | 2 |
| Yu, X | 2 |
| Zhang, L | 1 |
| Lu, W | 2 |
| Sun, F | 1 |
| Xu, P | 2 |
| Lan, G | 2 |
| Coirier, V | 1 |
| Lescoat, A | 1 |
| Chabanne, C | 1 |
| Fournet, M | 1 |
| Coiffier, G | 1 |
| Jouneau, S | 1 |
| Polard, E | 2 |
| Jégo, P | 1 |
| Costa, NT | 2 |
| Scavuzzi, BM | 1 |
| Iriyoda, TMV | 2 |
| Lozovoy, MAB | 1 |
| Alfieri, DF | 2 |
| de Medeiros, FA | 1 |
| de Sá, MC | 1 |
| Micheletti, PL | 1 |
| Sekiguchi, BA | 1 |
| Reiche, EMV | 1 |
| Maes, M | 1 |
| Simão, ANC | 2 |
| Dichi, I | 2 |
| Baker, JF | 2 |
| Sauer, B | 1 |
| Teng, CC | 2 |
| George, M | 1 |
| Cannon, GW | 8 |
| Ibrahim, S | 2 |
| Cannella, A | 2 |
| England, BR | 1 |
| Michaud, K | 5 |
| Caplan, L | 3 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 2 |
| Pereira, ICP | 1 |
| Sousa, NCF | 1 |
| Pereira, DMS | 1 |
| Mendes, SJF | 1 |
| Muniz, TF | 1 |
| Colares, VLP | 1 |
| Silva, BLR | 1 |
| Monteiro, CRAV | 1 |
| Martins, MMRS | 1 |
| Fernandes, AMR | 1 |
| Fernandes, ES | 1 |
| Bullock, J | 1 |
| Rizvi, SAA | 1 |
| Saleh, AM | 1 |
| Ahmed, SS | 1 |
| Do, DP | 1 |
| Ansari, RA | 1 |
| Ahmed, J | 1 |
| Silvagni, E | 1 |
| Bortoluzzi, A | 1 |
| Carrara, G | 1 |
| Zanetti, A | 1 |
| Govoni, M | 1 |
| Scirè, CA | 1 |
| Batty, K | 1 |
| Bazzichi, L | 1 |
| Nacci, F | 1 |
| Sinigaglia, L | 1 |
| Bianchino, L | 1 |
| Caporali, R | 2 |
| Lee, SY | 2 |
| Lee, SW | 3 |
| Chung, WT | 2 |
| Lin, M | 1 |
| Guo, R | 1 |
| Su, Z | 1 |
| Ke, S | 1 |
| Zeng, D | 1 |
| Mota, LMHD | 1 |
| Kakehasi, AM | 1 |
| Duarte, ALBP | 1 |
| Cruz, BA | 1 |
| Castelar Pinheiro, GDR | 1 |
| Laurindo, IMM | 1 |
| Ubirajara Silva de Souza, MPG | 1 |
| de Freitas, MVC | 1 |
| Louzada-Júnior, P | 1 |
| Xavier, RM | 2 |
| Wang, F | 1 |
| Li, H | 2 |
| Hao, X | 1 |
| Shen, G | 1 |
| Sun, Y | 2 |
| Xia, J | 1 |
| Nisar, MK | 1 |
| Tseng, CC | 1 |
| Lin, YZ | 1 |
| Lin, CH | 2 |
| Li, RN | 1 |
| Tsai, WC | 1 |
| Ou, TT | 1 |
| Wu, CC | 1 |
| Sung, WY | 1 |
| Yen, JH | 1 |
| Kwok, AMF | 1 |
| Morosin, T | 1 |
| Amorim, RBC | 1 |
| Santos, IA | 1 |
| Sacilotto, NC | 1 |
| Borghi, FM | 1 |
| Guimarães, MFBR | 1 |
| Pinto, MRDC | 1 |
| Resende, GG | 1 |
| Silva, HCD | 1 |
| Sauma, MFLDC | 1 |
| Sauma, ML | 1 |
| de Medeiros, JB | 1 |
| de Castro, GRW | 1 |
| Pinheiro, GDRC | 1 |
| Huang, RY | 2 |
| Pan, HD | 1 |
| Wu, JQ | 1 |
| Li, ZG | 5 |
| Qiu, P | 1 |
| Zhou, YY | 1 |
| Chen, XM | 2 |
| Xie, ZX | 1 |
| Xiao, Y | 1 |
| Huang, QC | 2 |
| Shin, K | 1 |
| Baek, HJ | 1 |
| Kang, YM | 1 |
| Cha, HS | 1 |
| Kang, SW | 1 |
| Park, SH | 4 |
| Jun, JB | 2 |
| Choi, IA | 1 |
| Song, YW | 1 |
| Liu, JJ | 1 |
| Li, R | 2 |
| Gan, YZ | 1 |
| Zhang, RJ | 1 |
| Cai, YM | 1 |
| Zhao, JX | 2 |
| Liao, H | 1 |
| Xu, J | 2 |
| Shi, LJ | 1 |
| Li, SG | 1 |
| Sun, XL | 1 |
| He, J | 1 |
| Ye, H | 1 |
| Koller, G | 1 |
| Cusnir, I | 1 |
| Hall, J | 1 |
| Ye, C | 2 |
| Yao, X | 1 |
| Wu, Y | 2 |
| Jiang, J | 1 |
| Liu, D | 1 |
| Hu, P | 1 |
| Chen, Z | 2 |
| Li, XP | 2 |
| Li, ZJ | 1 |
| Xu, L | 1 |
| Li, XM | 2 |
| Wang, ZM | 1 |
| Li, WQ | 1 |
| Keen, HI | 1 |
| Conaghan, PG | 1 |
| Tett, SE | 2 |
| Rodriguez-Rodriguez, L | 1 |
| Jover-Jover, JA | 1 |
| Fontsere, O | 1 |
| Peña-Blanco, RC | 1 |
| León, L | 1 |
| Fernández-Gutierrez, B | 2 |
| Abásolo, L | 1 |
| Pinho de Oliveira Ribeiro, N | 1 |
| Rafael de Mello Schier, A | 1 |
| Ornelas, AC | 1 |
| Pinho de Oliveira, CM | 1 |
| Nardi, AE | 1 |
| Silva, AC | 1 |
| Grzywa, M | 1 |
| Kadziela, M | 1 |
| Murdaca, G | 1 |
| Spanò, F | 1 |
| Puppo, F | 1 |
| Atzeni, F | 1 |
| Boiardi, L | 1 |
| Sallì, S | 1 |
| Benucci, M | 1 |
| Sarzi-Puttini, P | 1 |
| Cho, SK | 1 |
| Sung, YK | 1 |
| Choi, CB | 1 |
| Kwon, JM | 1 |
| Lee, EK | 2 |
| Ma, L | 1 |
| Liu, B | 1 |
| Jiang, Z | 2 |
| Jiang, Y | 1 |
| Frances, L | 1 |
| Guijarro, J | 1 |
| Marin, I | 1 |
| Leiva-Salinas, Mdel C | 1 |
| Bouret, AM | 1 |
| James, MJ | 1 |
| Spargo, LD | 3 |
| Metcalf, RG | 1 |
| Sullivan, TR | 1 |
| Rischmueller, M | 1 |
| Flabouris, K | 1 |
| Lee, AT | 1 |
| Luo, Q | 1 |
| Liu, W | 1 |
| Qian, C | 1 |
| Jin, B | 1 |
| Tao, F | 1 |
| Gu, Y | 2 |
| Shen, Y | 1 |
| Xu, Q | 1 |
| Chen, HH | 1 |
| Chen, DY | 2 |
| Lai, KL | 1 |
| Chen, YM | 2 |
| Chou, YJ | 1 |
| Chou, P | 1 |
| Huang, N | 1 |
| Arida, D | 1 |
| Silva, L | 1 |
| Skare, TL | 1 |
| Dudler, J | 1 |
| Tuerk, R | 1 |
| Handschin, T | 1 |
| Forster, A | 1 |
| Aletaha, D | 3 |
| Alasti, F | 1 |
| Smolen, JS | 16 |
| Velázquez Benito, A | 1 |
| Bellosta Diago, E | 1 |
| Santos Lasaosa, S | 1 |
| Pascual Millán, LF | 1 |
| Shahin, AA | 1 |
| El-Agha, S | 1 |
| El-Azkalany, GS | 1 |
| Rutanen, J | 1 |
| Kononoff, A | 1 |
| Arstila, L | 1 |
| Elfving, P | 1 |
| Koskela, H | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Richter, A | 1 |
| Strangfeld, A | 3 |
| Herzer, P | 1 |
| Wilden, E | 1 |
| Bussmann, A | 1 |
| Listing, J | 3 |
| Zink, A | 6 |
| Chatterjee, S | 1 |
| Sarkate, P | 1 |
| Ghosh, S | 1 |
| Biswas, M | 1 |
| Ghosh, A | 1 |
| Katayama, K | 2 |
| Okubo, T | 1 |
| Sato, T | 4 |
| Ito, H | 1 |
| Fukai, R | 1 |
| Baba, H | 1 |
| O'Doherty, CE | 4 |
| Foster, DJ | 2 |
| Suppiah, V | 1 |
| Upton, RN | 2 |
| Kim, SK | 1 |
| Hong, SH | 1 |
| Kwone, JT | 1 |
| Lee, S | 1 |
| Lee, AY | 1 |
| Cho, WY | 1 |
| Bat-Erdene, M | 1 |
| Choi, BD | 1 |
| Cho, MH | 1 |
| Santos-Moreno, PI | 1 |
| de la Hoz-Valle, J | 1 |
| Villarreal, L | 1 |
| Palomino, A | 1 |
| Sánchez, G | 2 |
| Castro, C | 1 |
| Siemion-Szcześniak, I | 1 |
| Bartoszuk, I | 1 |
| Bartosiewicz, M | 1 |
| Jakubowska, L | 1 |
| Wesołowski, S | 1 |
| Kuś, J | 1 |
| Corluy, L | 2 |
| Joos, R | 2 |
| Langenaken, C | 2 |
| Taelman, V | 2 |
| Raeman, F | 2 |
| Ravelingien, I | 2 |
| Vandevyvere, K | 2 |
| Lenaerts, J | 2 |
| Geens, E | 2 |
| Geusens, P | 2 |
| Vanhoof, J | 2 |
| Durnez, A | 2 |
| Remans, J | 2 |
| Vander Cruyssen, B | 2 |
| Van Essche, E | 2 |
| Sileghem, A | 2 |
| De Brabanter, G | 2 |
| Meyfroidt, S | 2 |
| Al-Abd, AM | 1 |
| Al-Abbasi, FA | 1 |
| Nofal, SM | 1 |
| Khalifa, AE | 1 |
| Williams, RO | 1 |
| El-Eraky, WI | 1 |
| Nagy, AA | 1 |
| Abdel-Naim, AB | 1 |
| Harman, H | 1 |
| Tekeoğlu, I | 1 |
| Kaban, N | 1 |
| Harman, S | 1 |
| Oliveira, AC | 1 |
| Mota, LM | 1 |
| Santos-Neto, LL | 1 |
| Simões, M | 1 |
| Martins-Filho, OA | 1 |
| Tauil, PL | 1 |
| Vandenbos, F | 1 |
| Figueredo, M | 1 |
| Tarhini, A | 1 |
| Ribière, J | 1 |
| Blasco-Morente, G | 1 |
| Notario-Ferreira, I | 1 |
| Rueda-Villafranca, B | 1 |
| Tercedor-Sánchez, J | 1 |
| Hamilton, JA | 1 |
| Bishop, JM | 1 |
| Bilasy, SE | 1 |
| Essawy, SS | 1 |
| Mandour, MF | 1 |
| Ali, EA | 1 |
| Zaitone, SA | 1 |
| van Nies, JA | 1 |
| Tsonaka, R | 1 |
| Gaujoux-Viala, C | 1 |
| van der Helm-van Mil, AH | 1 |
| Maskey-Warzęchowska, M | 1 |
| Karwat, K | 1 |
| Szczepankiewicz, B | 1 |
| Langfort, R | 1 |
| Szołkowska, M | 1 |
| Chazan, R | 1 |
| Díaz-Torné, C | 2 |
| Magallares, B | 1 |
| Hernández, MV | 2 |
| Reina, D | 1 |
| Corominas, H | 1 |
| Sanmartí, R | 2 |
| de la Serna, AR | 1 |
| Llobet, JM | 1 |
| Nolla, JM | 2 |
| Kujawski, J | 1 |
| Bernard, MK | 1 |
| Jodłowska, E | 1 |
| Czaja, K | 1 |
| Drabińska, B | 1 |
| Lin, KM | 1 |
| Cheng, TT | 1 |
| Lin, JC | 1 |
| Chen, CJ | 1 |
| Bae, J | 1 |
| Park, JW | 1 |
| Pfeil, A | 2 |
| Oelzner, P | 2 |
| Renz, DM | 2 |
| Hansch, A | 2 |
| Wolf, G | 2 |
| Böttcher, J | 2 |
| Vitry, AI | 1 |
| Ren, LM | 1 |
| Chen, LN | 2 |
| Zhu, P | 3 |
| Gu, F | 1 |
| Sun, LY | 1 |
| Liu, XY | 2 |
| Guo, JL | 1 |
| Bi, LQ | 1 |
| Hao, YJ | 1 |
| Zhang, ZL | 2 |
| Mei, YF | 1 |
| Zhang, ZY | 1 |
| Liu, HX | 1 |
| Li, XF | 3 |
| Fang, YF | 1 |
| Su, Y | 3 |
| Xiang, N | 1 |
| Zhang, MJ | 1 |
| Zhao, DB | 1 |
| Zuo, XX | 1 |
| Yang, M | 1 |
| Cummins, L | 1 |
| Katikireddi, VS | 1 |
| Shankaranarayana, S | 1 |
| Su, KY | 1 |
| Duggan, E | 1 |
| Videm, V | 1 |
| Pahau, H | 1 |
| Thomas, R | 1 |
| Rule, GS | 1 |
| Rockwood, AL | 1 |
| Johnson-Davis, KL | 1 |
| Yan, JY | 1 |
| Liu, ZH | 1 |
| Chu, YL | 1 |
| Molina Molina, MI | 1 |
| Pinochet Paiva, CM | 1 |
| Quezada Morales, JI | 1 |
| Sauer, BC | 1 |
| Jorgenson, E | 1 |
| Davis, L | 1 |
| Kim, G | 1 |
| Barner, JC | 1 |
| Rascati, K | 1 |
| Richards, K | 1 |
| Conway, R | 1 |
| Low, C | 1 |
| Coughlan, RJ | 1 |
| O'Donnell, MJ | 1 |
| Carey, JJ | 1 |
| Machado-Alba, JE | 1 |
| Ruiz, AF | 1 |
| Machado-Duque, ME | 1 |
| Gerosa, M | 1 |
| Schioppo, T | 1 |
| Meroni, PL | 1 |
| Keng, LT | 1 |
| Lin, MW | 1 |
| Huang, HN | 1 |
| Chung, KP | 1 |
| Bennike, TB | 1 |
| Ellingsen, T | 1 |
| Glerup, H | 1 |
| Bonderup, OK | 1 |
| Carlsen, TG | 1 |
| Meyer, MK | 1 |
| Bøgsted, M | 1 |
| Christiansen, G | 1 |
| Birkelund, S | 1 |
| Andersen, V | 1 |
| Stensballe, A | 1 |
| Park, SK | 1 |
| Lee, MY | 1 |
| Park, JH | 1 |
| Jeong, JH | 1 |
| Benzerdjeb, N | 1 |
| Ameur, F | 1 |
| Ikoli, JF | 1 |
| Sevestre, H | 1 |
| Liao, TL | 1 |
| Liu, HJ | 1 |
| Zhong, W | 1 |
| Zhao, L | 1 |
| Liu, T | 2 |
| Moon, SJ | 1 |
| Kim, EK | 1 |
| Jhun, JY | 1 |
| Lee, HJ | 1 |
| Lee, WS | 1 |
| Cho, ML | 1 |
| Min, JK | 1 |
| Sizova, L | 1 |
| Inokuma, S | 4 |
| Sagawa, A | 3 |
| Matsuda, T | 4 |
| Takemura, T | 3 |
| Ohtsuka, T | 1 |
| Saeki, Y | 3 |
| Takeuchi, T | 4 |
| Sawada, T | 4 |
| Karanikolas, G | 2 |
| Charalambopoulos, D | 2 |
| Vaiopoulos, G | 1 |
| Andrianakos, A | 2 |
| Rapti, A | 1 |
| Karras, D | 1 |
| Kaskani, E | 1 |
| Klimiuk, PA | 1 |
| Kita, J | 1 |
| Chwiecko, J | 1 |
| Sierakowski, S | 1 |
| Gugenberger, C | 1 |
| Donner, P | 1 |
| Naami, A | 1 |
| Berges, W | 1 |
| Rajakulendran, S | 1 |
| Gadsby, K | 1 |
| Deighton, C | 2 |
| Lippold, J | 1 |
| Eidner, T | 1 |
| Lehmann, G | 1 |
| Hein, G | 2 |
| Kaiser, WA | 1 |
| Homer, D | 1 |
| Nightingale, P | 1 |
| Jobanputra, P | 1 |
| Hassikou, H | 1 |
| El Haouri, M | 1 |
| Tabache, F | 1 |
| Baaj, M | 1 |
| Safi, S | 1 |
| Hadri, L | 1 |
| Rahmlow, M | 1 |
| Shuster, EA | 1 |
| Dominik, J | 1 |
| Deen, HG | 1 |
| Dickson, DW | 1 |
| Aksamit, AJ | 1 |
| Robles, HA | 1 |
| Freeman, WD | 1 |
| Caprioli, M | 1 |
| Bobbio-Pallavicini, F | 1 |
| Montecucco, C | 1 |
| Novak, S | 2 |
| Manda, G | 1 |
| Neagu, M | 1 |
| Constantin, C | 1 |
| Neagoe, I | 1 |
| Codreanu, C | 1 |
| Hierse, F | 1 |
| Kekow, J | 1 |
| von Hinueber, U | 1 |
| Tony, HP | 1 |
| Dockhorn, R | 1 |
| Beukelman, T | 1 |
| Onofrei, A | 1 |
| Cassell, S | 1 |
| Greenberg, JD | 1 |
| Kavanaugh, A | 2 |
| Reed, G | 1 |
| Strand, V | 21 |
| Kremer, JM | 9 |
| Yamanaka, H | 3 |
| Manger, B | 1 |
| Brasington, R | 1 |
| Herczynska, M | 1 |
| Kurzawski, M | 3 |
| Drozdzik, M | 1 |
| White, DH | 1 |
| Lynskey, NV | 1 |
| Jones, PB | 1 |
| Gergely, P | 1 |
| Poór, G | 3 |
| van der Heijden, JW | 1 |
| Oerlemans, R | 1 |
| Tak, PP | 5 |
| Assaraf, YG | 1 |
| Kraan, MC | 6 |
| Scheffer, GL | 1 |
| van der Laken, CJ | 1 |
| Lems, WF | 1 |
| Scheper, RJ | 1 |
| Dijkmans, BA | 5 |
| Jansen, G | 2 |
| Yukawa, N | 1 |
| Mimori, T | 2 |
| Chikura, B | 1 |
| Lane, S | 1 |
| Dawson, JK | 2 |
| Otsuka, T | 3 |
| Seror, R | 1 |
| Tubach, F | 1 |
| Guillemin, F | 3 |
| Nesheiwat, JP | 1 |
| Dillon, K | 1 |
| McGlothan, K | 1 |
| Zaman, M | 1 |
| Carbone, LD | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Tréchot, P | 1 |
| Østensen, M | 1 |
| Förger, F | 1 |
| Ochi, S | 2 |
| Taniguchi, K | 1 |
| Nagashima, M | 1 |
| Kelly, C | 1 |
| Alivernini, S | 1 |
| Mazzotta, D | 1 |
| Zoli, A | 1 |
| Ferraccioli, G | 1 |
| Tamborenea, MN | 1 |
| Mysler, E | 1 |
| Debonis, J | 1 |
| Schijedman, A | 1 |
| Bohanec Grabar, P | 2 |
| Grabnar, I | 1 |
| Rozman, B | 13 |
| Logar, D | 4 |
| Tomsic, M | 6 |
| Suput, D | 2 |
| Trdan, T | 1 |
| Peterlin Masic, L | 1 |
| Mrhar, A | 1 |
| Dolzan, V | 3 |
| Matsuno, T | 1 |
| Grabar, PB | 1 |
| Praprotnik, S | 3 |
| Nasonov, EL | 1 |
| Mora, C | 1 |
| González, A | 1 |
| Díaz, J | 1 |
| Quintana, G | 1 |
| Bes, C | 1 |
| Soy, M | 1 |
| Kim, SH | 2 |
| Yoo, WH | 3 |
| Alcorn, N | 1 |
| Saunders, S | 1 |
| Madhok, R | 2 |
| Nesa, L | 1 |
| Gobbi, C | 1 |
| Alba, P | 1 |
| Exeni, I | 1 |
| Albiero, E | 1 |
| Wong, SP | 1 |
| Chu, CM | 1 |
| Kan, CH | 1 |
| Tsui, HS | 1 |
| Ng, WL | 1 |
| Borges, H | 1 |
| Schnyder, JM | 1 |
| Frey, JG | 1 |
| Tschopp, JM | 1 |
| Henes, JC | 1 |
| Schedel, J | 1 |
| Kanz, L | 2 |
| Koetter, I | 1 |
| Wüsthof, M | 1 |
| Smirnova, A | 1 |
| Bacher, U | 1 |
| Kröger, N | 1 |
| Zander, AR | 1 |
| Schuch, G | 1 |
| Bokemeyer, C | 1 |
| Jo, YM | 1 |
| Kim, SY | 1 |
| Roh, MS | 1 |
| De Stefano, R | 1 |
| Frati, E | 1 |
| Nargi, F | 1 |
| Baldi, C | 1 |
| Menza, L | 1 |
| Hammoud, M | 1 |
| Galeazzi, M | 1 |
| Chambers, CD | 3 |
| Johnson, DL | 2 |
| Robinson, LK | 1 |
| Braddock, SR | 1 |
| Xu, R | 1 |
| Lopez-Jimenez, J | 1 |
| Mirrasoul, N | 1 |
| Salas, E | 1 |
| Luo, YJ | 1 |
| Jin, S | 1 |
| Jones, KL | 2 |
| Grijalva, CG | 2 |
| Kaltenbach, L | 1 |
| Arbogast, PG | 2 |
| Mitchel, EF | 2 |
| Griffin, MR | 2 |
| Seitz, CS | 1 |
| Berens, N | 1 |
| Bröcker, EB | 1 |
| Trautmann, A | 1 |
| Cutolo, M | 3 |
| Villaggio, B | 2 |
| Pizzorni, C | 1 |
| Paolino, S | 1 |
| Moretti, S | 1 |
| Gallo, F | 1 |
| Bonassi, S | 1 |
| Sulli, A | 2 |
| Seriolo, B | 2 |
| Montagna, P | 2 |
| Soldano, S | 1 |
| McLaren, ZL | 1 |
| Savage, RL | 3 |
| Kellner, H | 2 |
| Bornholdt, K | 1 |
| Chen, LA | 1 |
| Su, LH | 1 |
| Chang, YJ | 1 |
| Hsu, YL | 1 |
| Tsai, TH | 1 |
| Hajdyla-Banaś, I | 1 |
| Banas, T | 1 |
| Rydz-Stryszowska, I | 1 |
| Batko, B | 1 |
| Skura, A | 1 |
| Górnisiewicz, T | 1 |
| Pityńska-Korab, E | 1 |
| Osiri, M | 3 |
| Ricci, M | 1 |
| Rossi, P | 1 |
| De Marco, G | 1 |
| Varisco, V | 1 |
| Marchesoni, A | 2 |
| Zhang, JC | 1 |
| Kwakernaak, AJ | 1 |
| Houtman, PM | 4 |
| Weel, JF | 1 |
| Spoorenberg, JP | 1 |
| Jansen, TL | 5 |
| Hyrich, K | 1 |
| Askling, J | 1 |
| Arkema, E | 1 |
| Davies, R | 1 |
| Neovius, M | 1 |
| Simard, J | 1 |
| Symmons, D | 1 |
| Watson, K | 1 |
| Mittal, N | 1 |
| Sharma, A | 2 |
| Jose, V | 1 |
| Mittal, R | 1 |
| Wanchu, A | 2 |
| Bambery, P | 2 |
| Chlubek, D | 2 |
| Hameed, K | 1 |
| Mirza, AI | 1 |
| Ahmad, NM | 1 |
| Farman, S | 1 |
| Saeed, MA | 1 |
| Hameed, R | 1 |
| Umair, M | 1 |
| Ghafoor, E | 1 |
| Leban, J | 1 |
| Vitt, D | 1 |
| Schipper, LG | 1 |
| Kievit, W | 1 |
| den Broeder, AA | 1 |
| van der Laar, MA | 1 |
| Adang, EM | 1 |
| Fransen, J | 2 |
| van Riel, PL | 9 |
| Singer, O | 1 |
| Gibofsky, A | 1 |
| Behrens, F | 2 |
| Koehm, M | 1 |
| Burkhardt, H | 1 |
| Klatt, JC | 1 |
| Gröbe, A | 1 |
| Schmelzle, R | 1 |
| Atac, A | 1 |
| Heiland, M | 1 |
| Blessmann, M | 1 |
| Pohlenz, P | 1 |
| Adamski, H | 1 |
| Lopez, L | 1 |
| Chevrant-Breton, J | 1 |
| Dupuy, A | 1 |
| Gupta, R | 2 |
| Bhatia, J | 1 |
| Gupta, SK | 2 |
| Savoia, F | 1 |
| Gaddoni, G | 1 |
| Casadio, C | 1 |
| Spadola, G | 1 |
| Patrizi, A | 1 |
| Giacomini, F | 1 |
| Aldi, M | 1 |
| Ruiz, JM | 1 |
| Torrente-Segarra, V | 1 |
| Ros, S | 1 |
| Rodriguez de la Serna, A | 2 |
| Díaz-López, C | 1 |
| Babić-Naglić, D | 1 |
| Anić, B | 1 |
| Grazio, S | 1 |
| Martinavić Kaliterna, D | 1 |
| Sakellariou, GT | 1 |
| Sayegh, FE | 1 |
| Kapetanos, GA | 1 |
| Berberidis, C | 1 |
| Mohr, M | 1 |
| Jacobi, AM | 1 |
| Chatzidionysiou, K | 1 |
| Lie, E | 1 |
| Nasonov, E | 1 |
| Lukina, G | 1 |
| Hetland, ML | 1 |
| Tarp, U | 1 |
| Nordström, DC | 2 |
| Gomez-Reino, J | 1 |
| Pavelka, K | 1 |
| van Vollenhoven, RF | 1 |
| Gabay, C | 3 |
| Kiss, E | 1 |
| Kiss, CG | 1 |
| Ossowski, A | 1 |
| Piatek, J | 1 |
| Parafiniuk, M | 1 |
| Jagoda, JS | 1 |
| Rajapakse, CN | 1 |
| Kawai, VK | 1 |
| Delzell, E | 1 |
| Chen, L | 1 |
| Ouellet-Hellstrom, R | 1 |
| Herrinton, L | 1 |
| Stein, CM | 2 |
| Alvarez, PA | 1 |
| Saad, AK | 1 |
| Flagel, S | 1 |
| Mazzocchi, O | 1 |
| Blanco, MV | 1 |
| Palazzo, E | 1 |
| Yahia, SA | 1 |
| Du Pan, SM | 1 |
| Scherer, A | 1 |
| Finckh, A | 2 |
| Ichikawa, N | 1 |
| Golicki, D | 1 |
| Newada, M | 1 |
| Lis, J | 1 |
| Pol, K | 1 |
| Hermanowski, T | 1 |
| Tłustochowicz, M | 2 |
| Sieper, J | 1 |
| Ping, L | 1 |
| Wang, X | 1 |
| Tian, J | 1 |
| Wang, XR | 1 |
| An, Y | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Duan, TJ | 1 |
| Zhu, JX | 1 |
| Wang, LZ | 1 |
| Wang, CH | 1 |
| Wang, YF | 1 |
| Yang, R | 1 |
| Wang, GC | 1 |
| Lu, X | 1 |
| Jin, HT | 1 |
| Sun, L | 2 |
| Chen, HY | 1 |
| Cui, LF | 1 |
| Shu, R | 1 |
| Liu, BL | 1 |
| Li, GT | 1 |
| Li, ZB | 1 |
| Li, JF | 1 |
| Jia, B | 1 |
| Zhang, FX | 1 |
| Tao, JM | 1 |
| Han, SL | 1 |
| Lin, JY | 1 |
| Wei, MQ | 1 |
| Liu, XM | 1 |
| Ke, D | 1 |
| Hu, SX | 1 |
| Yang, XY | 1 |
| Huang, CB | 1 |
| Gao, M | 1 |
| Lai, P | 1 |
| Song, LJ | 1 |
| Mu, R | 1 |
| Davis, JM | 1 |
| Matteson, EL | 1 |
| Balasanthiran, A | 1 |
| Vakilgilani, T | 1 |
| Darzy, K | 1 |
| Axon, J | 1 |
| Schnabl, M | 2 |
| O'Doherty, C | 2 |
| Sorich, MJ | 1 |
| Yoo, HG | 1 |
| Yu, HM | 1 |
| Jeon, HS | 1 |
| Daïen, CI | 1 |
| Fesler, P | 1 |
| du Cailar, G | 1 |
| Daïen, V | 1 |
| Mura, T | 1 |
| Dupuy, AM | 1 |
| Cristol, JP | 1 |
| Ribstein, J | 1 |
| Perdan-Pirkmajer, K | 1 |
| Hočevar, A | 2 |
| Rotar, Ž | 1 |
| Žibert, J | 1 |
| Marolt, VF | 1 |
| Gučev, F | 1 |
| Tomos, P | 1 |
| Lachanas, E | 1 |
| Agathos, EA | 1 |
| Grigorakos, L | 1 |
| James, M | 1 |
| Sacnun, MP | 1 |
| Wojdyla, D | 1 |
| Saurit, V | 1 |
| Pinto, MR | 1 |
| Cordeiro de Azevedo, AB | 1 |
| da Silveira, IG | 1 |
| Ximenes, AC | 1 |
| Massardo, L | 1 |
| Rojas-Villarraga, A | 1 |
| Oñate, RV | 1 |
| Hernandez, MP | 1 |
| García-De La Torre, I | 1 |
| Khoury, VJ | 1 |
| Millán, A | 1 |
| Soriano, ER | 1 |
| Park, HJ | 1 |
| Kim, BK | 1 |
| Han, KH | 1 |
| Lee, SK | 1 |
| Kim, SU | 1 |
| Granger, B | 1 |
| Le Loet, X | 4 |
| Bergner, R | 1 |
| Peters, L | 1 |
| Schmitt, V | 1 |
| Löffler, C | 1 |
| Londono, J | 1 |
| Santos, AM | 1 |
| Santos, PI | 1 |
| Cubidez, MF | 1 |
| Guzman, C | 1 |
| Valle-Oñate, R | 1 |
| Pomirleanu, C | 1 |
| Ancuta, C | 1 |
| Miu, S | 1 |
| Chirieac, R | 1 |
| Bird, P | 1 |
| Griffiths, H | 1 |
| Tymms, K | 1 |
| Nicholls, D | 1 |
| Roberts, L | 1 |
| Arnold, M | 1 |
| Burnet, S | 1 |
| de Jager, J | 1 |
| Scott, J | 1 |
| Zochling, J | 1 |
| Littlejohn, G | 1 |
| Russell, AS | 1 |
| Mallon, C | 1 |
| Conner-Spady, B | 1 |
| Maksymowych, W | 1 |
| Verma, SK | 1 |
| Mishra, AK | 1 |
| Jaiswal, AK | 1 |
| Bolosiu, H | 1 |
| Perdriset, G | 1 |
| Nurmohamed, MT | 1 |
| van Halm, VP | 1 |
| Erkan, D | 1 |
| Yazici, Y | 1 |
| Harrison, MJ | 1 |
| Paget, SA | 1 |
| Scott, DL | 9 |
| Carulli, MT | 1 |
| Davies, UM | 1 |
| Geborek, P | 1 |
| Crnkic, M | 1 |
| Petersson, IF | 1 |
| Saxne, T | 1 |
| Soliotis, F | 1 |
| Glover, M | 1 |
| Jawad, AS | 1 |
| Venancie, PY | 1 |
| Cunnane, G | 1 |
| Warnock, M | 1 |
| Fye, KH | 2 |
| Daikh, DI | 1 |
| Legras, A | 1 |
| Bergemer-Fouquet, AM | 1 |
| Jonville-Bera, AP | 1 |
| Genovese, MC | 2 |
| Caldwell, JR | 1 |
| Cush, JJ | 2 |
| Furst, DE | 7 |
| Luggen, ME | 1 |
| Keystone, E | 2 |
| Weisman, MH | 1 |
| Bensen, WM | 1 |
| Kaine, JL | 1 |
| Ruderman, EM | 2 |
| Coleman, P | 2 |
| Curtis, DL | 1 |
| Kopp, EJ | 1 |
| Kantor, SM | 1 |
| Waltuck, J | 2 |
| Lindsley, HB | 2 |
| Markenson, JA | 1 |
| Crawford, B | 6 |
| Fernando, I | 2 |
| Simpson, K | 2 |
| Bathon, JM | 1 |
| Schiemann, U | 1 |
| Lim, V | 1 |
| Pande, I | 1 |
| Hill, RL | 1 |
| Topliss, DJ | 1 |
| Purcell, PM | 1 |
| Arreghini, M | 1 |
| Panni, B | 1 |
| Battafarano, N | 1 |
| Uziel, L | 1 |
| Hirohata, S | 1 |
| Maetzel, A | 4 |
| Tugwell, P | 8 |
| Wells, G | 6 |
| Bombardier, C | 4 |
| Schnarr, S | 1 |
| Hülsemann, JL | 1 |
| Zeidler, HK | 1 |
| Shea, B | 2 |
| Robinson, V | 2 |
| Suarez-Almazor, M | 3 |
| Chakravarty, EF | 1 |
| Sanchez-Yamamoto, D | 1 |
| Bush, TM | 1 |
| Schnabel, A | 1 |
| Gross, WL | 1 |
| Breedveld, FC | 13 |
| Schiff, MH | 2 |
| Kalden, JR | 11 |
| Emery, P | 20 |
| Eberl, G | 2 |
| Pincus, T | 2 |
| Koch, G | 1 |
| Amara, I | 2 |
| Wolfe, F | 5 |
| Cohen, S | 4 |
| Felson, D | 1 |
| Hoi, A | 1 |
| Littlejohn, GO | 1 |
| Moynihan, R | 1 |
| Cohen, SB | 2 |
| Iqbal, I | 1 |
| Bruyn, GA | 5 |
| Veenstra, RP | 1 |
| Halma, C | 1 |
| Grond, J | 1 |
| Miceli-Richard, C | 1 |
| Schattenkirchner, M | 6 |
| Sörensen, H | 1 |
| Breedveld, F | 1 |
| Ory, PA | 1 |
| Lee, CS | 1 |
| Chang, CK | 1 |
| Hamann, F | 1 |
| Ho, CY | 1 |
| Wong, CK | 1 |
| Li, EK | 2 |
| Tam, LS | 2 |
| Lam, CW | 1 |
| Schmidt, A | 1 |
| Schwind, B | 1 |
| Gillich, M | 1 |
| Brune, K | 1 |
| Hinz, B | 1 |
| Mohty, R | 1 |
| Chaby, G | 1 |
| Pannier, M | 1 |
| Defossez, C | 1 |
| Denoeux, JP | 1 |
| Lok, C | 1 |
| Canonne-Courivaud, D | 1 |
| Carpentier, O | 1 |
| Dejobert, Y | 1 |
| Hachulla, E | 1 |
| Delaporte, E | 1 |
| Stephenson, B | 1 |
| Doyle, J | 3 |
| Erra, A | 1 |
| Tomas, C | 1 |
| Barcelo, P | 1 |
| Vilardell, M | 1 |
| Marsal, S | 1 |
| Balabanova, RM | 4 |
| Bao, C | 1 |
| Chen, S | 1 |
| Lao, Z | 1 |
| Ni, L | 1 |
| Yu, Q | 1 |
| He, P | 1 |
| Ma, J | 1 |
| Xu, S | 1 |
| Ding, C | 1 |
| Fantini, F | 1 |
| Stamm, T | 2 |
| Kapral, T | 2 |
| Grisar, J | 1 |
| Machold, KP | 1 |
| Schooff, M | 1 |
| Wickersham, J | 1 |
| Rau, R | 2 |
| Kawai, S | 1 |
| Fischer, TW | 1 |
| Bauer, HI | 1 |
| Graefe, T | 1 |
| Barta, U | 1 |
| Elsner, P | 1 |
| Siva, C | 1 |
| Eisen, SA | 1 |
| Shepherd, R | 1 |
| Cunningham, F | 1 |
| Fang, MA | 1 |
| Finch, W | 1 |
| Salisbury, D | 1 |
| Singh, JA | 1 |
| Stern, R | 1 |
| Zarabadi, SA | 1 |
| Finesilver, AG | 1 |
| Lemmel, EM | 3 |
| de la Serna, R | 1 |
| Zerbini, CA | 2 |
| Brin, S | 2 |
| van Riel, P | 3 |
| Barak, A | 1 |
| Morse, LS | 1 |
| Schwab, I | 1 |
| Jaimes-Hernández, J | 1 |
| Robles-San Román, M | 1 |
| Suárez-Otero, R | 1 |
| Dávalos-Zugasti, ME | 1 |
| Arroyo-Borrego, S | 1 |
| Jakez-Ocampo, J | 2 |
| Richaud-Patin, Y | 2 |
| Granados, J | 1 |
| Sánchez-Guerrero, J | 1 |
| Llorente, L | 2 |
| McCurry, J | 1 |
| Sevilla-Mantilla, C | 1 |
| Ortega, L | 1 |
| Agúndez, JA | 1 |
| Ladero, JM | 1 |
| Díaz-Rubio, M | 1 |
| Schädlich, PK | 3 |
| Zeidler, H | 3 |
| Gromnica-Ihle, E | 4 |
| Schneider, M | 3 |
| Straub, C | 3 |
| Brecht, JG | 3 |
| Huppertz, E | 3 |
| Braun, MG | 1 |
| Van Rhee, R | 1 |
| Becker-Capeller, D | 1 |
| Fraenkel, L | 1 |
| Bogardus, ST | 1 |
| Concato, J | 1 |
| Felson, DT | 1 |
| Wittink, DR | 1 |
| Urushibara, M | 2 |
| Takayanagi, H | 1 |
| Koga, T | 1 |
| Kim, S | 1 |
| Isobe, M | 1 |
| Morishita, Y | 1 |
| Nakagawa, T | 1 |
| Löeffler, M | 1 |
| Kodama, T | 1 |
| Kurosawa, H | 1 |
| Taniguchi, T | 1 |
| Amano, K | 1 |
| Tsuzake, K | 1 |
| Kameda, H | 1 |
| Abe, T | 1 |
| Hansen, KE | 1 |
| Cush, J | 2 |
| Singhal, A | 1 |
| Cooley, DA | 1 |
| Patel, SR | 1 |
| Genovese, M | 2 |
| Sundaramurthy, S | 1 |
| Schiff, M | 3 |
| Haydar, AA | 1 |
| Hujairi, N | 1 |
| Kirkham, B | 2 |
| Hangartner, R | 1 |
| Goldsmith, DJ | 1 |
| Kerr, OA | 1 |
| Murray, CS | 1 |
| Tidman, MJ | 1 |
| Smeets, TJ | 2 |
| van Loon, MJ | 1 |
| Rivarola de Gutierrez, E | 1 |
| Abaca, H | 1 |
| Kalden, J | 1 |
| Scott, D | 2 |
| Smolen, J | 1 |
| Fiehn, C | 2 |
| Rochel, E | 2 |
| Ho, AD | 1 |
| Max, R | 1 |
| Van Roon, EN | 4 |
| Mourad, L | 2 |
| Griep, EN | 3 |
| Wilffert, B | 2 |
| Tobi, H | 3 |
| Brouwers, JR | 4 |
| Olsen, NJ | 2 |
| Strand, CV | 4 |
| van der Heijde, DM | 1 |
| Rüther, W | 2 |
| Burmester, GR | 2 |
| Cohen, JD | 1 |
| Jorgensen, C | 1 |
| Sany, J | 1 |
| Tomlinson, B | 1 |
| Bharadwaj, A | 1 |
| Haroon, N | 1 |
| Makolkin, VI | 1 |
| Shostak, NA | 1 |
| Chichasova, NV | 2 |
| Oliunin, IuA | 3 |
| Goriachev, DV | 1 |
| Loginova, TK | 1 |
| Riabkova, AA | 1 |
| Petukhova, NV | 1 |
| Men'shikova, IV | 1 |
| Suissa, S | 3 |
| Ernst, P | 2 |
| Hudson, M | 3 |
| Bitton, A | 1 |
| Kezouh, A | 1 |
| Kremer, J | 1 |
| Caldwell, J | 3 |
| Luggen, M | 1 |
| Bathon, J | 1 |
| Ruderman, E | 1 |
| Curtis, D | 1 |
| Kopp, E | 1 |
| Kantor, S | 1 |
| Weisman, M | 1 |
| Markenson, J | 1 |
| Cui, Y | 1 |
| Luo, rQ | 1 |
| Yao, RY | 1 |
| Ulusoy, H | 1 |
| Bilgici, A | 1 |
| Kuru, O | 1 |
| Celenk, C | 1 |
| van de Laar, MA | 2 |
| Janssen, M | 1 |
| Yska, JP | 1 |
| Keuper, R | 1 |
| Chikkamuniyappa, S | 1 |
| Kuzmanova, SI | 1 |
| Solakov, PT | 1 |
| Batalov, AZ | 1 |
| Staikova, ND | 1 |
| Andreev, SA | 1 |
| Russafov, PB | 1 |
| Holden, WL | 1 |
| Juhaeri, J | 1 |
| Dai, W | 1 |
| Scarazzini, L | 1 |
| Stang, P | 1 |
| Macdonald, J | 1 |
| Zhong, T | 1 |
| Lazarescu, A | 1 |
| Gan, BS | 1 |
| Harth, M | 1 |
| Laborde, F | 1 |
| Loeuille, D | 1 |
| Chary-Valckenaere, I | 1 |
| Martinez-Taboada, VM | 1 |
| Rodriguez-Valverde, V | 1 |
| Gonzalez-Vilchez, F | 1 |
| Armijo, JA | 1 |
| Vandooren, AK | 1 |
| Oliushin, IuA | 1 |
| Issa, SN | 1 |
| Bingham, SJ | 1 |
| Buch, MH | 1 |
| Kerr, MA | 1 |
| Valadäo Barcelos, AT | 1 |
| Welsing, PM | 2 |
| Severens, JL | 1 |
| Hartman, M | 1 |
| Laan, RF | 2 |
| Flendrie, M | 1 |
| Creemers, MC | 1 |
| Kiely, PD | 2 |
| Ito, S | 1 |
| Sumida, T | 1 |
| Kamata, Y | 1 |
| Nara, H | 1 |
| Kamimura, T | 1 |
| Haneda, K | 1 |
| Iwamoto, M | 1 |
| Masuyama, J | 1 |
| Okazaki, H | 1 |
| Minota, S | 1 |
| Maddison, P | 1 |
| Kiely, P | 1 |
| Lawson, T | 1 |
| Moots, R | 1 |
| Proudfoot, D | 1 |
| Reece, R | 1 |
| Sword, R | 1 |
| Taggart, A | 1 |
| Thwaites, C | 1 |
| Williams, E | 1 |
| Thomasset, SC | 1 |
| Ong, SL | 1 |
| Large, SR | 1 |
| Capriotti, T | 1 |
| Knab, J | 1 |
| Goos, M | 1 |
| Dissemond, J | 1 |
| Goëb, V | 1 |
| Berthelot, JM | 2 |
| Joly, P | 1 |
| Mejjad, O | 2 |
| de Quatrebarbes, J | 1 |
| Reynaud-Hautin, C | 1 |
| Lioté, H | 1 |
| Martin, K | 2 |
| Bentaberry, F | 2 |
| Dumoulin, C | 2 |
| Longy-Boursier, M | 1 |
| Lifermann, F | 1 |
| Haramburu, F | 2 |
| Dehais, J | 2 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Bolten, W | 1 |
| Ochi, T | 1 |
| Kawabata, D | 1 |
| Nakajima, A | 1 |
| Sugii, S | 1 |
| Koch, GG | 1 |
| Reddy, SV | 1 |
| Khullar, M | 1 |
| Govindrajan, S | 1 |
| Fath, R | 1 |
| Derk, CT | 1 |
| Ranganath, VK | 2 |
| Kaltwasser, JP | 2 |
| Takeishi, M | 1 |
| Akiyama, Y | 1 |
| Akiba, H | 1 |
| Adachi, D | 1 |
| Hirano, M | 1 |
| Mimura, T | 1 |
| Kochbati, S | 1 |
| Ben Miled, M | 1 |
| Boussema, F | 1 |
| Ktari, S | 1 |
| Daoud, L | 1 |
| Ben Rhouma, S | 1 |
| Ben Amor, G | 1 |
| Chérif, O | 1 |
| Rokbani, L | 1 |
| Igolkina, EV | 1 |
| Brodetskaia, KA | 1 |
| Imametdinova, GR | 1 |
| Kopp, HG | 1 |
| Moerike, K | 1 |
| Hartmann, JT | 1 |
| Antoni, C | 1 |
| Alvaro-Gracia, JM | 1 |
| Vergne-Salle, P | 1 |
| Léger, DY | 1 |
| Bertin, P | 1 |
| Trèves, R | 1 |
| Beneytout, JL | 1 |
| Liagre, B | 1 |
| Chan, V | 1 |
| Charles, BG | 1 |
| Hoekstra, M | 1 |
| Bernelot Moens, HJ | 1 |
| Gómez Rodríguez, N | 1 |
| Zulaica Garate, A | 1 |
| Cobo Ibáñez, T | 1 |
| Yehia Tayel, M | 1 |
| Balsa Criado, A | 1 |
| Hernández Sanz, A | 1 |
| Martín Mola, E | 1 |
| Khanna, D | 1 |
| Park, GS | 1 |
| Paulus, HE | 1 |
| Simpson, KM | 1 |
| Elashoff, D | 1 |
| Dorrier, C | 3 |
| Rozin, A | 1 |
| Yigla, M | 1 |
| Guralnik, L | 1 |
| Keidar, Z | 1 |
| Vlodavsky, E | 1 |
| Nahir, AM | 1 |
| Balbir-Gurman, A | 1 |
| Elias, AR | 1 |
| Tam, CC | 1 |
| David-Bajar, KM | 1 |
| Capellino, S | 1 |
| Gabelle, A | 1 |
| Antoine, JC | 1 |
| Hillaire-Buys, D | 1 |
| Coudeyre, E | 1 |
| Camu, W | 1 |
| Lestan, B | 1 |
| Erzen, D | 1 |
| Petric, V | 1 |
| Rintelen, B | 1 |
| Andel, I | 1 |
| Sautner, J | 1 |
| Leeb, BF | 1 |
| Litinsky, I | 1 |
| Paran, D | 1 |
| Levartovsky, D | 1 |
| Wigler, I | 1 |
| Kaufman, I | 1 |
| Yaron, I | 1 |
| Yaron, M | 1 |
| Caspi, D | 1 |
| Elkayam, O | 1 |
| D'Amore, M | 1 |
| Minenna, G | 1 |
| D'Amore, S | 1 |
| Highton, J | 1 |
| Boyd, IW | 1 |
| Chapman, P | 1 |
| Antoniades, C | 1 |
| Katsilambros, N | 1 |
| Alexander, D | 1 |
| Friedrich, B | 1 |
| Abruzzese, T | 1 |
| Gondolph-Zink, B | 1 |
| Wülker, N | 1 |
| Aicher, WK | 1 |
| Hanna, FY | 1 |
| Jakob, A | 1 |
| Porstmann, R | 1 |
| Rompel, R | 1 |
| Perdriger, A | 1 |
| Kuntz, JL | 1 |
| Brocq, O | 1 |
| Kara-Terki, R | 1 |
| Loet, XL | 1 |
| Pavy, S | 1 |
| Deslandre, CJ | 1 |
| Debiais, F | 1 |
| Zhao, YX | 1 |
| Dendooven, A | 1 |
| De Rycke, L | 1 |
| Verhelst, X | 1 |
| Mielants, H | 1 |
| Veys, EM | 1 |
| De Keyser, F | 1 |
| Chonlahan, J | 1 |
| Halloran, MA | 1 |
| Hammonds, A | 1 |
| Grover, R | 1 |
| Dhir, V | 1 |
| Aneja, R | 1 |
| Arya, V | 1 |
| Galle, A | 1 |
| Marwaha, V | 1 |
| Fuerst, M | 1 |
| Möhl, H | 1 |
| Baumgärtel, K | 1 |
| Hirabayashi, Y | 1 |
| Shimizu, H | 1 |
| Kobayashi, N | 1 |
| Kudo, K | 1 |
| Miremont-Salamé, G | 1 |
| Antony, T | 1 |
| Jose, VM | 1 |
| Paul, BJ | 1 |
| Thomas, T | 1 |
| Bernatsky, S | 1 |
| Kashevarov, RIu | 1 |
| Smirnov, AV | 1 |
| Aleksandrova, EN | 1 |
| Lequerré, T | 1 |
| Jouen, F | 1 |
| Brazier, M | 1 |
| Clayssens, S | 1 |
| Klemmer, N | 1 |
| Ménard, JF | 1 |
| Daragon, A | 1 |
| Tron, F | 1 |
| Wardwell, NR | 1 |
| Miller, R | 1 |
| Ware, LB | 1 |
| Resman-Targoff, BH | 1 |
| Dimitrova, P | 1 |
| Ivanovska, N | 1 |
| Harigai, M | 1 |
| Mizoguchi, F | 1 |
| Iwai, H | 1 |
| Hagiyama, H | 1 |
| Oka, T | 1 |
| Miyasaka, N | 1 |
| Teraki, Y | 1 |
| Hitomi, K | 1 |
| Sato, Y | 1 |
| Hamamatsu, Y | 1 |
| Izaki, S | 1 |
| Castro, JS | 1 |
| Snih, SA | 1 |
| Blanco, LP | 1 |
| Esteva, MH | 1 |
| Macgregor, EG | 1 |
| González, M | 1 |
| Granados, Y | 1 |
| Marín, F | 1 |
| Rosas, A | 1 |
| Tristano, A | 1 |
| Chirinos, E | 1 |
| Mundaraín, L | 1 |
| Sanoja, G | 1 |
| Zambrano-Marín, G | 1 |
| Rodríguez, MA | 1 |
| Kho, LK | 1 |
| Kermode, AG | 1 |
| Magne, D | 1 |
| Mézin, F | 1 |
| Palmer, G | 1 |
| Guerne, PA | 1 |
| Balakrishnan, C | 1 |
| Dasgupta, B | 1 |
| Meyer, O | 1 |
| de Bandt, M | 1 |
| Lioté, F | 1 |
| Maillefert, JF | 1 |
| Wendling, D | 2 |
| Richards, BL | 1 |
| Spies, J | 1 |
| McGill, N | 1 |
| Richards, GW | 1 |
| Vaile, J | 1 |
| Bleasel, JF | 1 |
| Youssef, PP | 1 |
| Wisłowska, M | 1 |
| Jakubicz, D | 1 |
| Agrawal, S | 1 |
| van der Kooij, SM | 1 |
| de Vries-Bouwstra, JK | 1 |
| Goekoop-Ruiterman, YP | 1 |
| van Zeben, D | 1 |
| Kerstens, PJ | 1 |
| Gerards, AH | 1 |
| van Groenendael, JH | 1 |
| Hazes, JM | 1 |
| Allaart, CF | 1 |
| Schoels, M | 1 |
| Suzuki, Y | 1 |
| Wakabayashi, T | 1 |
| Saito, E | 1 |
| Suwa, A | 1 |
| Jacki, S | 1 |
| Heilig, B | 1 |
| Lampe, M | 1 |
| Wiesmüller, G | 1 |
| Richter, C | 1 |
| Röther, E | 1 |
| Gao, I | 1 |
| Ju, JH | 1 |
| Kim, SI | 1 |
| Lee, SI | 1 |
| Chung, SH | 1 |
| Lee, J | 1 |
| Lee, SS | 1 |
| Yoon, HJ | 1 |
| Yoon, CH | 1 |
| Kim, HY | 1 |
| Martin, N | 1 |
| Innes, JA | 1 |
| Lambert, CM | 1 |
| Turnbull, CM | 1 |
| Wallace, WA | 1 |
| Ohtsubo, H | 1 |
| Suka, M | 1 |
| Yoshida, K | 2 |
| Bertele', V | 1 |
| Assisi, A | 1 |
| Di Muzio, V | 1 |
| Renzo, D | 1 |
| Garattini, S | 1 |
| Zhang, JH | 1 |
| Wang, JP | 1 |
| Wang, HJ | 1 |
| Chambers, C | 1 |
| Koren, G | 2 |
| Tutuncu, ZN | 1 |
| Johnson, D | 1 |
| Raczkiewicz-Papierska, A | 1 |
| Dudek, A | 1 |
| Bachta, A | 1 |
| Zawadyl, B | 1 |
| Sułek, M | 1 |
| Tchetverikov, I | 1 |
| van El, B | 1 |
| Hanemaaijer, R | 1 |
| DeGroot, J | 1 |
| Huizinga, TW | 1 |
| Smeets, JG | 1 |
| Löwe, SH | 1 |
| Veraart, JC | 1 |
| Toyokawa, Y | 1 |
| Kingetsu, I | 1 |
| Yasuda, C | 1 |
| Yasuda, J | 1 |
| Kurosaka, D | 1 |
| Yamada, A | 1 |
| Jenks, KA | 1 |
| Stamp, LK | 1 |
| O'Donnell, JL | 1 |
| Chapman, PT | 1 |
| Bingham, CO | 1 |
| Miner, MM | 1 |
| Sawamukai, N | 1 |
| Saito, K | 1 |
| Nakayamada, S | 1 |
| Ra, C | 1 |
| Borm, GF | 1 |
| Lemmens, WA | 1 |
| Saruhan-Direskeneli, G | 1 |
| Inanc, M | 1 |
| Fresko, I | 1 |
| Akkoc, N | 1 |
| Dalkilic, E | 1 |
| Erken, E | 1 |
| Karaaslan, Y | 1 |
| Kinikli, G | 1 |
| Oksel, F | 1 |
| Pay, S | 1 |
| Yucel, E | 1 |
| Yentür, SP | 1 |
| Duymaz-Tozkir, J | 1 |
| Yilmaz, V | 1 |
| Yazici, H | 1 |
| Konice, M | 1 |
| Direskeneli, H | 1 |
| Koyama, T | 1 |
| Ohtani, R | 1 |
| Niiro, H | 1 |
| Yoshizawa, S | 1 |
| Harada, M | 1 |
| Dehler, S | 1 |
| Carloni, A | 1 |
| Piciucchi, S | 1 |
| Giannakakis, K | 1 |
| Nori, G | 1 |
| Zobel, BB | 1 |
| Poletti, V | 1 |
| Kaliterna, DM | 1 |
| Horvath, IF | 1 |
| Szanto, A | 1 |
| Csiki, Z | 1 |
| Szodoray, P | 1 |
| Zeher, M | 1 |
| Kremer, AE | 1 |
| Budenhofer, U | 1 |
| Beuers, U | 1 |
| Rust, C | 1 |
| Chopra, A | 1 |
| Saluja, M | 1 |
| Lagu-Joshi, V | 1 |
| Sarmukadam, S | 1 |
| Mladenovic, V | 1 |
| Domljan, Z | 1 |
| Jajic, I | 1 |
| Mihajlovic, D | 1 |
| Dordevic, J | 1 |
| Popovic, M | 2 |
| Dimitrijevic, M | 4 |
| Zivkovic, M | 1 |
| Campion, G | 1 |
| Jevtic, V | 1 |
| Watt, I | 1 |
| Presetnik, M | 1 |
| Bartlett, RR | 3 |
| Brendel, S | 1 |
| Zielinski, T | 1 |
| Schorlemmer, HU | 1 |
| Silva Júnior, HT | 1 |
| Morris, RE | 2 |
| Fox, RI | 2 |
| Ortlepp, D | 1 |
| Laggerbauer, B | 1 |
| Müllner, S | 1 |
| Achsel, T | 1 |
| Kirschbaum, B | 1 |
| Lührmann, R | 1 |
| Pisetsky, D | 1 |
| Stefanovic, D | 1 |
| Pejnovic, N | 1 |
| Popovic, R | 1 |
| Glisic, B | 1 |
| Obradovic, S | 1 |
| Larsen, A | 3 |
| Loew-Friedrich, I | 5 |
| Oed, C | 5 |
| Rosenburg, R | 5 |
| Robb-Nicholson, C | 1 |
| Cherin, P | 1 |
| Robinson, DR | 1 |
| Badii, M | 1 |
| Korff, KJ | 1 |
| Ferraccioli, GF | 1 |
| De Vita, S | 1 |
| Arriola, ER | 1 |
| Lee, NP | 1 |
| Weinblatt, ME | 2 |
| Coblyn, JS | 2 |
| Maier, AL | 1 |
| Helfgott, SM | 1 |
| Morrell, M | 1 |
| Byrne, VM | 1 |
| Kaymakcian, MV | 1 |
| Yocum, DE | 1 |
| Thompson, A | 2 |
| Weaver, A | 2 |
| Fleischmann, R | 1 |
| Cannon, G | 1 |
| Fox, R | 2 |
| Moreland, L | 3 |
| Olsen, N | 2 |
| Furst, D | 2 |
| Kaine, J | 2 |
| Sharp, J | 2 |
| Hurley, F | 2 |
| Herrmann, ML | 2 |
| Frangou, CG | 1 |
| Wahl, GM | 1 |
| Kirschbaum, BJ | 2 |
| Prakash, A | 1 |
| Jarvis, B | 1 |
| Schuna, AA | 1 |
| Megeff, C | 1 |
| Sharp, JT | 1 |
| Leung, H | 1 |
| Infante, R | 1 |
| Lahita, RG | 1 |
| Moder, KG | 1 |
| Luong, BT | 1 |
| Chong, BS | 1 |
| Lowder, DM | 1 |
| Schleyerbach, R | 1 |
| Dawes, PT | 1 |
| Gömör, B | 1 |
| Van Den Bosch, F | 1 |
| Nordström, D | 1 |
| Bjorneboe, O | 1 |
| Dahl, R | 1 |
| Horslev-Petersen, K | 1 |
| Molloy, M | 1 |
| Tikly, M | 2 |
| Goldenberg, MM | 1 |
| Monteagudo Sáez, I | 1 |
| López Longo, FJ | 1 |
| González Fernández, CM | 1 |
| Carreño Pérez, L | 1 |
| de Koster, BM | 1 |
| Elferink, JG | 1 |
| Post, WJ | 1 |
| Graninger, WB | 2 |
| Naranjo Hernández, A | 1 |
| Reece, RJ | 2 |
| Barg, EC | 1 |
| Farnell, J | 1 |
| Veale, DJ | 2 |
| So, A | 1 |
| Dudler, M | 1 |
| Hewitson, PJ | 1 |
| Debroe, S | 1 |
| McBride, A | 1 |
| Milne, R | 1 |
| Auer, J | 1 |
| Hinterreiter, M | 1 |
| Allinger, S | 1 |
| Kirchgatterer, A | 1 |
| Knoflach, P | 1 |
| Simon, LS | 1 |
| Yocum, D | 1 |
| Andresen, PN | 1 |
| Hansen, G | 1 |
| Hørslev-Petersen, K | 1 |
| Dayer, JM | 1 |
| Dixon, JA | 1 |
| Falchuk, KR | 1 |
| Mikuls, T | 1 |
| Kemp, E | 1 |
| Nielsen, H | 1 |
| Petersen, LJ | 1 |
| Gam, AN | 1 |
| Dahlager, J | 1 |
| Horn, T | 1 |
| Larsen, S | 1 |
| Olsen, S | 1 |
| Davis, JS | 1 |
| Talip, F | 1 |
| Walker, N | 1 |
| Khan, W | 1 |
| Zimmermann, B | 1 |
| van de Putte, LB | 2 |
| Alldred, A | 1 |
| Kozer, E | 1 |
| Moretti, ME | 1 |
| Shadick, N | 1 |
| Helfgott, S | 1 |
| O'Dell, JR | 1 |
| Koh, ET | 1 |
| O'Dell, J | 1 |
| Ringertz, B | 1 |
| Petersson, I | 1 |
| Wildy, KS | 1 |
| Wasko, MC | 1 |
| Kucharz, EJ | 1 |
| Hughes, LB | 1 |
| Moreland, LW | 1 |
| Tu, S | 1 |
| Liu, P | 1 |
| Williams, BD | 1 |
| Jones, P | 1 |
| Williams, RB | 1 |
| Hoshi, K | 1 |
| Hiida, M | 1 |
| Nash, P | 1 |
| Yazdani, C | 1 |
| McLaughlin, T | 1 |
| Cummins, G | 1 |
| Holm, EA | 1 |
| Balslev, E | 1 |
| Jemec, GB | 1 |
| Doyle, JJ | 1 |
| Calabrese, DC | 1 |
| Konop, R | 1 |
| Cannon, E | 1 |
| Maves, TK | 1 |
| Casberg, JJ | 1 |
| Meske, L | 1 |
| Coleman, IC | 1 |
| Orland, BI | 1 |
| Florentine, MJ | 1 |
| Southwell, Y | 1 |
| Harris, MR | 1 |
| Yoder, DM | 1 |
| Pisetsky, DS | 1 |
| St Clair, EW | 1 |
| Beaman, JM | 1 |
| Hackett, LP | 1 |
| Luxton, G | 1 |
| Illett, KF | 1 |
| Kaplan, MJ | 1 |
| Radjenovic, A | 1 |
| O'Connor, PJ | 1 |
| Ridgway, JP | 1 |
| Gibbon, WW | 1 |
| Rødevand, E | 1 |
| Johnsen, V | 1 |
| Hochberg, MC | 1 |
| Tracy, JK | 1 |
| Flores, RH | 1 |
| Aringer, M | 1 |
| Drosos, AA | 1 |
| McCarey, DW | 1 |
| Capell, HA | 1 |
| Lyons Jones, K | 1 |
| Konttinen, YT | 1 |
| Sanders, S | 1 |
| Harisdangkul, V | 1 |
| Hojnik, M | 1 |
| Kos-Golja, M | 1 |
| Accetto, R | 1 |
| Dolenc, P | 1 |
| Ollendorf, DA | 1 |
| Peterson, AN | 1 |
| Huse, DM | 1 |
| McCoy, CM | 1 |
| Johnson, DM | 1 |
| Burgardt, C | 1 |
| Reinhold-Keller, E | 1 |
| Choi, HK | 1 |
| Seeger, JD | 1 |
| Kuntz, KM | 1 |
| Simón, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial[NCT02930343] | Phase 3 | 136 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Due to time constraints, the study was halted prematurely) | ||
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| Etude et Suivi Des POlyarthrites Indifférenciées Récentes[NCT03666091] | 813 participants (Actual) | Observational | 2002-11-13 | Active, not recruiting | |||
| A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.[NCT01172639] | Phase 4 | 400 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design[NCT01881308] | Phase 4 | 320 participants (Actual) | Interventional | 2013-06-17 | Completed | ||
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis[NCT05112484] | 600 participants (Anticipated) | Observational | 2023-10-01 | Not yet recruiting | |||
| Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in[NCT03649061] | Phase 4 | 284 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area[NCT03430388] | 600 participants (Actual) | Interventional | 2018-01-31 | Completed | |||
| Impact of Association of Individual and Group Therapeutic Education Sessions on the Acquisition of Safety Skills by Patients With Chronic Inflammatory Rheumatism (CIR) Treated With Subcutaneous Biotherapy, Compared to Individual Therapeutic Education Sess[NCT03838939] | 120 participants (Actual) | Interventional | 2019-01-21 | Completed | |||
| Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients[NCT00596206] | Phase 3 | 124 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy[NCT02087696] | Phase 4 | 122 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| [NCT00037336] | 0 participants | Observational | 2001-09-30 | Completed | |||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis[NCT02424877] | 165 participants (Actual) | Interventional | 2013-08-01 | Completed | |||
| Clinical (Sleep, Pain and Atrial Fibrillation) and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery[NCT05853250] | 345 participants (Actual) | Interventional | 2017-06-26 | Completed | |||
| Prospective Randomized Trial Comparing Clamp Versus Clampless Robot Assisted Partial Nephrectomy[NCT02287987] | 200 participants (Anticipated) | Interventional | 2014-10-31 | Enrolling by invitation | |||
| Aromatherapy for Management of Chemotherapy-induced Symptoms[NCT02670941] | Early Phase 1 | 31 participants (Actual) | Interventional | 2016-01-31 | Terminated (stopped due to Slow accrual; Received grant funding for a similar but different study.) | ||
| Potential Benefits of the Somatic Psychoeducational Intervention for Improving the Health and Wellness of Healthcare Providers[NCT05766852] | 70 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| A Home-based Personalized Multidomain RCT From the Canadian Therapeutic Platform for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP)[NCT05375513] | 275 participants (Anticipated) | Interventional | 2023-06-05 | Recruiting | |||
| Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain.[NCT05090683] | 197 participants (Actual) | Interventional | 2021-10-15 | Active, not recruiting | |||
| Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.[NCT02833714] | 26 participants (Actual) | Observational | 2016-01-31 | Terminated | |||
| MAIN STUDY: Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? SUB-STUDY: Analysis of JCV Antibody Index in MS Patients Treated With[NCT01970410] | Phase 4 | 55 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Observational Study of Hair Fall in Rheumatoid Arthritis Patients Treated With Low Dose Methotrexate[NCT02591823] | 80 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ultrasound 7 score (US-7) Calculates ultrasound score in 7 joints using greyscale and power doppler to evaluate for disease activity (synovitis, tenosynovitis) and damage (erosions) Score minimum value= 0 Maximum value = 108 Higher score indicates worse disease (NCT02930343)
Timeframe: 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Group 1- MTX+LEF+HCQ | 3.5 |
| Group 2- MTX+SSZ+HCQ | 4 |
Indian version of Health assessment Questionnaire (iHAQ) Comprises of 12 questions relating to functional activity iHAQ score ranges from 0 to 3 (minimum 0, maximum 3) Higher scores indicate more disability (NCT02930343)
Timeframe: 12 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Group 1- MTX+LEF+HCQ | 0.7 |
| Group 2- MTX+SSZ+HCQ | 0.5 |
"EULAR response criteria for Rheumatoid arthritis includes- estimation of DAS 28 ESR, that includes-~Tender joint count 28~Swollen joint count 28~ESR~Patient global assessment of health" (NCT02930343)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Group 1- MTX+LEF+HCQ | 40 |
| Group 2- MTX+SSZ+HCQ | 37 |
Infections, transaminitis, nausea, vomiting, derranged renal function tests etc (NCT02930343)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total number of any adverse events | Serious adverse events | Any gastrointestinal adverse reaction | Nausea | Diarrhea | Switch to parenteral Methotrexate | Raised liver enzymes > 2 times upper limit normal | Herpes labialis | upper respiratory tract infection | urinary tract infection | Hypertension | hairfall | Cytopenia | |
| Group 1- MTX+LEF+HCQ | 15 | 0 | 11 | 4 | 1 | 5 | 1 | 0 | 5 | 1 | 1 | 2 | 0 |
| Group 2- MTX+SSZ+HCQ | 21 | 0 | 16 | 6 | 1 | 14 | 1 | 2 | 5 | 0 | 0 | 2 | 0 |
"Number of patients with a change of > 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.~A change of > 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients." (NCT01172639)
Timeframe: Baseline-week104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 71 |
| CoBRA Slim High Risk Group | 62 |
| CoBRA Avant-garde High Risk Group | 64 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 26 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 64 |
| CoBRA Slim High Risk Group | 71 |
| CoBRA Avant-garde High Risk Group | 69 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 34 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 69 |
| CoBRA Slim High Risk Group | 72 |
| CoBRA Avant-garde High Risk Group | 61 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 23 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 63 |
| CoBRA Slim High Risk Group | 57 |
| CoBRA Avant-garde High Risk Group | 57 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 29 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 42 |
| CoBRA Slim High Risk Group | 33 |
| CoBRA Avant-garde High Risk Group | 44 |
| CoBRA Slim Low Risk Group | 12 |
| Tight Step Up Low Risk Group | 12 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 31 |
| CoBRA Slim High Risk Group | 28 |
| CoBRA Avant-garde High Risk Group | 41 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 13 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 36 |
| CoBRA Slim High Risk Group | 27 |
| CoBRA Avant-garde High Risk Group | 39 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 15 |
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
"Mean time to first Gadolinium enhancing (GAD+) lesion in months." (NCT01970410)
Timeframe: 24 months
| Intervention | Months (Mean) |
|---|---|
| Teriflunomide | 19.6 |
Mean time to 3-month sustained disability worsening (SDW) in months. SDW is defined as an increase of ≥ 1 point for patients with EDSS of 1.0-5.0, and ≥ 0.5 points for patients with an EDSS of 5.5-6.0, sustained for 3 months. Patients with ≥ 1 point increase in EDSS in whom a second measure was not obtained 3 months later were not included as SDW. (NCT01970410)
Timeframe: 24 months
| Intervention | Months (Mean) |
|---|---|
| Teriflunomide | 22 |
Mean time of new T2 or enlarging T2 Lesions (NCT01970410)
Timeframe: 24 months
| Intervention | Months (Mean) |
|---|---|
| Teriflunomide | 19.2 |
Number of patients relapses free by month 24. (NCT01970410)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Teriflunomide | 25 |
"Number of patients with a >= 20% reduction of AJAI.~The AJAI serostatus categories used in the study were negative (<0.2), positive (0.41-0.89) and high positive (≥0.90). The 0.2-0.4 range is frequently reported as indeterminate. We defined a change of 20% or greater as a meaningful increase or decrease in the AJAI." (NCT01970410)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Anti-JCV Antibody Status (Sub-Study) | 20 |
142 reviews available for leflunomide and Rheumatoid Arthritis
| Article | Year |
|---|---|
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Heart Dis | 2022 |
The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; | 2020 |
[Systematic reviews of effects of Tripterygium Glycosides Tablets on pro-inflammatory factors in rheumatoid arthritis].
Topics: Animals; Arthritis, Rheumatoid; Cytokines; Drugs, Chinese Herbal; Glycosides; Humans; Leflunomide; M | 2020 |
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
[Perioperative management of immunosuppressive treatment in patients undergoing joint surgery].
Topics: Adrenal Cortex Hormones; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, R | 2017 |
Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Bendamustine Hydrochloride; Humans; Isox | 2018 |
Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; | 2018 |
Rheumatoid Arthritis: A Brief Overview of the Treatment.
Topics: Adrenal Cortex Hormones; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Mo | 2018 |
Safety evaluation of leflunomide in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical T | 2013 |
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Topics: Antibodies, Blocking; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheum | 2013 |
[Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review].
Topics: Adult; Alopecia Areata; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Lef | 2015 |
Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials.
Topics: Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lung Diseases; Ran | 2016 |
Challenges and treatment options for rheumatoid arthritis during pregnancy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Hydroxychloroquine | 2016 |
Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.
Topics: Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 2016 |
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disea | 2008 |
DMARDS and infections in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infections; Isoxazoles; Leflunomide; Methotrexa | 2008 |
[The efficacy and safety of the combination of leflunomide (Arava) and biological agents in treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Isoxazoles; Leflunom | 2008 |
[Antirheumatic agents for treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Gold Sodium Thiomalate; Humans; Isoxazoles; L | 2008 |
[New ways in the management of rheumatoid arthritis in Hungary].
Topics: Abatacept; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, | 2007 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Thera | 2009 |
Clinical expression of leflunomide-induced pneumonitis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; | 2009 |
Management of RA medications in pregnant patients.
Topics: Abatacept; Acetaminophen; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoc | 2009 |
[Rituximab treatment of rheumatoid arthritis: new evidence].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antirheumatic Agents | 2009 |
Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; M | 2011 |
Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Drug Therapy, Combination; | 2009 |
[Referring to an unusual case: pulmonary affection and rheumatoid arthritis].
Topics: Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchiectasis; Dyspnea; Female; | 2009 |
Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Rheumatoid; Etoricoxib; Female; Gram-Posi | 2010 |
New-onset psoriasis associated with etanercept therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles | 2010 |
Pregnancy course and neonatal outcome after exposure to leflunomide--2 cases report and review of literature.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Infant | 2009 |
Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Dihydroorotate | 2011 |
Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug | 2011 |
Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheuma | 2011 |
[Systemic autoimmune disorders and pregnancy].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Antiphospholipid Syndrome; Arthrit | 2011 |
[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 5. Leflunomide and mizoribine].
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male | 2011 |
Progressive multifocal leukoencephalopathy in autoimmune diseases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rhe | 2012 |
[ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Cartilage; Clinical Trials as Topic; Cy | 2012 |
Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2012 |
[Off-label therapy of rheumatoid arthritis and spondyloarthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Dose-Response Relationship, Drug; | 2012 |
My treatment approach to rheumatoid arthritis.
Topics: Abatacept; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2012 |
Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular | 2002 |
Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Drug Eruptions; Erythema; Etanercept; Female; Humans; Immunoglobulin G | 2002 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic | 2002 |
[Efficacy of leflunomide].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Double-Bli | 2002 |
Leflunomide for treating rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz | 2003 |
Leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Hu | 2003 |
Leflunomide for the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Human | 2003 |
Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
Topics: Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Randomized Control | 2003 |
Interpreting radiographic data in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2003 |
T-cell-activation inhibitors in rheumatoid arthritis.
Topics: Abatacept; Adjuvants, Immunologic; Arthritis, Rheumatoid; Double-Blind Method; Humans; Immunoconjuga | 2003 |
[Current concepts of pharmacotherapy in rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 2003 |
[New drugs and treatment strategies for rheumatoid arthritis].
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anti | 2003 |
Is leflunomide as safe and effective in the treatment of rheumatoid arthritis as other DMARDs?
Topics: Adjuvants, Immunologic; Antirheumatic Agents; Arthritis, Rheumatoid; Evidence-Based Medicine; Humans | 2003 |
[Emergence of new therapeutic agents for collagen diseases and some of the problems].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, Rheumatoid; Clinical Tri | 2003 |
Newer approaches to the treatment of rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2003 |
[Collagen diseases and rheumatic diseases].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Drug Therapy, Com | 2004 |
New drugs for rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2004 |
New drugs for rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2004 |
New drugs for rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2004 |
New drugs for rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2004 |
The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topi | 2004 |
Leflunomide: a manageable safety profile.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose | 2004 |
Lefunomide in combination therapy.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Dru | 2004 |
What I would like to know about leflunomide.
Topics: Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide | 2004 |
Safety overview of new disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cytokines; Humans; Isoxazoles; Leflunomide; Treatment O | 2004 |
Overview of radiologic efficacy of new treatments.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disea | 2004 |
Leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Monitoring; Drug Therapy | 2004 |
[Diagnosis and therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2004 |
Leflunomide in the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trial | 2004 |
Rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Azathioprine; Cyclop | 2003 |
Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites.
Topics: Antimetabolites; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Metho | 2004 |
[Basic therapy of rheumatoid arthritis with leflunomide (review)].
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Ma | 2004 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Fa | 2004 |
The broadening use of leflunomide in clinical practice.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Immunosuppressive Agents; | 2004 |
Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug Tole | 2005 |
The 'alphabet' of rheumatoid arthritis treatment.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2004 |
[Respiratory complications of new treatments for rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lung Diseases; Methotr | 2004 |
[Guidelines for RA therapies].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2005 |
[Disease modifying anti-rheumatic drugs (DMARDs): an overview].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Cysteine; Evidence-Based Medicine; Gold So | 2005 |
[Leflunomide for therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Is | 2005 |
[Adverse effects of DMARDs in treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Hematologic Diseases; H | 2005 |
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cost-Benefit Analysis; Drug C | 2005 |
Rheumatoid arthritis: an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Dif | 2005 |
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheum | 2005 |
Leflunomide: long-term clinical experience and new uses.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Indus | 2005 |
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Immunologic Factor | 2005 |
[Disease modifying antirheumatic drugs with inhibitory effect on osteoclastogenesis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cell Differentiation; Humans; Isoxazoles; Leflunomide; | 2005 |
[Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Fe | 2005 |
Leflunomide and warfarin interaction: case report and review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis, Rheumatoid; Atrial Fibrillation; | 2006 |
Medical therapy: where are we now?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 2006 |
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Topics: Aged; Aging; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Glomerular Filtration Rate; | 2007 |
[Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Disease Progres | 2007 |
[Rational therapeutic approach in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2006 |
[Effective combination therapy of TNF antagonists with DMARDs].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2007 |
[Economic evaluation of a new treatment for rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2007 |
Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.
Topics: Abnormalities, Drug-Induced; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprin | 2007 |
Treatment, management, and monitoring of established rheumatoid arthritis.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2007 |
[Leflunomide (Arava) in the treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomi | 2007 |
Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard.
Topics: Absorption; Alkylating Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthri | 1995 |
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Arthritis, Rheumatoid; Autoimm | 1996 |
Leflunomide and malononitrilamides.
Topics: Aniline Compounds; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Cr | 1997 |
Mechanism of action of leflunomide in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Cycle; Dihydroorotate Dehydrogenase; Huma | 1998 |
Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomi | 1998 |
[62nd Congress of the American College of Rheumatology, San Diego, 8-12 November 1998].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheuma | 1999 |
Treatment advances in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 1999 |
Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.
Topics: Adenosine; Arthritis, Rheumatoid; Cell Division; Cytokines; Drug Therapy, Combination; Humans; Immun | 1999 |
T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Arthritis, Rheumatoid; Clone Cells; Genetic P | 1999 |
New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; In | 1999 |
Mechanism of action for leflunomide in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; | 1999 |
Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Arthritis, Rheumatoid; Enzyme | 1999 |
Leflunomide: a review of its use in active rheumatoid arthritis.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isox | 1999 |
Investigational treatments in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; | 1999 |
New drugs for the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2000 |
Recent advances in the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 1999 |
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthri | 2000 |
New medications for use in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Fe | 2000 |
Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2000 |
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Dihydr | 2000 |
The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical | 2000 |
Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Administration, Oral; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 1999 |
[Leflunomide: a new treatment for an old disease].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Lefluno | 2000 |
Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Cost | 2000 |
New and future drug therapies for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2000 |
Leflunomide for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immuno | 2000 |
[Leflunomide for active rheumatoid arthritis].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxaz | 2000 |
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Division; Dihydroorotate Oxidas | 2000 |
The treatment of rheumatoid arthritis: a review of recent clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trial | 1999 |
Therapy of rheumatoid arthritis: new developments and trends.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Controlled Clinical Trials as Topi | 1999 |
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosp | 2001 |
Leflunomide and methotrexate.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Isoxazoles; Leflu | 2001 |
Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II a | 2001 |
How is it best to treat early rheumatoid arthritis patients?
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2001 |
New disease modifying agents in adult rheumatoid arthritis.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immu | 2001 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat | 2001 |
[Rheumatic pain].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheum | 2001 |
Economic and quality-of-life impact of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Cost of Il | 2001 |
Progress in the treatment of rheumatoid arthritis.
Topics: Analgesics; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclo | 2001 |
Leflunomide Aventis Pharma.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Tr | 2001 |
[Leflunomide--a new disease modifying anti-rheumatic agent].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Contraindications; Drug Interactions; Humans; Isoxazole | 2001 |
"Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Double-Blind Meth | 2001 |
Treating rheumatoid arthritis with new disease modifying drugs.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Tumor Necrosis Facto | 2002 |
Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy.
Topics: Animals; Arthritis, Rheumatoid; Cyclosporine; Cytokines; Gene Expression Regulation; Humans; Immunos | 2002 |
[New drug treatments for rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, | 2000 |
[Leflunomide in the treatment of rheumatoid arthritis].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase III | 2002 |
Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials | 2002 |
Advances in the medical management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2002 |
98 trials available for leflunomide and Rheumatoid Arthritis
| Article | Year |
|---|---|
Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 2022 |
Sustained Drug Treatment Alters the Gut Microbiota in Rheumatoid Arthritis.
Topics: Adult; Arthritis, Rheumatoid; Clostridium; Drugs, Chinese Herbal; Female; Gastrointestinal Microbiom | 2021 |
Combination of Methotrexate and Leflunomide Is Efficient and Safe for 60 Patients with Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combination; Humans; Interleukin-1; Interle | 2022 |
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Deprescriptions; Drug | 2020 |
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Topics: Adult; Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort St | 2019 |
Effect of adjuvant therapy with electroacupuncture on bone turnover markers and interleukin 17 in patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; C-Reactive Protein; Combined Modality Therapy; Electroacupuncture; Fem | 2019 |
Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; | 2020 |
Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; | 2020 |
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug The | 2021 |
Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; | 2017 |
[Rheumatoid arthritis treated with acupoint application of
Topics: Acupuncture Points; Antirheumatic Agents; Arthritis, Rheumatoid; Drugs, Chinese Herbal; Humans; Isox | 2016 |
Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg.
Topics: Adult; Arthritis, Rheumatoid; Asian People; Case-Control Studies; Female; Humans; Hypertension; Immu | 2019 |
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Combined Modality Therapy; Female; Humans; Isoxa | 2018 |
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroq | 2019 |
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Drug The | 2019 |
Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combinatio | 2019 |
Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration S | 2019 |
Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Aspartate Aminotransferases; C | 2013 |
[Effects of leflunomide in treating patients with rheumatoid arthritis of different Chinese medical syndrome patterns].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Male; Medic | 2013 |
Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Docosahexaenoic Acids | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chi-Square Distribution; Ch | 2016 |
Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chemical and Drug Induced | 2015 |
[Treatment of Refractory Rheumatoid Arthritis by Huayu Tongbi Recipe Combined Methotrexate].
Topics: Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Drug Therapy, Combination; Drugs, Chinese H | 2015 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Female; | 2008 |
The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chemokine CCL2; Chemokine CCL5; Chemokines | 2009 |
Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Counseling; Female; Hum | 2009 |
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Disease Progression; Drug Th | 2010 |
Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Di | 2010 |
Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Diarrhea; Double-Blind Metho | 2011 |
Leflunomide in Pakistani patients with rheumatoid arthritis: prospective study in daily rheumatology practice.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Isoxazoles; | 2011 |
Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients.
Topics: Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Arthritis, Rheumatoid; Aspartate Aminotrans | 2011 |
Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; M | 2012 |
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Combined Modality Therapy; Disability Evaluation; Early | 2012 |
Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Echocardiography; Etanerce | 2013 |
Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration S | 2013 |
The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Follow-Up Studies; Health S | 2002 |
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Arthritis, Rheumatoid; Diarrh | 2002 |
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Health Status; Humans; Isoxazoles; | 2003 |
The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Pro | 2003 |
Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Growth Inhibitors; Humans; Immunosuppressive Ag | 2003 |
Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Disability Evaluation; Enzyme Inhibitors; Female | 2003 |
Rheumatoid arthritis treatment with weekly leflunomide: an open-label study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Fema | 2004 |
Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 2004 |
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
Topics: Adult; Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Division; Cells, C | 2004 |
Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Humans; Immunos | 2004 |
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2005 |
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; | 2004 |
Leflunomide in the treatment of refractory rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Female; Health Status; Humans; Isoxazoles; Joints; Le | 2003 |
Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Biomarkers; Citrulline; Female; Humans; Immunosuppressive Agents; Isox | 2005 |
[Leflunomide in the treatment of rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazo | 2005 |
[Evaluation of rheumatoid arthritis activity in clinical practice].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazo | 2005 |
[Experience in long-term therapy of active rheumatoid arthritis with leflunomide].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 2005 |
Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Female; Folic Acid; Hem | 2005 |
Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Monitoring; | 2006 |
The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Interleukin-10; Interleuki | 2006 |
Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therap | 2006 |
[Clinical observation on effects of leflunomid and total glucosides of paeony on rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Drugs, Chinese Herbal; Fe | 2006 |
Leflunomide and methotrexate combination therapy in daily clinical practice.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Isoxazoles; Leflunomide; Met | 2006 |
Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis.
Topics: Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Dr | 2006 |
[An antidestructive effect of leflunomide in early rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Disease Progression; Drug Administration Sched | 2006 |
Effect of leflunomide on the peripheral nerves in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Isoxazoles; Leflunomide; Male; Middle A | 2007 |
Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anti | 2007 |
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthr | 2007 |
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug The | 2007 |
[Clinical study on effect of total panax notoginseng saponins on immune related inner environment imbalance in rheumatoid arthritis patients].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 2007 |
[Leflunomide as a second choice treatment in patients with rheumatoid arthritis].
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinati | 2007 |
Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients.
Topics: Aged; alpha-Macroglobulins; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Prot | 2008 |
The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.
Topics: Adult; Alleles; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Drug Administra | 2007 |
Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinati | 2008 |
Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Immunos | 1995 |
Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Antigens, CD; Arthritis, Rheumatoid; Cell Adhesion; Cell Aggregation; Female | 1996 |
Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Double-Blind Method; Female; | 1998 |
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
Topics: Algorithms; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; | 1999 |
Leflunomide for active rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 1999 |
Leflunomide for active rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 1999 |
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Asparta | 1999 |
Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Adjuvants, Immunologic; Adult; Aged; Arthritis, Rheumatoid; Disability Evaluation; Dose-Response Rel | 1999 |
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 1999 |
Disease modification in rheumatoid arthritis with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind M | 1999 |
Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind M | 1999 |
Leflunomide improves quality of life in rheumatoid arthritis.
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis | 1999 |
Leflunomide versus methotrexate: a comparison of the European and American experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind M | 1999 |
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progre | 2000 |
Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment e
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind M | 2000 |
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Co | 2000 |
Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.
Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Chemotaxis, Leukocyte; Crotona | 2000 |
Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind M | 2000 |
Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Do | 2001 |
A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Hum | 2001 |
Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Stud | 2001 |
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; C | 2001 |
Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2001 |
Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2002 |
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; | 2002 |
Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
Topics: Adult; Aged; Anaphylaxis; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoa | 2002 |
Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Isoxazoles | 2002 |
367 other studies available for leflunomide and Rheumatoid Arthritis
| Article | Year |
|---|---|
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
Topics: Arthritis, Rheumatoid; Chlortetracycline; Combinatorial Chemistry Techniques; Enzyme Inhibitors; Flu | 2008 |
Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis: A protocol for systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Meta-Analysis as Topic; Methotrexa | 2021 |
Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Crotonates; Drug | 2022 |
Leflunomide in combination with JAK inhibitors in the treatment of rheumatoid arthritis: a case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Leflunomide | 2022 |
Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Herpes Zoster; Humans; Infections; Lefl | 2022 |
Efficacy of leflunomide in the treatment of palindromic rheumatism.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Leflunomide; Methotr | 2022 |
Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rhe | 2022 |
Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Drug Monitoring; Humans; Isoxazoles; Leflunomide; Treatment Outcome | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Methotrexate; Retrospective Studie | 2022 |
Comparative efficacy and safety of JAK inhibitors and leflunomide in rheumatoid arthritis: A protocol for systematic review and meta-analysis.
Topics: Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Leflunomide; Meta-Analysis as Topic; Review | 2022 |
Treatment with Rituximab in Rheumatoid Pneumoconiosis: A Case Report.
Topics: Aged; Arthritis, Rheumatoid; Caplan Syndrome; Humans; Leflunomide; Male; Pneumoconiosis; Rituximab | 2023 |
The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cytochromes b5; Female; Humans; Isoxazoles; Leflunomide | 2023 |
Chitosan coated clove oil-based nanoemulsion: An attractive option for oral delivery of leflunomide in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chitosan; Clove Oil; Drug-Related Side Effects | 2023 |
Leflunomide exposure through second trimester of pregnancy: A case report.
Topics: Arthritis, Rheumatoid; Cholestyramine Resin; Female; Humans; Isoxazoles; Leflunomide; Pregnancy; Pre | 2023 |
Comparative analysis of multiorgan toxicity induced by long term use of disease modifying anti-rheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Creatinine; Humans; Leflunomide; Methotrexate; Renal In | 2023 |
Development and in vivo evaluation of therapeutic phytosomes for alleviation of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Arthritis, Rheumatoid; Curcumin; Leflunomide; Phytosomes; Rats | 2023 |
The prognostic value of whole-genome DNA methylation in response to Leflunomide in patients with Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; DNA; DNA Methylation; Humans; Leflunomide; Prognosis | 2023 |
Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology.
Topics: Adult; Arthritis, Rheumatoid; Female; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agen | 2019 |
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis.
Topics: Acriflavine; Adult; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Aryl Hydrocarbon Recept | 2019 |
Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Topics: Abatacept; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirh | 2020 |
Targeting the CRP-HIF1α axis in RA improves response to leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide | 2019 |
Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study.
Topics: Adult; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Isoxazole | 2019 |
The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009-2018).
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reacti | 2020 |
Atypical Presentation of Choroidal Folds: Steroid-induced Central Serous Chorioretinopathy-like Maculopathy
Topics: Aged; Arthritis, Rheumatoid; Central Serous Chorioretinopathy; Choroid Diseases; Drug Therapy, Combi | 2019 |
Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hu | 2020 |
Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chi-Square Distributio | 2020 |
Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Topics: Adult; Arthritis, Rheumatoid; Crotonates; Dihydroorotate Dehydrogenase; Drug Monitoring; Enzyme Inhi | 2021 |
Leflunomide-induced recurrent-transient ischaemic attacks in a patient with rheumatoid arthritis: first case report.
Topics: Aged, 80 and over; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Ischemic Attack, Transie | 2020 |
Q Fever, CNS Vasculitis, and Stroke: A Case Report.
Topics: Adult; Anti-Bacterial Agents; Arthritis, Rheumatoid; Cholestyramine Resin; Humans; Leflunomide; Male | 2020 |
[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].
Topics: Antibodies, Viral; Arthritis, Rheumatoid; Betacoronavirus; Biological Therapy; Coronavirus Infection | 2020 |
A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
Topics: A549 Cells; Aniline Compounds; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Line; Cell | 2020 |
Onychodystrophy following the use of leflunomide for seronegative rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflun | 2020 |
Leflunomide-Induced Autoimmune Hepatitis in a Patient With Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Hepatitis, Autoimmune; Humans; Leflunomide | 2021 |
Disease-modifying antirheumatic drugs and organising pneumonia.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Female; Humans; | 2021 |
Leflunomide as a cause of collagenous colitis: an entity to consider.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Colitis, Collagenous; Humans; Isoxazoles; Leflunomide | 2021 |
Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies | 2021 |
Synergistic and receptor-mediated targeting of arthritic joints via intra-articular injectable smart hydrogels containing leflunomide-loaded lipid nanocarriers.
Topics: Animals; Arthritis, Rheumatoid; Chitosan; Hyaluronic Acid; Hydrogels; Leflunomide; Rats | 2021 |
Leflunomide-induced delayed onset colitis.
Topics: Arthritis, Rheumatoid; Colitis; Humans; Immunosuppressive Agents; Leflunomide | 2021 |
Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cytochromes b5; Female; Genotype; Humans; | 2021 |
Leflunomide - A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Adverse Drug Reaction Reporti | 2017 |
A Case of Cavitary Pulmonary Mycobacterium Avium Intracellulare Infection in the Setting of Leflunomide Treatment.
Topics: Aged; Antitubercular Agents; Arthritis, Rheumatoid; Drug Monitoring; Drug Substitution; Female; Huma | 2017 |
Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, | 2017 |
[SUSTAINABILITY OF RITUXIMAB IN CONCOMMITANT TREATMENT WITH METHOTREXATE OR LEFLUNOMIDE IN PATIENTS WITH RHEUMATOID ARTHRITIS].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Isoxazoles; Leflunom | 2017 |
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Dat | 2017 |
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Autoant | 2017 |
Effects of Amerindian Genetic Ancestry on Clinical Variables and Therapy in Patients with Rheumatoid Arthritis.
Topics: Adult; Age Factors; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Ar | 2017 |
Pulmonary arterial hypertension in four patients treated by leflunomide.
Topics: Arthritis, Rheumatoid; Female; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Leflunomid | 2018 |
Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Advanced Oxidation Protein Products; Aged; Antirheumatic Agents; Arthritis, Rheum | 2018 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis.
Topics: Adalimumab; Adult; Anemia; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; | 2018 |
Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Topics: Abatacept; Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; | 2018 |
No live vaccines for people being treated with leflunomide.
Topics: Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Vaccines | 2018 |
Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report.
Topics: Arthritis, Rheumatoid; Calcinosis; Female; Humans; Immunosuppressive Agents; Leflunomide; Middle Age | 2018 |
Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Collagen Type III; Collagen Type IV; Disease M | 2019 |
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therap | 2018 |
Toxic Epidermal Necrolysis Induced by Leflunomide in a Patient With Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; Humans; Leflunomide; Stevens-Johnson Syndrome | 2021 |
Early arthritis clinic is effective for rheumatoid and psoriatic arthritides.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antirheumatic Agents; Arthritis, Psoria | 2019 |
Genetic and epigenetic alteration of the programmed cell death 1 in rheumatoid arthritis.
Topics: Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Stu | 2019 |
Leflunomide-induced colitis in association with enterocutaneous fistula in an immunosuppressed patient with renal transplant and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Colitis; Diarrhea; Humans; Immunocompromised Host; Immunosuppressive Ag | 2019 |
Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Cross-Sectional Studies; Female; Humans; | 2019 |
Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; H | 2019 |
Reversible alopecia areata: a little known side effect of leflunomide.
Topics: Adult; Alopecia Areata; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Leflunomide | 2019 |
A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Topics: Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Weight; Crotona | 2019 |
Coated nanostructured lipid carriers targeting the joints - An effective and safe approach for the oral management of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Arthritis, Rheumatoid; Chitosan; Chondroitin Sulfates; Drug Carriers; | 2019 |
Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Fe | 2013 |
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.
Topics: Adult; Aged; Antirheumatic Agents; Anxiety; Arthritis, Rheumatoid; Comorbidity; Depression; Female; | 2013 |
[The conversion of hypothyroidism into hyperthyroidism during leflunomide with povidone iodine treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Combinations; Female; Humans; Hyperthyroidism; Hyp | 2013 |
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Hu | 2013 |
Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2013 |
Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis.
Topics: Adult; Aged; Antibodies; Antigens, CD1d; Arthritis, Rheumatoid; B-Lymphocytes, Regulatory; Blood Sed | 2014 |
Multiple eruptive keratoacanthomas associated with leflunomide.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carcinoma, Squamous Cell; Drug | 2013 |
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthri | 2013 |
Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: a nationwide population-based cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Drug Therapy, Combination; Etanerce | 2013 |
The hypouricemiant effect of leflunomide.
Topics: Adult; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide | 2014 |
RAISE - rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation.
Topics: Abatacept; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, C | 2013 |
Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2015 |
[Acute sensory-motor axonal neuropathy (Guillain-Barre syndrome) following vertebroplasty].
Topics: Accidental Falls; Arthritis, Rheumatoid; Female; Guillain-Barre Syndrome; Humans; Immunocompromised | 2014 |
The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheum | 2014 |
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fema | 2014 |
Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Resp | 2014 |
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovasc | 2013 |
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2015 |
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Genetic Predi | 2014 |
Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide.
Topics: Aged; Arthritis, Rheumatoid; Female; Glomerular Filtration Rate; Humans; Inflammation; Isoxazoles; L | 2015 |
Ascidian tunicate extracts attenuate rheumatoid arthritis in a collagen-induced murine model.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Collagen; Isoxazoles; Leflunomide; Mice; T | 2014 |
Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cohort Stu | 2015 |
[Acute interstitial pneumonia in patient with rheumatoid arthritis treated with leflunomide].
Topics: Acute Disease; Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Idiopathic Inte | 2014 |
Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Synergism; Drug | 2014 |
Factors influencing ultrasonographic remission in patients with rheumatoid arthritis.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic A | 2015 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumat | 2015 |
[Pleuro-pericarditis developed under a leflunomide therapy].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Pericard | 2015 |
[Subacute cutaneous lupus erythematosus induced by golimumab].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Eruptions; Drug Therapy, C | 2015 |
69-year-old woman with rheumatoid arthritis presents with shortness of breath and cough.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bronchoalveolar Lavage; Bronch | 2014 |
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort S | 2015 |
Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Fatal Outcome; Humans; Isoxazoles; Leflunomide; Lung | 2015 |
Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response | 2015 |
On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Binding Sites; Crotonates; Dihydroorotate Dehydrogenase | 2015 |
Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Topics: Adalimumab; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumato | 2015 |
Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental | 2016 |
Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Bone Density; Disease Progre | 2015 |
Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Biological Products; Clinical Decision-Makin | 2017 |
Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Crotonates; Cytochrome P-450 CYP1A2; Female; | 2016 |
Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2015 |
Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS.
Topics: Arthritis, Rheumatoid; Chromatography, Liquid; Crotonates; Dihydroorotate Dehydrogenase; Drug Monito | 2016 |
Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Body Weight; | 2016 |
Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Hispani | 2016 |
Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia.
Topics: Abatacept; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumat | 2016 |
Proteome Analysis of Rheumatoid Arthritis Gut Mucosa.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Case-Control Studies; Citr | 2017 |
Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.
Topics: Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Cost-Benefit Analysis; Drug Costs; Etanercept; Fe | 2016 |
Primary cardiac B cell lymphoma: Manifestation of Felty's syndrome or TNFα antagonist.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Felty Syndrome; Female; Heart Neoplasms; Humans; | 2016 |
Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Disease Management; Humans; Isoxazoles; Lefl | 2017 |
Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Mon | 2017 |
IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; | 2017 |
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid | 2017 |
Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Japan; Leflunomide; L | 2008 |
[Persistent diarrhea and loss of weight during therapy with leflunomide].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Colitis, Lymphocytic; Diabetes Mellitus, Type 1; Diarrh | 2008 |
Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alcohol Drinking; Antirheumatic Agents; Arthri | 2008 |
Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Female; Finger Joint; Humans | 2009 |
Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Cholestyramine Resin; Female; Glucocorticoids; | 2008 |
Leflunomide-associated progressive multifocal leukoencephalopathy.
Topics: Arthritis, Rheumatoid; Biopsy; Brain; Cytarabine; Humans; Immunosuppressive Agents; Injections, Intr | 2008 |
Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one month therapy with leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; B-Lymphocytes; Case-Control Studies; CD4-Positive T-Lym | 2009 |
Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2009 |
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis | 2010 |
[Leflunomide in combination with TNF-blockers for Methotrexate intolerance].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2009 |
Disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Hydroxychloroquine; Isoxazoles; L | 2009 |
The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Carrier State; Conserved Sequence; Dihydroorotat | 2009 |
Leflunomide use in New Zealand. A national prospective post-marketing study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cohort Studies; Female; Follow-Up | 2009 |
Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily G, Member 2 | 2009 |
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Weight; Female; Humans; Isoxazoles; Japan; L | 2009 |
Measure of function in rheumatoid arthritis: individualised or classical scales?
Topics: Activities of Daily Living; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation | 2010 |
An elderly man with rheumatoid arthritis and dyspnea.
Topics: Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Mal | 2009 |
[Leflunomide and Lyell syndrome].
Topics: Adult; Arthritis, Rheumatoid; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Isoxazoles; L | 2009 |
Leflunomide-induced polymyositis in a patient with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Alanine Transaminase; Anti-Inflammatory Agents; Antirheumatic Agents; Arthri | 2009 |
Leflunomide and the lung.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lung Diseases | 2009 |
Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Female; | 2009 |
Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.
Topics: Adult; Aged; Antirheumatic Agents; Argentina; Arthritis, Rheumatoid; Biological Products; Cross-Sect | 2010 |
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Aryl | 2009 |
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chi-Square Distribution; Disease P | 2009 |
Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP1A2; Dihydroorotate Dehydroge | 2009 |
Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Crotonates | 2009 |
[Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2009 |
Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; CA-125 Antigen; Diagnosis, Differential; Female; Humans | 2011 |
[Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Epidem | 2007 |
Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy.
Topics: Adult; Alveolitis, Extrinsic Allergic; Anion Exchange Resins; Antirheumatic Agents; Arthritis, Rheum | 2009 |
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; A | 2010 |
Severe aplastic anaemia following leflunomide therapy.
Topics: Adult; Anemia, Aplastic; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2010 |
Disseminated cutaneous and visceral Kaposi sarcoma in a woman with rheumatoid arthritis receiving leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; S | 2012 |
Birth outcomes in women who have taken leflunomide during pregnancy.
Topics: Adult; Anticholesteremic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Birth Weight; Body Siz | 2010 |
Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission.
Topics: Adverse Drug Reaction Reporting Systems; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies | 2010 |
Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Cells, Cultured; Dose-Resp | 2010 |
Comment on: Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Cause of Death; Humans; Isoxazoles; Japan | 2010 |
Leflunomide in combination therapy for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Drug Therapy, Combination; Humans; Infection | 2010 |
Pharmacotherapy: Is there a place for leflunomide in the treatment of RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 2010 |
Macrophage activation syndrome after leflunomide treatment in an adult rheumatoid arthritis patient.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Macrophage Acti | 2010 |
[Combined therapy in a patient with generalized aggressive periodontitis and rheumatoid arthritis: a 15-year follow up case].
Topics: Adult; Aggressive Periodontitis; Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; | 2010 |
A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor.
Topics: Arthritis, Rheumatoid; Azathioprine; Biological Assay; CD4-Positive T-Lymphocytes; Female; Glucocort | 2011 |
Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Biomarkers; Cohort St | 2011 |
Value of the small cohort study including a physical examination for minor structural defects in identifying new human teratogens.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antidepressive Agents; Arthritis, Rheumatoid; Carbamaz | 2011 |
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2012 |
The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Estrogen Receptor alpha; Estrogen Receptor beta; Female | 2011 |
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Cost of Illness; Cost-Benefit Ana | 2011 |
A series of complications after third molar osteotomy in a pancytopenia patient and spontaneous healing after bone marrow transplantation.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Marrow Transplantati | 2011 |
Photodistributed eruption with rhabdomyolisis due to leflunomide.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2011 |
A case of eczematous and vesicular dermatitis during anti-TNFalpha therapy for rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnostic Errors; Drug Eruptions; Drug Synergis | 2011 |
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Di | 2011 |
[Treatment of rheumatoid and psoriatic arthritis--review of leflunomide].
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 2010 |
Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Resistance; Drug Substitution; Drug T | 2012 |
Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchoalveolar Lava | 2011 |
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Dr | 2012 |
Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; D | 2011 |
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2011 |
Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hypertension, Pulmonary; Isoxazo | 2012 |
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients.
Topics: Abatacept; Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2012 |
[Sulphasalazine in patients with rheumatoid arthritis in China: a cross-sectional study].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2012 |
A case of severe staphylococcal septicaemia: septic arthritis and a mediastinal abscess following leflunamide therapy for rheumatoid arthritis.
Topics: Abscess; Adrenal Cortex Hormones; Anti-Bacterial Agents; Arthritis, Infectious; Arthritis, Rheumatoi | 2010 |
Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Cytochrome P-450 CYP2C19; Diarrhe | 2012 |
Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Arthriti | 2013 |
Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; B | 2013 |
Pulmonary aspergillosis in chronic leflunomide treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2012 |
Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dihydroorotate Dehydrogenase; Female; Hapl | 2012 |
Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Managemen | 2012 |
Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Dose-Response Relationship, Dr | 2012 |
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Cohort Studi | 2012 |
Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Crotonates; Female; Hum | 2013 |
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Child; Colombia; Drug Therapy, Co | 2012 |
A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Isoxazoles; L | 2013 |
The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Cross-Sectional Studies; Drug Therapy, | 2013 |
A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience.
Topics: Adrenal Cortex Hormones; Alberta; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; F | 2013 |
Leflunomide-induced chronic cough in a rheumatoid arthritis patient with pulmonary tuberculosis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Arthritis, Rheumatoid; Cough; | 2013 |
Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Costs and Cost Analysis; Etaner | 2002 |
Peripheral neuropathy: an unwanted effect of leflunomide?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Female; H | 2002 |
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2002 |
Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide.
Topics: Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Iso | 2002 |
Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Immuno | 2002 |
[2 years data of controlled trials with leflunomide vs. methotrexate and leflunomide vs. sulfasalazine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Follow-Up Studies; Humans; Is | 2002 |
Fatal hepatitis with leflunomide and itraconazole.
Topics: Aged; Antifungal Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury, Chronic; Dia | 2002 |
Summaries for patients. Combination therapy for rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Arthritis, Rheumatoid; Diarrh | 2002 |
Leflunomide can potentiate the anticoagulant effect of warfarin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis, Rheumatoid; Drug Synergism; Hema | 2002 |
Pancytopenia associated with leflunomide and methotrexate.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2003 |
Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2003 |
Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cost-B | 2002 |
Unproven hypothesis that leflunomide is better than methotrexate as measured by magnetic resonance imaging: comment on the article by Reece et al.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz | 2003 |
The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Perso | 2003 |
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2003 |
A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Clinical Trials, | 2003 |
Aminotransferase levels during treatment of rheumatoid arthritis with leflunomide in clinical practice.
Topics: Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Follow-Up Stud | 2003 |
FDA officials argue over safety of new arthritis drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug and Narcotic Control; Humans; I | 2003 |
Anti-glomerular basement membrane antibody-associated renal failure in a patient with leflunomide-treated rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Basement Membrane; Female; Humans; Immunocompromised Host; Immunosuppressive | 2003 |
Brain abscess in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Brain; Brain Abscess; Emergencies; Humans; Immunosuppressive Agents; Isoxazol | 2003 |
[Can a combination therapy with leflunomide be recommended for patients with active rheumatoid arthritis?].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Resistance; Drug Therapy, Combination; Humans; Iso | 2003 |
Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chemokine CCL17; Chemokine CCL2; Chemokine C | 2003 |
Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
Topics: Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Chromatography, High Pressure Liquid | 2003 |
[Drug hypersensitivity syndrome induced by leflunomide].
Topics: Arthritis, Rheumatoid; Drug Eruptions; Female; Humans; Immunosuppressive Agents; Isoxazoles; Lefluno | 2003 |
[Lichenoid drug reaction to leflunomide].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopsy; Drug Eruptions; Female; Huma | 2003 |
Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2003 |
Is the recommended dose of leflunomide the best regimen to treat rheumatoid arthritis patients?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female | 2003 |
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Chi-Squa | 2003 |
Correlation between clinical response to treatment and radiographic progression: comment on the article by Strand and Sharp.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Radiography | 2003 |
Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Erythema Multiforme; | 2003 |
Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2003 |
Leflunomide (Arava)-induced cystoid macular oedema.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Macular Edema; Male; M | 2004 |
Weekly leflunomide as monotherapy for recent-onset rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female | 2004 |
Japan deaths spark concerns over arthritis drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cause of Death; Drug Approval; Human | 2004 |
Leflunomide-induced acute hepatitis.
Topics: Adjuvants, Immunologic; Aged; Anion Exchange Resins; Arthritis, Rheumatoid; Chemical and Drug Induce | 2004 |
[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit A | 2004 |
[Development and/or increase of rheumatoid nodules in RA patients following leflunomide therapy].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2004 |
Patient preferences for treatment of rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Computer Simulation; Et | 2004 |
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Carrier Proteins; Cell Differe | 2004 |
The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Ant | 2004 |
Interstitial lung disease and disease modifying anti-rheumatic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz | 2004 |
Chronic overdose of leflunomide inducing interstitial nephritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Overdose; Humans; Isoxazo | 2004 |
Subacute cutaneous lupus erythematosus associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Humans; Isoxazoles; | 2004 |
Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Fema | 2004 |
Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Huma | 2004 |
Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthr | 2004 |
Leflunomide-induced aseptic meningitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Mal | 2004 |
Peripheral neuropathy in patients on leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studies; Humans; Isoxazoles; Leflunomide; Per | 2004 |
Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infliximab; Isoxazoles; | 2004 |
[Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Humans; Immunosuppressive | 2004 |
Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2004 |
Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studi | 2004 |
[Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arteritis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2004 |
Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Human | 2005 |
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
Topics: Aged; Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Crotonates; | 2005 |
Streptococcal toxic shock syndrome and sepsis manifesting in a patient with chronic rheumatoid arthritis.
Topics: Accidental Falls; Adrenal Cortex Hormones; Aged; Amputation, Surgical; Anti-Bacterial Agents; Antirh | 2004 |
Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2004 |
Vasculitis associated with the use of leflunomide.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2004 |
Life-threatening hypertriglyceridemia during leflunomide therapy in a patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Hypertriglyceridemia | 2004 |
Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hypertension, Pulmonary; Isoxazol | 2004 |
Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopsy; Colitis; Colon; Colon | 2005 |
Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.
Topics: Adjuvants, Immunologic; Antibodies, Antinuclear; Antibodies, Monoclonal; Antirheumatic Agents; Arthr | 2004 |
Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Female; | 2004 |
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Antibodies, Monoclona | 2005 |
Interstitial lung disease associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lun | 2004 |
Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Human | 2004 |
Post-coronary artery bypass graft liver failure: a possible association with leflunomide.
Topics: Aged; Arthritis, Rheumatoid; Coronary Artery Bypass; Fatal Outcome; Female; Gastrointestinal Hemorrh | 2005 |
Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy.
Topics: Aged; Arthritis, Rheumatoid; Cholestyramine Resin; Debridement; Female; Humans; Immunosuppressive Ag | 2005 |
Leflunomide-induced subacute cutaneous lupus erythematosus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Lupus Erythema | 2005 |
Neuropathy associated with leflunomide: a case series.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; | 2005 |
[Treatment with leflunomide in rheumatoid arthritis].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Europe; Humans; Isoxazoles; | 2005 |
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Disability Evaluat | 2005 |
Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Health Status; Humans; Isoxazoles; Leflunomide; Methotr | 2005 |
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Ger | 2005 |
[When to begin rheumatism treatment? Initial combination therapy helps fastest].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclo | 2004 |
[Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sediment | 2004 |
Leflunomide induced acute interstitial pneumonia.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Cholestyramine Resin; Drug Therapy, Combination; Fema | 2005 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra | 2005 |
Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Topics: Active Transport, Cell Nucleus; Aniline Compounds; Anti-Inflammatory Agents; Apoptosis; Arthritis, R | 2005 |
Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Aged; Aniline Compounds; Arthritis, Rheumatoid; Cross-Sectional Studi | 2005 |
Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Humans; Iso | 2005 |
[Development of dermatomyositis in a woman with rheumatoid arthritis treated with leflunomide].
Topics: Arthritis, Rheumatoid; Dermatomyositis; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflun | 2005 |
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Comb | 2005 |
Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lung Diseases; M | 2006 |
Subacute cutaneous lupus erythematosus associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 2005 |
Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blotting, Western; Coculture | 2006 |
[Leflunomide-related severe axonal neuropathy].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Axons; Cranial Nerve Diseases; | 2005 |
Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bias; Epidemiologic Studies; Hu | 2005 |
Leflunomide-associated tuberculosis?
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Immunos | 2006 |
Severe hepatotoxicity in a rheumatoid arthritis patient switched from leflunomide to methotrexate.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Female; | 2005 |
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agen | 2006 |
Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Australia; Cohort Studies; | 2006 |
The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Rheumatoid; Cell Surviva | 2006 |
Disease modifying treatment for feline rheumatoid arthritis.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Breeding; Cat Diseases; | 2005 |
[Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; S | 2006 |
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Isoxazoles; Leflunomide | 2006 |
Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Ant | 2006 |
Severe infections following leflunomide therapy for rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Mid | 2006 |
Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Combined Modality Thera | 2006 |
Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Aged; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Lung; | 2006 |
Peripheral neuropathy associated with leflunomide: is there a risk patient profile?
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Complications; | 2007 |
Antirheumatic drug use and the risk of acute myocardial infarction.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Cohort Studies; Female; Hum | 2006 |
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Bi | 2007 |
Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Male; Pulmonary | 2006 |
Influence of leflunomide on gastrointestinal Candida albicans infection induced in naive and arthritic newborn mice.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Candida albicans; Candidiasis; Collagen; Colon | 2006 |
Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Autopsy; Cholestyramine | 2006 |
Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; | 2006 |
Leflunomide-induced toxic epidermal necrolysis.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; | 2006 |
Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, R | 2007 |
Leflunomide-induced peripheral neuropathy.
Topics: Adjuvants, Immunologic; Aged; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Female; Human | 2007 |
The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Proliferatio | 2006 |
Pulmonary adverse events with leflunomide--myth or reality?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; L | 2007 |
Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Decision Support Techniques; Drug Administr | 2007 |
Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Myc | 2007 |
Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Drug Administration Schedule | 2007 |
Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Korea; Leflunomide; Lung Di | 2007 |
Hypersensitivity pneumonitis associated with leflunomide therapy.
Topics: Aged; Alveolitis, Extrinsic Allergic; Arthritis, Rheumatoid; Biopsy; Humans; Immunosuppressive Agent | 2007 |
New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2007 |
Cutaneous infections with Stenotrophomonas maltophilia in patients using immunosuppressive medication.
Topics: Adjuvants, Immunologic; Adult; Aged; Arthritis, Rheumatoid; Cross Infection; Cyclophosphamide; Femal | 2007 |
Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient.
Topics: Aged; Anemia, Macrocytic; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2007 |
Leflunomide-associated infections in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cellulitis; Female; Hospitalization; Human | 2007 |
Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Topics: Aniline Compounds; Apoptosis; Arthritis, Rheumatoid; Cell Survival; Cells, Cultured; Chronic Disease | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
A simple sample size formula for analysis of covariance in randomized clinical trials.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2007 |
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female | 2008 |
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Topics: Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Confounding F | 2009 |
Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopsy; Diagnosis, Differenti | 2008 |
Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide.
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Female; Humans; Isoxazoles; Leflunomide; Lung Disease | 2008 |
[A 47-year-old dog breeder with chronic polyarthritis, weight loss and high fever].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2008 |
Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP1A2; Diarrhea; Dose-Response | 2008 |
Use of contrast enhanced MRI in the assessment of therapeutic response to a disease-modifying antirheumatic drug. Case study of a patient with rheumatoid arthritis--6- and 24-month follow up.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Monitoring; Female; Follow-Up S | 1995 |
Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis.
Topics: Antigens, CD; Arthritis, Rheumatoid; Cell Aggregation; Cells, Cultured; Humans; Immunosuppressive Ag | 1996 |
The mammalian homologue of Prp16p is overexpressed in a cell line tolerant to Leflunomide, a new immunoregulatory drug effective against rheumatoid arthritis.
Topics: Adenosine Triphosphatases; Amino Acid Sequence; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ar | 1998 |
New treatments for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase | 1998 |
Leflunomide approved for rheumatoid arthritis; other drugs nearing approval.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 1998 |
New drugs for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 1998 |
Rheumatoid arthritis drugs show promise.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, Rheumatoid; Etanercept; | 1999 |
I have rheumatoid arthritis and have been taking methotrexate. I'm interested in the new drugs that have been in the news lately. Just how effective are they?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Hu | 1999 |
Clinical therapeutics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase | 1999 |
National Meeting of the American College of Rheumatology. November 8-12, 1998, San Diego, California.
Topics: Aniline Compounds; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Rheumatoid; Crotonat | 1999 |
Leflunomide for the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; | 1999 |
Changing the course of rheumatoid arthritis. Introduction.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 1999 |
[Rheumatoid arthritis: a new basic therapy. Proliferating T-cells controlled].
Topics: Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activat | 2000 |
Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy; | 2000 |
[Treatment of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cytokines; Dec | 2000 |
Leflunomide: a new DMARD for rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthri | 2000 |
[Recent progress in the treatment of rheumatoid polyarthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Immunosuppressive | 2000 |
Severe pancytopenia after leflunomide in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bone Marrow; Female; Filgrastim; Gra | 2000 |
Efficacy and safety of leflunomide in active rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Is | 2000 |
Serious liver disease in a patient receiving methotrexate and leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; I | 2000 |
Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Glomerulonephritis; Humans; I | 2001 |
Current management of rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Aged; Algorithms; Antirheumatic Agents; Arthritis, Rheumatoid; Case M | 2001 |
Treatment of Felty's syndrome with leflunomide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Felty Syndrome; Humans; Immunosuppressive Agents; Isoxa | 2001 |
Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.
Topics: Abnormalities, Drug-Induced; Adult; Arthritis, Rheumatoid; Female; Half-Life; Humans; Immunosuppress | 2001 |
Leflunomide-associated weight loss in rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2001 |
Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disability Evaluation; Female; | 2001 |
Conventional DMARD options for patients with a suboptimal response to methotrexate.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Resistance; | 2001 |
[Chronic polyarthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; | 2001 |
[Leflunomide--the first specific disease-modifying drug against rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rh | 2001 |
[Application of leflunomide in the treatment of patients with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 2001 |
New therapeutic approaches to the management of rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Infliximab; Iso | 2001 |
[Leflunomide plus methotrexate. Hope for patients with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Thera | 2001 |
Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Cost of Illnes | 2001 |
Is there a place for leflunomide in the treatment of rheumatoid arthritis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Inju | 2001 |
Vasculitis occurring during leflunomide therapy.
Topics: Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Middle Age | 2001 |
Discussion. Treatment algorithm: managing rheumatoid arthritis.
Topics: Algorithms; Antirheumatic Agents; Arthritis, Rheumatoid; Deductibles and Coinsurance; Disease Manage | 2001 |
Effect of hemodialysis on leflunomide plasma concentrations.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biotrans | 2002 |
[New basic therapeutic drugs from the viewpoint of evidence-based therapy].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Etane | 2001 |
Leflunomide in treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide | 2002 |
Monitoring leflunomide (Arava) as a new potential teratogen.
Topics: Abnormalities, Drug-Induced; Arthritis, Rheumatoid; Female; Humans; Infant, Newborn; Isoxazoles; Lef | 2002 |
Leflunomide and hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Hypertension; Isoxazoles; Le | 2002 |
Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, | 2002 |
Leflunomide-associated skin ulceration.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2002 |
[Drug therapy and malpractice exemplified by combination leflunomide and methotrexate therapy].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Drug Interactions; Drug Therapy, Combina | 2002 |
[Leflunomide + methotrexate combination therapy from the physician's viewpoint].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Drug Interactions; Drug Therapy, Combina | 2002 |
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
Topics: Analysis of Variance; Arthritis, Rheumatoid; Cohort Studies; Cost-Benefit Analysis; Decision Making; | 2002 |
Clinical pharmacokinetics of leflunomide.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Availability; Bi | 2002 |